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Abstract 
The cells of the immune system expresses an array of different ion channels, yet 
their roles in these cells are not fully understood. The large-conductance voltage 
and calcium-activated potassium channel (BK channel) is a potassium ion channel, 
which is found in a wide variety of cells and tissues. Their biophysical properties and 
expression in excitable cells are extensively studied. However, their role in immune 
cells is unclear. In this thesis I have investigated the role of BK channels in 
macrophages.  
The expression of BK channels in the RAW264.7 mouse macrophages cell line was 
characterised by Western blot, immunofluorescence imaging and 
electrophysiological recordings. BK channels were predominantly associated with 
intracellular compartments in resting macrophages. Activation of RAW264.7 with 
ultrapure lipopolysaccharide (LPS) resulted in the upregulation of BK channel 
protein on the plasma membrane and the channel activity. 
To investigate the function of BK channels in these cells, both genetic and 
pharmacological approaches were used. These studies suggested that the role of 
the BK channel in macrophages is dependent on the sub-cellular location of the 
channel. Importantly this thesis suggests that plasma membrane located BK 
channels regulate the release of tumour necrosis factor- (TNF- and interleukin-6 
receptor  (IL-6R from activated macrophages. IL-6 release was not affected. 
These results together suggested that a disintegrin and metalloprotease domain 17 
(ADAM17) enzyme is negatively regulated by the plasma membrane BK channel. 
This thesis proposes a novel interaction between ion channels and the activity of a 
membrane metalloprotease. This project also identified the dynamic movement of 
BK channels during activation of macrophages. 
ADAM17 regulates the release of a diverse range of proteins including cytokines, 
growth factors, receptors and adhesion molecules, which are implicated in many 
fields including immunology, tissue regeneration, neurology and tumour growth. It is 
anticipated that this finding could stimulate further research. 
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 Chapter 1 Introduction 
1.1 Inflammation  
1.1.1 General concepts of inflammation   
Inflammation is a protective process, which is initiated by a disturbance to cellular or 
tissue homeostasis.  Ultimately the aim of this process is to eliminate the initial or 
continuing insult, initiate healing and eventually restore normal tissue homeostasis. 
Although inflammation was first recognised by the Egyptians, circa 300 B.C., the 
visible changes associated with inflammation were first defined by Celsus 
(approximately 30 B.C.- 38 A.D.) and described as cardinal signs of inflammation. 
These signs were termed ‘redness’, ‘heat’ and ‘swelling’. To these was added ‘pain’ 
by Virchow and ‘loss of function’ later by John Hunter (1728-1793 A.D.). Although 
exact people responsible for the last two signs is still debated. These ‘cardinal signs’ 
are caused by the physiological changes in surrounding tissue and the 
microcirculation, which result in the exudation of plasma and emigration of 
leukocytes from blood vessels to the area of injury.  
 
The beneficial nature of inflammation was first recognised by Galen (approximately 
129-216 A.D.) in the 3rd century A.D. Galen interpreted the inflammation associated 
with infection has to be beneficial for host wound repair. However the concept that 
the inflammation was a cause of the disease dominated over ensuing centuries. It 
was John Hunter in 18th century in his thesis on ‘Gun Shot Wounds’ who explicitly 
referred to Inflammation as a physiological or ‘salutary’, process. He described 
inflammation response as a salutary process to remove insults and to restore the 
normal state of the tissue. He expressed his views in following words; 
“But if inflammation develops, regardless of the cause, still it is an effort whose 
purpose is to restore the parts to their natural functions.”  
 
In the late 19th to early 20th century, the cellular aspects of inflammatory responses 
began to be elucidated. Rudolf Virchow (1821-1902 A.D.) began to investigate the 
cellular components of inflammation, which was followed by the discovery of 
phagocyte by Eile Metchnikoff (1845-1916 A.D.). This described an important role of 
phagocytosis in protection against pathogen invasion (Lord Florey, 1970). 
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It is now established that the inflammatory response is essential in host defence, 
and an inability to produce a sufficient inflammatory response results in immune 
deficiency diseases causing life threating infections. Immunodeficiency can occur in 
both the innate and adaptive immune response. Innate immune deficiencies include 
chronic granulomatosis diseases, which is caused by genetic defect in the reactive 
oxygen species producing enzyme, NADPH oxidase (Roos et al., 1996).  In severe 
combined immune deficiency, a deficiency of the adaptive immune system, patients 
have impairment of T-cell development causes. In both cases patients suffer from 
opportunistic, severe infections by bacterial, viral and fungal infections (Aloj et al., 
2012).  
 
However, beside this ‘physiological inflammation’, which is essential for continued 
wellbeing, it is also recognised that the inflammation can cause tissue damage and 
pathology. Classically, ‘pathological inflammation’ is associated with excessive 
and/or an inappropriate inflammatory responses. For example, septic shock and 
anaphylaxis are associated with excessive inflammatory reactions, which, in severe 
cases, could lead to the multiple organ failure and death (Boghner and Lichtenstein, 
1991; Angus and van der Poll, 2013). Moreover, the general concept of what 
inflammation is in differing situations is still developing. In past the 15 years, an 
intermediate tissue condition between normal and inflamed tissue conditions have 
been introduced and termed ‘para-inflammation’. While the exact definition of para-
inflammation is still to be determined, this condition refers to prolonged and low 
grade inflammatory reactions which causes gradual tissue damage and alter 
responsiveness to endogenous signalling molecules including hormones and 
neurotransmitters (Medzhitov, 2008). This may contribute to the development of 
many chronic diseases such as diabetes, arthrosclerosis and neurodegenerative 
diseases (Nathan, 2002).  Inflammation plays an important role in tissue protection 
and in homeostasis but alternatively, contributes to disease, it is important to 
investigate the mechanisms and mediators which are responsible for controlling and 
eliciting this fundamental process.  
 
Central to inflammatory response is the immune system, which has evolved a 
diverse range of immune cell populations with specialised functions, molecular 
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signalling pathways and various chemical mediators to bring about the protective 
effects of inflammation (Medzhitov, 2008). The immune system can be divided into 
two parts, the innate and adaptive systems. The innate responses provide the first 
line of defence against many common pathogens. The adaptive immune system 
evolved later than innate system and importantly, provides the immune systems with 
a memory and greater response against previously encountered pathogens. The 
components of innate immune system are important in the initiation of the 
inflammatory response and provide a bridge to the adaptive system, for example, 
antigen is presented by macrophages to T cells. (Janeway et al., 2001). The central 
questions in inflammation research are how do these cells recognise the presence 
of noxious inflammatory stimuli? And how do they regulate the appropriate 
responses to these stimuli?  
 
1.1.2 Pattern recognition receptors  
Inflammation can be induced by a variety of stimuli including, microbial infections, 
molecules associated with tissue injury and cell death, tissue neoplasm, and the 
conditions associated with abnormal tissue conditions/environment, such as obesity, 
hypoxia and neoplasms (Hotamisligil et al., 1993; Jiang et al., 2005; Akira et al., 
2006). The nature of the initial inflammatory insult is important in determining the 
property and magnitude of subsequent inflammatory response. An efficient 
inflammatory response results in the most appropriate responses to the stimuli. 
However, this needs the ability of the immune cells to recognise a broad range of 
noxious stimuli quickly and to respond rapidly toward the insult. Therefore the 
principles of “broad”, “quick” and “appropriate” are central to inflammation. To 
accommodate the first two principles, the innate immune system has evolved a 
series of receptors which recognise differing chemical entities, which are not usually 
found under normal tissue conditions. These are termed pattern recognition 
receptors (PRRs). PRRs express the conserved recognition sites, which bind to 
variable chemical epitopes on invading microorganisms termed pathogen 
associated molecular patterns (PAMPs), or endogenous chemical moieties  
associated with cellular stress, damage associated molecular patterns (DAMPs). 
Some members of PPRs are endocytic, soluble proteins- they sense, are activated 
and elicit their repose in the extracellular fluid. These endocytic PRRs include 
Pentaxin, C-type leucine like receptors and the plasma components of complement 
cascade. Alternatively cell associated PRRs are found on/in host cells and activate 
the cells inflammatory response. Examples of cell-associated PRRs are toll-like 
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receptors (TLRs), nucleotide-binding oligomerization domain (NOD)-like receptors, 
DNA sensors, such as absent in melanoma 2, RNA sensors such as retinoic acid 
inducible gene-1 and melanoma differentiation-associated protein-5. These cell-
associated PRRs are expressed at various cellular locations which include 
cell/plasma membrane, the cytoplasm and various intracellular compartments. 
Recently it has been demonstrated that some cell associated PRRs can be found in 
multiple cellular compartments (Akira et al., 2006). This variation in locations 
enables the host to respond to different levels of microbial invasions (Takeuchi and 
Akira, 2010). For example, lipopolysaccharide (LPS), a component of gram-negative 
bacterial cell wall, is detected by TLR2 heterodimers and/or TLR4 homodimers on 
the plasma membrane and causes the release of inflammatory cytokines and 
phagocytosis. Whereas LPS in the cytosol is associated with higher bacterial load 
and causes the activation of caspase-11 and subsequent cell death (Hagar et al., 
2013).  
 
1.2 Toll-like receptor pathways 
1.2.1 TLR structure 
 One of the best characterised families of PRRs is the TLR superfamily. Initially toll 
receptors, the homology of the TLRs, were discovered in Drosophila. At present, 10 
types of TLRs have been identified in human and 13 in mice, Table 1-1. These 
receptors can be expressed on the plasma or intracellular membranes. The differing 
subcellular localisation of the receptor is thought to enable effective detection of 
extracellular or intracellular pathogen as well as allowing the selective recruitment of 
signalling proteins.  
 
All TLRs contain a ligand binding domain and a toll/interleukin-1 receptor (TIR) 
homology domain, which are separated by a transmembrane region. The ligand 
binding site of TLRs consists of a leucine-rich repeat (LRR) of 20-30 amino acids, 
forming a conserved horseshoe-like tertiary protein structure. The LRRs have a 
signature consensus sequence motif, L(XX) LXL (XX) NXL (XX) L (XXXXXXX) L 
(XXX) with N=asparagine, L=leucine and X=any amino acid (Kang and Lee, 2011). 
These LRR conserved sequences compose the hydrophobic core of the receptor, 
with variations the X amino acids, influencing its selectivity to particular ligands. 
LRRs are generally considered as protein binding domains which facilitate protein-
protein interactions (Kobe and Deisenhofer, 1995). However due to the slight 
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variations in its amino acid sequence in TLRs, LRRs in TLRs bind to a chemically 
more diverse set of ligands (Song and Lee, 2012). These ligands include peptides, 
lipids and nucleic acids, and possibly oxidised forms of lipoproteins. For example, 
the absence of asparagine in TLR1, 2, 4 and 6 leads to the formation of a 
hydrophobic pocket in its LRR region allowing the receptors to bind lipid based 
ligands. It is therefore not surprising that certain lipids found in bacterial, fungal and 
viral pathogens or released during tissue stress can act as ligands for TLRs (Song & 
Lee, 2012). Table 1-1 lists TLRs, their ligands and cellular locations. The molecular 
mechanisms of ligand binding differ between TLRs, however, they all form dimers 
when binding to their ligands. These dimers can be homo- or hetero-dimer in nature 
and once formed, the dimers fold their ligand in the regions between the two LRRs. 
The dimerization of the receptors is facilitated by the TIR-domains. The TIR-domain 
is important in the formation of the dimers and the recruitment of the adaptor 
molecules which also contain TIR-domains.  
 
Five TIR-domain containing adaptor proteins have identified in human. These are 
myeloid differentiation factor 88 (MyD88), TIR-domain containing adaptor protein 
inducing IFN- (TRIF), MyD88 adaptor like protein (Mal), TRIF related adaptor 
molecule (TRAM) and sterile alpha and armadillo-motif containing proteins (SRAM). 
Each member of TLR dimers recruits a specific combination of these five adaptor 
proteins that initiates different but overlapping inflammatory signalling cascades. It 
was suggested that this specificity, together with the TLRs ligand selectivity, enables 
the activation of most appropriate immune response directed towards the initiation 
stimuli (O’Neill and Bowie, 2007). Therefore the combination of receptor locations, 
ligand binding specificity and selective adaptor protein recruitment allows a quick 
and appropriate response to a broad class of exogenous and endogenous 
molecules. It also can be suggested that these combinatory interactions allow a 
diverse range of signalling cascades to be established. To date TLR4 mediated 
pathway represents the most well characterised signalling pathway among the TLRs 
family. 
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Table 1-1 TLR superfamily  
Table shows the identified members of TLR superfamily in mouse and human. Each member of receptors is activated by specific set of ligand, which can be 
classified as microbial, endogenous or synthetic in nature. 
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1.2.2 TLR4 
TLR4 has a hydrophobic ligand binding region and as a result as high affinity for 
lipid based ligands. For example, lipid A epitopes found in LPS is considered to be a 
most potent activator of this receptor (Raetz and Whitfield, 2002; Kang and Lee, 
2011; Song and Lee, 2012). As such LPS are a strong activators of the TLR4 and is 
strongly implicated in septic shock (Poltorak et al., 1998). Binding of LPS to TLR4 is 
facilitated by extracellular adaptor proteins, LPS binding protein (LBP) and myeloid 
differentiation factor 2 (MD2) (Miyake, 2006).LPS binding leads to the formation of 
TLR4 homodimers and the recruitment of either activated MyD88 and/or TRIF 
adaptor proteins. Depending on the adaptor protein recruited, MyD88 or TRIF, 
distinct pathways are activated (Kawai and Akira, 2006). 
 
MyD88 dependent pathway 
MyD88 is composed of 296 amino acids with a C-terminus TIR domain and N-
terminus death domain. In addition to TLR4 pathway, the protein is recruited by 
TLR2, TLR5, TLR7 and TLR9. The activation of MyD88 dependent pathway is 
thought to contribute to strong and rapid inflammatory responses. MyD88 knockout 
mice have been shown to be highly susceptible to S. aureus infections indicating the 
importance of this pathway in the host’s defence against bacterial infections 
(Takeuchi et al., 2000). In comparison, the activation of MyD88 dependent pathway 
by LPS injection causes an excessive and destructive inflammation. MyD88 
deficiency protects animals from lethal endotoxin shock by decreasing pro-
inflammatory cytokine production, including, TNF- and IL-6 (Kawai et al., 1999). 
These studies have demonstrate the importance of MyD88 dependent pathway 
mediated inflammation and a role of this pathway in protection against bacterial 
infections.  
 
The binding of MyD88 to the activated TLR4 homo-dimer requires another TIR-
containing adaptor Mal. Mal functions as a bridge between the TLR4 dimers and 
MyD88 (Fitzgerald et al., 2001; Horng et al., 2002; Yamamoto et al., 2002). Mal is 
composed of 235 amino acids with phosphatidyllinositol-4,5-biphosphate 
(PtdLns(4,5)P2) binding domains near the N-terminus and a TIR-domain proximal to 
the C-terminus. The PtdLns(4,5)P2 binding domain of Mal has been shown to define 
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its expression on the plasma membrane (Jenkins and Mansell, 2010). The plasma 
membrane localisation of this adaptor protein serves to set the starting point of 
MyD88 dependent signalling to the cell surface and enables the death domain (DD) 
of MyD88 to interact with IL-1R associated kinase-4 (IRAK-4). The IRAK-4 
subsequently recruits IL-1R associated kinase-1 (IRAK-1), forming the IRAK-1-
IRAK-4 complex. The IRAK-1-IRAK4 complex dissociates from the receptors and 
interacts with TNF-receptor associated factor 6 (TRAF6), which exists in cytoplasm 
(Kawai and Akira, 2006).  TRAF6 is a RING-finger domain containing protein and 
functions as an ubiquitin ligase. Together with ubiquitin-conjugating enzyme E2 and 
ubiquitin-conjugating enzyme 13, TRAF6 mediates the polyubiquitination of 
substrate proteins at Lys-63. The substrates for this Lys-63 polyubiqutination include 
the NF-kB essential modifier (NEMO, also IKK, and TRAF6 itself (Walsh et al., 
2015).  Polyubiquitination enables NEMO and TRAF6 to associate with 
transforming-growth–factor--activated kinase 1 (TAK1) and TAK1-binding protein 2 
(TAB2).  TAK1 is subsequently polyubiquitinated at Lys-63 and this activates the 
kinase function of the TAK1, initiating two distinct signalling pathways (Wang et al., 
2001). In the first pathway, TAK1 phosphorylates IB kinase  (IKK) of IKK 
complex and increases its enzymatic activity. The IKK then phosphorylates a 
natural inhibitor for NF-B, IB. The phosphorylation of IB acts as a signal for its 
polyubiqutination and subsequent degradation by the proteasome (Deng et al., 
2000; Chen, 2005). The dissociation of IB from NF-B leads to NF-B’s 
translocation to the nucleus and binding to DNA binding sites for NF-B. NF-B 
activation results in the increased expression of pro-inflammatory molecules, 
including tumour necrosis factor- (TNF- interleukin-6 (IL-6), tumour necrosis 
factor receptor 1 (TNFR1) and TNFR 2, and adhesion molecules.  
 
The second pathway is mediated by TAK1. TAK1 phosphorylates mitogen-activated 
protein kinases (MAPKs), including JNK and p38. This phosphorylation ultimately 
leads to the activation of transcription factor, activated protein-1 (AP-1). This 
pathway can contributes to both pre- and post-transcriptional regulation of pro-
inflammatory mediator release (Kawai and Akira, 2006).  
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Finally TRAF6 has also been shown to directly activate interleukin regulatory factor 
5 (IRF5) and IRF7 by polyuibiutination. This results in the late phase production of 
TNF- and production of interferon- (IFN-respectively (Walsh et al., 2015).  
 
TRIF dependent pathway 
The second branch of the TLR4 inflammatory signalling occurs via TRIF. This 
pathway is known to facilitate the later phase activation of NF-B and has been 
recognised to contribute to the production of type 1 IFNs. Mice deficient in TRIF 
have been shown to have a normal early phase activation of NF-B via the MyD88 
dependent pathway, whereas they have an impaired activation of IRF3 and IFN 
production (Yamamoto et al., 2003a). TRIF is a 712 amino acid protein containing a 
TIR domain in the central region and recruits receptor interacting protein (RIP) 
homotypic interaction motif (RHIM) in the C-terminus (Jenkins and Mansell, 2010). 
TRIF dependent pathways can be initiated from the endosomal membrane and/or 
the plasma membrane. The TIR-containing adaptor protein, TIR related adaptor 
molecule (TRAM), has an analogous role to Mal in the TRIF dependent pathway 
acting as a bridge between TLR4 and TRIF (Yamamoto et al., 2003b).  The 
chemical modification of TRAM is speculated to be crucial in regulating TRIF 
pathway from differing cellular localisations. In contrast to Mal, TRAM does not 
contain a PtdLns(4,5)P2 binding domain and therefore does not contribute to its 
association with the plasma membrane. Mytristoylation of TRAM does enable the 
TRAM to localise to the plasma membrane and interact with the TLR4 homodimer 
(Rowe et al., 2006). The second study has also demonstrated that the 
phosphorylation of TRAM is required for its adaptor function (McGettrick et al., 2006). 
Once recruited, TRAM mediates trafficking of TLR4 into endosome. Once at the 
endosomal membrane, TLR4 recruits TRIF (Kagan et al., 2008). Activated TRIF 
then interacts with TRAF3 and other adaptor molecules. This molecular association 
leads to auto-ubiquitination of TRAF3 and activation of TANK-1 binding kinase 1 
(TBK-1). Finally TBK-1, in conjunction with IKK leads to the phosphorylation of 
IRF3 to induce the type 1 IFNs (Häcker et al., 2011). However TRIF may also 
contributed to the NF-B activation and has also been suggested to directly activate 
TRAF6, leading to the ubiquitination of NF-B, IRF5 and IRF7 (Sato et al., 2003). 
Furthermore TRIF is also been shown to activate RIP1 via its C-terminus RHIM 
domain with the subsequent recruitment of NEMO, resulting in the activation NF-B 
(Jenkins and Mansell, 2010).  
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The TLR4 signalling culminates in the activation of at least 5 transcription factors. 
These factors upregulate the transcription of genes encoding inflammatory 
mediators, receptors and cell adhesion molecules. Among these factors, NF-B is 
considered to be the most important in inflammation.  
 
Figure 1-1 TLR4 signalling pathways 
LPS binds to TLR4 in conjunction with LPS binding protein (LBP) and myeloid differentiation 
factor (MD2) and results in the homodimer formation. Activated TLR4 homodimers recruit 
toll/interleuckin-1 receptor homology domain (TIR) containing adaptor proteins resulting in 
MyD88 or TRIF dependent signalling pathways. In MyD88 dependent pathway, MyD88 binds 
to TLR4 homodimers via Mal. Subsequently MyD88 interacts with IL-R associated kinase-4 
(IRAK-4) and IRAK-1 via death domain (DD). IRAK-1 and IRAK-4 complex activates TNF-
receptor associated factor 6 (TRAF6) and TRAF activates transforming growth factor  
activated kinase 1 (TAK1) and TAB2 resulting in activation of NF-B dimers, p50 and p60 
and/or activation of AP-1 via JNK1/2 and p38 MAP kinases. TRIF dependent pathway: LPS 
bound TLR4 homodimers binds to TIR related adaptor molecule (TRAM) and TRAM facilitate 
endocytosis of TLR4 complex where the receptor complex activate TRIF. TRIF causes to the 
activation of TRAF3 and TRAF6 and subsequently TAK-1 binding kinase 1 (TBK-1), which 
activates IKK leading to activation of IRF3. TRIF also activate AP-1 and NF-B via RIP1, 
which activates TRAK-TAK1 complex. Adapted from O’Neil, L. and Browie, A.  (2007) Nature 
Reviews Immunology, 7 (5) 353-364. 
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1.2.3 NF-B 
The NF-B family of transcription factors consist of five members, p65 also called 
RelA, c-Rel, RelB, p50 (p100 full length precursor) and p52 (p105 full length 
precursor). These members can form hetero- and homo-dimers resulting in at least 
12 different combinations of transcription factors. All five members of NF-B 
possess a rel homology domain (RHD) at their N-terminus which facilitates protein 
dimerization and sequence specific DNA binding (Vallabhapurapu and Karin, 2009). 
The structure of the RHD has been revealed by X-ray crystallization studies and is 
composed of two immunoglobulin-like folds, one which facilitates dimerization and 
the other which mediates DNA recognition. p65, c-Rel and RelB have a transcription 
activation domain (TAD), which is essential in initiating NF-B target gene 
expression, while p50 and p52 lack the TAD domain and require dimerization with 
other members of the family to initiate protein transcriptions. Alternatively the 
dimerization of these members can results in blocking of NF-B transcription sites 
(Napetschnig and Wu, 2013). The combinations of transcriptionally active NF-B 
dimers are suggested to be specific to tissue types and lead to differing upstream 
signalling pathway and cellular responses. In general, the NF-B heterodimer 
composed of p65/p50 is most frequently activated via TLR4 signalling. This p65/p50 
dimer is often referred as ‘classical NF-B’ and results in the production of pro-
inflammatory cytokines. 
 
Under normal conditions, NF-B dimers are sequestered in the cytoplasm by a 
family of IB proteins containing multiple ankyrin repeats which bind to partially 
mask the nuclear localisation signals (NLS) present in NF-B dimers. The classical 
examples are IB, IB, and IB. Recently it has been shown that some NF-B 
proteins, p100 and p105 have ankyrin repeats in C-terminal, which also have IB 
like activity. Each IB member selectively binds to particular sets of NF-B dimers 
which have different kinetics for the activation of NF-B. As described in 1.2.2, TLR4 
signalling causes phosphorylation and ubiquitination on IB resulting in its 
proteasomal degradation. IB dissociation from the dimer unmasks the NLS of p65 
and causes the nuclear translocation of the NF-B dimer. 
 
Both MyD88 and TRIF dependent pathway activates NF-B, however, it was 
suggested that these pathways regulates different temporal phases of NF-B 
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activation (Kawai and Akira, 2006). MyD88 deficient cells have been reported to 
have impaired NF-B activation at early time points (2-3 hours) but show a normal 
peak of the NF-B transcriptional activation at later time point. However the deletion 
of MyD88 and TRIF resulted in the essential loss of NF-B activity. Together these 
results suggest that while MyD88 pathway is required for an efficient NF-B 
activation, TRIF dependent pathway can contribute to the NF-B when MyD88 is not 
activated (Yamamoto et al., 2003a). Finally NF-B leads to the expression of IB 
subunit, thus the activation negative regulatory thus establishing a negative 
feedback loop.  
 
At the cellular level, the activation of the classical NF-B dimer increases the 
transcription of genes encoding numerous pro-inflammatory molecules and results 
in strong inflammatory responses. The expression of proteins induced by NF-B 
include cytokines TNF-, IL-6, IL-1; growth factors, granulocyte-macrophage 
colony stimulating factor (GM-CSF); chemokines, IL-8, RANTES, macrophage 
inflammatory protein-1; monocyte chemotactic protein-1; and enzymes inducible 
nitric oxide synthase, phospholipase 2 and cyclooxygenase-2 (COX-2) and 
adhesion molecules, vascular cell adhesion molecule-1 (VCAM-1), intracellular 
adhesion molecule-1 (ICAM-1) and E-selectin  (Bonizzi and Karin, 2004).  
 
Taken together, we can see the activation of PPRs leads to robust proinflammatory 
responses via NF-B activation. While this response has now been characterised in 
many different cell types, the leukocytes represent the cells most identified with 
these receptors and pathways in acute inflammation.  
 
1.3 Cells in innate immune system 
Leukocytes represent the most important cells in the innate immune system. These 
cells can be divided into two types, polymorphonuclear cells (PMNs) or mononuclear 
cells (MNs). These cells can be further subdivided and have clear roles in the 
development, maintenance and resolution of inflammation. In general, inflammatory 
response is initiated by tissue resident macrophages or mast cells. This activation 
results in the migration of PMNs into the site of inflammation, usually neutrophils, 
followed by the migration of the monocytes/macrophages to the site of inflammation. 
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It is the macrophage (along the dendritic cells) which represents the conduit 
between the innate and adaptive immunity, and/or the inflammatory lesion resolution 
or progression. Due to this, the macrophage has both a large array of PPRs and the 
ability to produce a diverse range of biological mediators, the production of which is 
dependent on the extracellular environment the macrophage encounters. 
 
1.4 Macrophages 
A wide range of PRRs, including TLR4, and their associated signalling components 
are found in macrophages (Mukhopadhyay et al., 2009). They are involved in almost 
all steps of acute inflammatory responses and considered as a major component of 
innate immune system. In general, macrophages are divided into tissue resident 
macrophages and inflammatory/migratory macrophages (although in inflammation, 
the majority of macrophages at sites of inflammation are derive from migratory 
monocytes). However, macrophages are highly heterogenetic in nature and shows 
distinct anatomical and biological features depending on the tissue they are located 
in. For instance, alveolar macrophages (lung), Kupffer cells (liver), Langham cells 
(skin), peritoneal macrophages (gut) and osteoclast (bones), all have distinct biology 
and functions. As well as functional and morphological heterogeneity at the tissue 
level, macrophages from the same tissue also show heterogeneity. For instance, 
microglia shows diverse morphology depending on the location in the brain and 
distinct macrophages populations are found within the spleen (Perdiguero and 
Geissmann, 2016).  
 
Attempts have been made to discover the origin of macrophage, and to classify its 
diverse populations. The precursor of tissue macrophage populations originates 
from bone marrow, postnatal spleen, embryonic yok sac (initial source of microglia 
in mice during development) or foetal liver in the embryo (Davies et al., 2013). 
During the inflammatory response, bone-marrow derived monocytes in the 
circulation migrate into the site of inflammation and differentiate into the 
macrophages. Differentiation of monocytes into macrophages provides important 
control points of macrophage physiology and differing colony stimulating factors 
(CSFs) regulate this process depending on the macrophage population. For 
example, the presence of colony stimulated factor-1 (CSF-1), a ligand for colony 
stimulated factor-1 receptor (CSF-1R), IL-34, GM-CSF and the expression of CSF-
1R are required for the maintenance of tissue resident macrophage populations 
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(Gordon et al., 2014). CSF-1 is considered to regulate peritoneal macrophages and 
Kupffer cells differentiation, IL-34 is thought to be required for microglia and 
Langerhans cells differentiation and GM-CSF for alveolar macrophages 
differentiation. The differentiation of circulating blood monocytes to macrophages 
involves the GM-CSF and CSF-1 (Mosser and Edwards, 2008). The identification of 
the origin of macrophages may provide a clue to inhibit the pathogenic functions of 
macrophages and CSFs currently represent important targets for controlling 
macrophage actions in diseases (Lenzo et al., 2012).  
 
During acute inflammatory responses tissue resident macrophages along with mast 
cells are thought to be the first cells to recognise the inflammatory stimuli via PRRs 
and as a result the activated macrophages secret a wide range of inflammatory 
mediators, such as cytokines, chemokines, amines, fatty acid metabolites and 
complement components. These molecules act on the vascular endothelial cells and 
increasing its permeability and thus leading to formation of inflammatory oedema. 
Neutrophils are usually the first cell to migrate to the site of inflammation and there 
they secret toxic granules containing proteases and release reactive oxygen species 
(ROS), which attempt to destroy the invading pathogens. Subsequently 
macrophages are recruited which can phagocytose pathogens, dead cells and/or 
tissue debris. Due to the different mechanisms of macrophage activation, 
researchers have attempted to classify macrophages by their activation states. For 
example a early simple form of classification considered macrophages to be either 
classically activated (M1) and considered to be proinflammatory macrophages, while 
alternatively activate macrophages (M2) are associated with the hormonal immunity 
and wound healing(Mills et al., 2000; Tzachanis et al., 2002; Gordon and Martinez, 
2010). These early classification criteria have been developed over past 15 years. 
While this classification may be useful to obtain detailed information on their 
response and cell surface molecule expression patterns under extreme conditions in 
vitro and in vivo, any group classification criteria may lead to simplistic explanations 
for macrophages function in the complex tissue environments encountered in 
pathology (Gordon et al., 2014). Indeed, even within macrophage cell lines, a 
significant degree of heterogeneity is observed, which is not due to the genetic 
instability found in some cell lines (Ravasi et al., 2002). Indeed the contribution of 
macrophage heterogeneity to normal physiological and pathological responses is 
relatively under-researched area. 
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In addition to macrophage heterogeneity, another hallmark of macrophage biology is 
cell plasticity. This is the ability of macrophages to change their array of mediators 
released in response to extracellular ques. An example of this is the effect of 
phagocytosis on macrophage function. Originally macrophages were distinguished 
for their remarkable ability to phagocytose material (Metschnikoff, 1884; Flannagan 
et al., 2012). Phagocytosis is important during the pro-inflammatory phase of the 
inflammation, as well as during inflammation resolution, however the molecules 
release in each of these cases is reported to be pro- or anti-inflammatory in nature 
respectively. Phagocytosis of invading pathogen or necrotic materials could lead to 
the release of proinflammatory mediators. In contrast, phagocytosis of apoptotic 
materials could cause the release of anti-inflammatory materials (Flannagan et al., 
2012). However it is important to note that most of these studies are conducted with 
the purified stimuli, and may not represent the complex tissue environment found in 
inflammatory lesions. An important question to address is how do macrophages 
continually regulate the release inflammatory mediators to finesse the body’s 
response to particular noxious stimuli? In macrophages, this exquisite control of 
mediator release is mediated by the diversity of the PRR expression and 
intracellular mechanism to finely regulate cytokine release from activated 
macrophages. 
 
Besides the macrophages role in inflammation the macrophage also play a part in 
numerous physiological processes. Research has demonstrated their involvement in 
the development, maintenance of tissue homeostasis, tissue repair and metabolism 
of nutrients. The role of the macrophage development is seen by the lethal 
phenotype observed when macrophages population is inhibited in mice (Wynn et al., 
2013). 
 
1.4.1 Macrophages production of cytokines 
Of central importance to the role of macrophages in inflammation is the production 
of cytokines. Depending on the definition, to date approximately 130 cytokines have 
been descried. These cytokines include ILs, CSFs, IFNs, TNF superfamily, 
chemokines, CCL1-28, CXCL1-17 and CX3CL-1 and growth factors. These proteins 
are released from macrophages in response to a diverse range of inflammatory 
stimuli, which are recognised by various receptors on macrophages, such as PRRs. 
Along with IL-1 the most important cytokines described are TNF- and IL-6. These 
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inflammatory mediators play vital roles in control of innate immune responses and 
inhibition of these mediators leads to the increased susceptibility to tuberculosis and 
opportunistic infections. At the same time, these mediators are found upregulated in 
many inflammatory pathologies including arthritis, atherosclerosis, asthma, 
neurodegenerative diseases, diabetes, fibrosis and cancer. These mediators 
represent important therapeutic targets and the understanding of mechanisms by 
which these mediators are released from macrophages is important (Murray and 
Wynn, 2011; Arango Duque and Descoteaux, 2014).  The classical stimulator for 
TNF- and IL-6 production is LPS stimulation via TLR4. As discussed, LPS 
signalling result in the activation of NF-B.  
 
IL-6 is known as a pleiotropic cytokine with proinflammatory, anti-inflammatory and 
regenerative actions (Hunter and Jones, 2015). The cytokine induces the acute-
phase inflammatory responses as well as the promotion of T cells subtypes and 
differentiation of B-cells (Klimpel, 1980; Yoshizaki et al., 1984; Woloski and Fuller, 
1985; Yasukawa et al., 1987; Kopf et al., 1994). IL-6 elicits its biological responses 
from the cell mainly via two different signalling pathways. Firstly, signalling through 
membrane bound IL-6 receptor  (IL-6R) and gp130 which is termed classical 
signalling, and signalling through the soluble form of receptor, IL-6R in 
combination with membrane bound gp130 is termed trans-signalling, Figure 1-2. IL-
6Ris secreted from leukocytes and the elevated level of IL-6R is associated with 
chronic inflammatory conditions (Jones et al., 2001). Secondly, signalling via IL-6R 
trans-signalling is known to exert proinflammatory action of IL-6 and associated with 
the pathologies of chronic inflammations including colitis, tissue fibrosis, 
inflammatory arthritis, allergy, neuroinflammation, cardiovascular diseases and 
cancers (Campbell et al., 2014; Tanaka et al., 2014). Trans-signalling has also been 
shown to be important in the recruitment and activation of leukocytes, the 
development and maintenance of T cell populations and their effector functions 
(Rose-John and Heinrich, 1994; Jones et al., 2001). IL-6 signalling via membrane 
bound IL-6R is termed classical signalling, which controls an acute inflammatory 
reaction, apoptosis of immune cells and haematopoiesis (Kopf et al., 1994; Hunter 
and Jones, 2015). Particularly in brain, the classical signalling is thought to mediate 
homeostatic processes including energy metabolisms, control of fever, fatigue and 
loss of appetite (Schöbitz et al., 1995). 
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Figure 1-2 Classical and Trans-signalling of IL-6  
Two mechanisms of IL-6 signalling.  a) Trans-signalling; IL-6 binds to soluble IL-6R and the 
IL-6 and soluble IL-6R complex bind to transmembrane protein gp130 on the plasma 
membrane of cells leading to proinflammatory response. B) Classical signalling: IL-6 bind to 
plasma membrane bound IL-6R and gp130 leading to tissue regeneration/cell proliferation. 
Adapted from Wolf,J. et al (2014) Cytokine, 70:11-20. 
 
TNF- is a potent inflammatory mediator and considered to be the central to 
inflammatory responses.  The cytokine is not only important in inflammation but also 
in many fields of biology including neurology, developmental biology and cancer 
(Aggarwal et al., 2012). Production of this cytokine is regulated at multiple levels- 
including the transcription of the gene, mRNA stability, message translation, protein 
transport to the plasma membrane and the final release. 
 
1.4.2 Control of TNF- mRNA 
Activation of TLR4 initiates the rapid transcription of TNF- in macrophages. The 
mRNAs of many inflammatory proteins including TNF- are unstable and represent 
a control mechanism. In these cases, it is suggested that the mRNA stability is as an 
important parameter in determining the total amount of cytokine expressed (Rabani 
et al., 2011). It has been shown that the initial robust production of TNF-from 
macrophages is due to the stabilisation of TNF- mRNA with several mechanisms 
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being suggested to stabilize the TNF- mRNA. TNF- mRNA is also the subject of 
various post-transcriptional modifications, which include alternative splicing of 
mRNA, mRNA polyadenylation, and the regulation of initiation and termination of 
protein translation (Carpenter et al., 2014).  
 
The transcription of TNF- mRNA during LPS stimulation is rapid and transient, with 
the transcript also being subject of degradation (Clark et al., 2003). The rate of 
mRNA decay is very important in determining the extent of translation of TNF-. The 
mRNA for TNF-, is known to express conserved AU rich sequences in the 3’ 
untranslated terminal region (UTR) of the gene and this region is termed AU rich 
element (ARE). ARE is found in mRNAs of many inflammatory proteins and has 
been demonstrate to have a key role in destabilizing mRNAs (Shaw and Kamen, 
1986; Xu et al., 1997). TNF- is known to be highly sensitive to degradation and 
contains the shortest version of ARE, with a 34 nucleotide 6 times AUUUA motifs in 
the 3’UTRs. However the relation between the length of ARE regions and the 
cytokine’s mRNA stability has yet to be fully characterised. Currently there are 20 
ARE-binding proteins described and once bound to the AREs, these proteins 
stimulate the decay of mRNAs. Among these ARE-binding proteins, tristetraprolin 
(TTP) and AU-rich element RNA-binding protein (AUF1) have key roles in facilitating 
the degradation of TNF- mRNA. Mice lacking TTP or AUF1 have been shown to 
have excessive inflammatory responses. In comparison, other ARE binding proteins 
act to stabilise mRNA by competing for binding regions with the “destablizing” ARE 
binding proteins without destabilizing effect. This in turn limits the effect of these 
destabilizing ARE-binding proteins. Examples of these “inhibitory” ARE binding 
proteins include, Y-box binding protein 1, embryonic lethal, abnormal vision (ELAV), 
Hu-antigen R (HUR) and ELAV-like protein 4 (HUD). The overall relationship 
between different ARE binding proteins regulates TNF- mRNA stability. The 
activation of p38 MAPK downstream of TLR4 activation has been shown to stabilise 
the ARE containing mRNAs by altering the affinity of ARE binding proteins for the 
mRNA. For example the phosphorylation of TTP by p38 decreases its affinity to 
ARE and sequesters the TTP for the degradation (Stoecklin et al., 2004). This 
favours the binding of HUR to ARE thus stabilising TNF- mRNA and in turn 
upregulate its translation (Tiedje et al., 2012). Proteins whose mRNAs are stabilised 
by p38 include TNF-, IL-8, IL-1, COX-2 and GM-CSF (Clark et al., 2003). 
However it must be noted that HURs are also involved in stabilization of mRNAs of 
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anti-inflammatory proteins. Therefore the role for HUR in inflammatory conditions is 
yet to be fully elucidated.  
 
Another element, constitutive decay element, expressed in TNF- 3’UTR causes the 
decay of TNF- mRNA independently of AREs (Stoecklin et al., 2003). Additionally it 
has emerged that microRNAs (miRNAs) modulate mRNA decay in macrophages. 
miRNAs are non-coding RNAs which pair to complementary 3’UTR sequences of 
target mRNAs. This essentially forms a miRNA and mRNA complex causing the 
inhibition of the target mRNA via RNA induced silencing complex (RISC). The RISC 
inhibits mRNA translation and/or initiates the decay of target transcript. It has 
become evident that the miRNAs are important in the control of inflammatory 
responses in macrophages.  
 
mRNAs which have an extended 3’UTR downstream of a stop codon are down-
regulated by the regulator of nonsense transcripts (UPF) proteins, UPF1-3, in the 
process called nonsense mediated decay (NMD). In this process, phosphorylation of 
the UPF1 causes the endonucleotic cleavage of the transcript. In macrophages, 
inhibition of NMD by the deletion of UPF2 upregulates 186 different gene transcripts, 
suggesting a significant contribution of NMD in the control of mRNA stability 
(Weischenfeldt et al., 2008).  
 
1.4.3 Translational control of TNF- 
The translation initiation of existing mRNAs allows the rapid production of 
inflammatory mediators. This is particularly relevant to innate immune responses 
which involve fast onset responses. Eukaryotic translation initiation factor 2 (eIF2) is 
considered to be an important regulator in innate immunity. Eukaryotic translation 
initiation factor 2B (elF2B) works via recycling between a GTP active complex and 
GDP in inactive complex of translation complex. Phosphorylation of elF2 is known to 
inhibit its recycling and supresses the translation initiation of cellular mRNAs 
(Donnelly et al., 2013). In addition, TLR4 or TLR3 activation causes the 
dephosphorylation of eIF2B via TRIF activation, resulting in frequent activation and 
translation of protein in comparison cell stressors such as ER stress which inhibits 
protein translation. 
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Another structural element which regulates translation is poly (A) tail in 3’ end of 
mRNA. This provides a binding site for a poly (A) binding protein which interacts 
with various translation initiation factors and is required in translation. TNF- mRNA 
is constitutively expressed in resting macrophages. However this constitutively 
expressed TNF- mRNA lacks poly (A) tail and therefore cannot produce TNF-. 
LPS activation causes the appearance of mRNA TNF- with poly (A) tail which 
could enhance the production of TNF- (Crawford et al., 1997). 
 
1.4.4 Regulation of TNF- release and actions 
Once translated, TNF- protein starts to accumulate in Golgi complex as early as 20 
minutes after cell activation (Shurety et al., 2000) and is directed to the plasma 
membrane via trans-Golgi network (TGN)-derived vesicle. Once the vesicle is fused 
with the plasma membrane, TNF- is expressed as a transmembrane protein trimer 
consisting of three 26 kDa (mTNF-) monomers. The final control mechanism for 
the cytokine is the release from the plasma membrane via ecoto-domain shedding 
by metalloproteinases (Stow et al., 2009). A disintegrin and metalloproteases protein 
17 (ADAM17) or Tumour necrosis factor- converting enzyme (TACE) is considered 
to be the main sheddase for TNF-(Black et al., 1997; Moss et al., 1997). The 
actions of TNF- a due to its binding to its receptors, TNFR1, (CD120a, p55) and 
TNFR2 (CD120b, p75), where it initiates a variety of intracellular cell signalling 
pathways and leads to the cellular responses (Sedger and McDermott, 2014). 
Figure 1-3 summarises these TNF- signalling pathways. 
 
Macrophages are a major source of TNF- along with other cytokines and control 
mechanisms for the production and release of these cytokines release are 
significant in regulating inflammation. It is therefore not surprising that cell signalling 
mechanisms, which lead to this cytokine release, including TLR4 signalling and 
secretory pathways are extensively studied in macrophages (Stow et al., 2009; 
Rutledge et al., 2012). As discussed above, macrophages have a great capacity to 
sense their surrounding environment via PPRs, initiate cell signalling mechanisms 
and produce the relevant inflammatory mediators via precise regulation of 
transcription and post-transcriptional mechanisms. As both sensing its environment 
and regulation of protein release are regulated at the plasma membrane, it is 
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surprising that the class of protein intimately involved in membrane biology, namely 
ion channels, has only received limited attention in the study of macrophage biology. 
The aim of this thesis is to investigate ion channels in macrophages.   
 
 
 
Figure 1-3 TNF- signalling via TNFR1 or TNFR2 
a) Soluble TNF- (sTNF) and membrane bound TNF- (mTNF) signal via TNF- receptor 1 
(TNFR1), which contains tumour necrosis factor receptor 1 associated death domain 
(TRADD) in cytoplasmic region. The ligation of sTNF/mTNF and initiates the activation of 
transcription of NF-B, mitogen activated protein kinases (MAPKs), caspase-8 or mixed 
lineage kinase like protein (MLKL) leading to inflammation, tissue degeneration, apoptosis 
and/or necrosis. b) mTNF binds to TNFR2 with a higher affinity and via TNF-receptor 
associated factor 2 (TRAF2), this initiates the activation of MAPKs, NF-B and protein kinase 
B (AkT) leading to tissue regeneration, cell survival/proliferation and/or inflammation. 
Adapted from Kalliolias,G. and Iashkiv, L., (2016) Nature Reviews Rheumatology, 12:4-62. 
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1.5 Ion channels in immune systems 
1.5.1 Evolution of ion channels and function in immune cells 
From evolutionary point of view, once the building blocks of life had occurred DNA, 
RNA and simple proteins, the next important step for life to occur was to bring these 
molecules close and keep them together, i.e. the packaging of the life chemicals. 
The answer to this was the evolution of lipid membranes. However the use of 
membranes to package the chemicals brought a new problem. This was essentially 
osmotic problems. Again the evolutionary answer to this osmotic problem was the 
arrival of the channels, which conduct ion species across the membranes. The use 
of “ion channels” by ancient cells together with protein pumps also allowed the 
generation of ion gradient, which contributed to the evolution of energy producing 
pathways such as proton gradient pathways. It is from these beginnings, the ion 
channel evolved and now play fundamental role in every cell of the body and 
virtually all physiological responses. Indeed, ion channels are still important in 
osmotic regulation, for example, the regulation of cell volume as well as in 
multicellular processes, such as cell signalling and nerve transmission. The 
activation of these ion channels allows passive movement of sets of ion species 
across the membranes and this selective movement of ions is essential in regulating 
cell volume, setting membrane potentials and facilitating cellular signalling 
processes. 
 
In the cells of immune system, ion channels have also been shown to have 
important functions. These are not only on general cellular processes, e.g. 
regulation of cellular volume, but also on specific immune responses. For instance 
transient receptor potential melastin 2 (TRPM2) or transient receptor potential 
vaniloid 2 (TRPV2) knock-out mice showed susceptibility to infection with 
L.mocytogenes indicating the importance of these channels in anti-microbial 
responses. It has also been suggested that there is a link between a mutation in a 
gene encoding ORAI1, part of the calcium release activated channel (CRAC) and 
immunodeficiency and autoimmunity, therefore indicating the essential role for these 
channels in defence mechanisms (Feske, 2009). The role of these ion channels are 
also studied at the individual cell population level and with T-lymphocyte populations 
probably the most well studied example. A variety of ion channels are found in T-
lymphocytes; CRACs; members of transient receptor potential cation channel 
subfamily, TRPM2, TRPM4 and TRPM7; voltage gated calcium channels; non-
selective cation channel; P2PX7; Zinc channels, ZIP3, ZIP6 and ZIP8; potassium 
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channels, KV1.3, KCa3.1, K2P3.1; sodium channels; Chloride channels; GABAA and 
cystric fibrosis transmembrane conductance regulator. These channels have been 
reported to be involved in cell proliferation, cell survival and chemotaxis (Launay et 
al., 2004; Srivastava et al., 2008; Cahalan and Chandy, 2009).   
 
1.5.2 Macrophages and ion channels 
Macrophages have been found to express a wide array of ion channels. These 
include KV1.3, KV1.5, BK; inward rectifier potassium channels (Kir2.1); CRAC channels; 
voltage-gated proton (HV) channels; P2X7; and TRP channels, TRPC1, TRPC3, 
TRPC6, TPRM2 and TRPV2 (Gallin, 1984, 1991; Gallin and Sheehy, 1985; 
DeCoursey and Cherny, 1996; DeCoursey et al., 1996; Berthier et al., 2004; Liu et 
al., 2007; Nagasawa et al., 2007; Yamamoto et al., 2008; Schilling and Eder, 2009; 
Finney-Hayward et al., 2010; Gao et al., 2010; Di et al., 2011; Santoni et al., 2013; 
Stebbing et al., 2015). The role of these ion channels in macrophages is not 
completely understood and in many instances only investigated in resting 
macrophages. Several studies have indicated the involvement of proton channels in 
the NADPH oxidase activity and TRPV2 channels in the macrophage migration. 
However in comparison to that of the T-lymphocytes or to excitable cells, relatively 
little research has focused on the role of these ion channels in activated 
macrophages, Table 1-2.  
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Ion channels Macrophage cell type  Reference 
KV1.3 Human alveolar macrophages Mackenzie et al., 2003 
KCa1.1 PMA differentiated THP-1, Microglia DeCoursey et al., 1996 
Kir2.1 PMA differentiated THP-1, J774.1 Gallin., 1985 
DeCoursey et al., 1996, 
KCa3.1 Microglia, Human PBMCs DeCoursey and Cherny, 1996 
Stebbing et al., 2015  
CRAC Human PBMCs Gao.et.al, 2010 
HV THP-1,Microglia Eder and DeCoursey. 2011 
Stebbing et al., 2015 
P2X7 Mouse BMDMs, Microglia Guerra et al.,2003  
Cavaliere et al., 2005 
TRPC1 7-ketocholesterol stimulated THP-1 Berthier et al., 2004 
TRPC3 Rat monocytes Liu et al., 2007 
TRPC6  Human alveolar macrophages Finney-Hayward et al., 2010 
TPRM2 Mouse PBMCs Di et al., 2011 
Yamamoto et al., 2008 
TRPV2 Human PBMCs Santoni et al., 2013 
 
Table 1-2 Ion channel expression in monocytes and macrophages 
Reported expression of ion channels in monocytes and macrophages. BMDM: bone marrow 
derived macrophages, CRAC: Ca
2+
 release-activated channels, KCa1.1: large conductance 
voltage-and calcium- activated potassium channel (BK channel), KV: voltage gated 
potassium channels, KCa3.1: small conductance Ca
2+
/calmodulin-activated K
+
 channel, HV: 
voltage-gated proton channel, PBMC: Peripheral blood mononuclear cells, PMA: Phorbol 12-
myristate 13-acetate, TRPC: transient receptor potential canonical, TRPM: transient receptor 
potential melastatin, TRPV: transient receptor potential vanilloid. 
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1.6 BK channels 
As stated above, macrophages express a diverse array of ion channels. One of 
these channels is the BK channel. The BK channel are characterised by its large 
conductance and also noted for the diverse range of endogenous modulators which 
can regulate its opening. These two characteristics suggest that the channel may be 
involved in multiple cellular functions which allow the integration of extracellular 
signals into intracellular cell signalling pathways. As macrophages are known to 
respond to numerous extracellular stimuli, it was speculated that the BK channel 
could be involved in regulating macrophage functions.  
 
1.6.1 Physiological roles for BK channels 
The BK channel, also known as large conductance calcium- and voltage-potassium 
channel, Maxi-K, Slo-1 or KCa1.1, is highly selective to K
+ ions. The channel is 
characterised by high K+ selectivity, large conductance (250 pS in symmetrical K+ 
concentrations) and its allosteric opening mechanisms by a rise in intercellular Ca2+ 
concentration and membrane depolarization (Cui et al., 2009). The large 
conductance for K+ and the unique allosteric opening mechanisms enable BK 
channel to integrate changes in Ca2+ with differing membrane potentials (Hoshi et al., 
2013). The opening and closing of the BK channels contribute to fast after-
hyperpolarization, regulation of action potential frequency, neurotransmitter release 
in some neurons (Contreras et al., 2013).  
 
BK channels are ubiquitously expressed. In particular, the function of BK channels in 
excitable tissues, such as in neurons and smooth muscle cells have been well 
characterised. For example, BK channels in smooth muscle cells contribute to 
muscle relaxation and are thought to provide protection from vascular hypertension. 
It has also been proposed that BK channels have roles in the regulation of circadian 
rhythm, inducing ethanol tolerance and the generations of nociception, although 
these channel functions may be location dependant (Contreras et al., 2013; Whitt et 
al., 2016).  In humans, the dysfunction of BK channels is linked to a number of 
pathologies including epilepsy, dyskinesia, seizure, incontinence, asthma, 
hypertension, alcoholism and cancer. Therefore pharmacological modulation of this 
channel is of clinical interest (Ghatta et al., 2006; Bentzen et al., 2014) 
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1.6.2 Channel structure and gating mechanisms of BK channels 
1.6.2.1 Crystal structure and function  
The structure of BK channels has been determined by studies using x-ray 
crystallography (Wu et al., 2010; Yuan et al., 2010). These studies have revealed 
the 3D structure of the core part of the human BK channel at a resolution below 10 
Å. This core part of the protein contains the gating ring and cytoplasmic Ca2+ binding 
sites. The crystallography was made in absence of Ca2+ binding to the channel 
protein. Thus it is assumed that the described structure represents the closed 
channel (Yuan et al., 2010).  
 
The core forming part of the channel is composed of four identical  subunits (BK 
Slo-1). The BK subunit contains approximately 1100 amino acids and is encoded 
by one gene, KCNMA1 or alternatively named SLO-1. The BK tetramer can form 
the functional part of a BK channel but native channels are likely to be associated 
with auxiliary  and/or  subunits.  The crystal structure defined on the plasma 
membrane each BK is formed by seven, S0-S6, transmembrane helices with the 
extracellular N-terminus, intercellular C-terminus domain with the S5-S6 region 
forming the selectivity filter of the pore (Wu et al., 2010). Positively charged S2, S3 
and S4 together with S1 and S0 serving as the voltage sensor domain. S0 segment 
has also been shown to contribute to the stabilization of auxiliary subunits 
expressions, 1-4- and 1-4-subunits with the BK protein. The transmembrane 
region and N-terminus accounts for one third of the amino acid residues of the BK 
protein with the remaining part consisting of the cytoplasmic domains. This relatively 
large cytoplasmic domain contains binding regions for Ca2+, Mg2+ and various 
endogenous signalling molecules (Cui et al., 2009; Contreras et al., 2013; Hoshi et 
al., 2013).  
 
The crystallography studies showed that four BK subunits assemble as a gating 
ring of total eight regulator of conductance of potassium 1 (RCK1) and RCK2 
domains (Yuan et al., 2010a). The gating ring of the BK channel has been shown to 
have a relatively large central hole around 20 Å, which permit ions to move between 
pore regions into intracellular parts. These RCK1 and 2 have hydrophobic 
interactions involving residues on-helices and this hydrophobic interactions 
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appeared to be conserved among RCK domains. Near to the end of RCK2 domain, 
there is a high affinity Ca2+ binding site. This structure is known as Ca2+ bowl, 
connected by short helix. The study also showed that the gating ring of the 
channel is linked to the S5-S6 linker pore-forming region by a strand-like structure 
which appeared to be free from any non-covalent interaction from other protein 
residues. This may allow the effective coupling of pore region to gating ring (Yuan et 
al., 2010). 
 
1.6.2.2 The gating mechanism of BK channels 
The precise mechanism by which the voltage sensor and the Ca2+ region integrate 
to cause the opening of the BK channel is still to be elucidated. However, studies 
suggest that membrane depolarization pushes the positively charged S4 segment 
toward the extracellular side and this movement rearranges other segments in the 
voltage sensor region of BK (S0-S3), which leading to opening of the pore via S6- 
regulator of potassium conductance (RCK) linker region. For the Ca2+ mediated 
opening, Ca2+ binding to the channel causes the release of free energy. It is 
proposed that this energy is transduced into mechanical force and opens the 
channel pore. Both the binding of Ca2+ and voltage sensor activation increase the 
probability of the channel opening and these two factors can have synergistic 
influences on each other’s activity. At molecular level, the activation of the voltage 
sensor domain has been shown to increase the affinity of the channel to Ca2+.and 
the binding of Ca2+ enhances the voltage sensor activation. Therefore the activation 
of both factors is normally required to achieve the maximum probability that the ion 
conduction gate is open (Open probability: Po) (Cui et al., 2009). This mechanism is 
in contrast to other K+ channels including voltage gated K+ channels and other 
calcium-activated K+ channels. In Kv, the activation always causes the opening of 
the channel due to 4-8 times bigger electric charge on the voltage sensor region 
than that of BK channels which couples the voltage sensing and pore region tightly. 
In small and/or intermediate conductance calcium activated K+ channels, the binding 
of Ca2+ activates the channels. However under certain conditions, the requirement 
for BK channels to open in the presence of high Ca2+ and increased voltage may 
become redundant. It has been reported that BK channels can open at high 
membrane voltage without a rise in Ca2+. In addition high intracellular Ca2+ has been 
shown to open the channels at negative voltage (Hoshi et al., 2013). The BK 
tetramer can be co-assembled with various combinations of auxiliary subunits, 1-4 
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and/or 1-4 in a tissue specific manner, and the assembly with these subunits has 
an impact on the gating properties of the channel (Kyle and Braun, 2014). The 
sensitivity of BK channels to the membrane voltage and Ca2+ is subject to the 
expression of these auxiliary subunits. While another divalent ion, Mg2+, is not an 
activator of the BK channel but has also been reported to enhance the coupling 
strength between the ion conduction gate and voltage sensor domain at mM 
concentrations (Cui et al., 2009). 
 
Another mechanism by which BK channel open probability can be changed is via 
alternative splicing of the BK gene. As previously stated BK is encoded by one 
gene, KCNMA1. In the case of BK it is theoretically possible that the alternative 
splicing can give rise to variety of polypeptides and some of these variants have 
been reported to show altered Ca2+ sensitivity, channel kinetics, localization and 
sensitivity to endogenous molecules. However, only several variants are fully 
characterised to date. Finally post-translational modifications, such as 
phosphorylation and palmitoylation of BK proteins can also lead to alterations in 
BK channel activity and localizations depending on which amino acid residue is 
modified (Srivastava et al., 2008, Jeffries et al., 2010). 
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Figure 1-4 BK channel structure and binding sites for endogenous signalling 
molecules. 
BK channel core  subunit is composed of 7 transmembrane (TM) segments, S0-S6, 
connected through intra- and extracellular loops with the N-terminus facing the extracellular 
side and C-terminus facing the intracellular side. S1-S4 confers voltage sensing and the C-
terminus contains binding sites for Ca
2+
, Mg
2+
 and the other endogenous molecules, and K
+
 
ion conducting ring, regulator for conductance of K
+
 (RCK) regions. ROS: reactive oxygen 
species. Adapted from Hou,S. et al (2009) Physiology 24(1) :26-35. 
1.6.3 BK channel auxiliary subunits 
BK tetramer can form a functional BK channel; however whether the expression of 
BK channels formed of only a BK tetramer is present under physiological condition 
or not is not known. It has been known that BK tetramer can interact with several 
auxiliary subunits, 1-4 and/or 1-3 (Contreras et al., 2012; Zhang and Yan, 2014). It 
is believed that each BK monomer can bind one  subunit, therefore the 
relationship 4 x (1  subunit to 1 auxiliary  subunit). As previously mentioned the 
presence of different auxiliary subunits changes the properties of BK channels 
(Hoshi et al., 2013). It is therefore not surprising that different subunits are found in 
differing tissues and results in wide range of the biophysical and pharmacological 
properties of channels. This may equip the channel to facilitate more diverse 
physiological processes (Orio et al., 2002). 
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To date the majority of research has focused on the expression and function of the  
subunits. The expression of subunit is known to be tissue specific and was first 
observed in bovine tracheal smooth muscles. This was later categorized as the 1 
subunit (Knaus et al., 1994a; Orio et al., 2002). To date, four variations of  
subunits,1, 2,3 and 4, have been cloned from mammalian tissues (Wallner et 
al., 1999; Behrens et al., 2000; Brenner et al., 2000). Each  subunit is composed of 
2 transmembrane domains, connected by a loop on the extracellular side of the 
membrane. The expression of these subunit changes the gating properties of the 
channel. 1 and 2 have been shown to increase the sensitivity of the BK channel to 
Ca2+ and voltage, and slows the opening and closing kinetics of the channel. 3 
subunit is known to speed up the deactivation of the channel. The 4 expression 
has only been found in the brain tissue (Orio et al., 2002; Contreras et al., 2012, 
2013). The BK channels with 4 subunits has been reported to shows the slower 
opening and closing kinetics to a greater degree than 1 and 2 subunits. In 
addition the presence of 4 confers the resistance to the channel blocking peptides, 
charybdotoxin and iberiotoxin (IbTX) (Meera et al., 2000).  
Recently, a second class of BK channels auxiliary subunits have been discovered, 
which are designated as  subunits. Four  subunits have been identified and each 
subunit has approximate molecular weight of 35 kDa and are single transmembrane 
proteins. Intriguingly the  subunits also contain LRRs, which has previously 
described as the hallmark of PRRs, at their N-terminus (Yan and Aldrich, 2012). The 
first characterised subunit was 1, LRRC26. This subunit was discovered in a 
prostate cancer cell line, LNCaP to shift the half maximal activation voltage of BK 
channel by approximately -140 mV, allowing channel in absence of intracellular Ca2+ 
(Yan and Aldrich, 2010). It has been suggested that this change in gating properties 
could allow channels to operate in non-excitable tissues. The other three  subunits, 
2 (LRRC52), 3 (LRRC55) and 4 (LRRC38) respectively, are also known to shift 
the channel activation voltage toward negative, although to less extent than the 1 
subunit. 
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1.6.4 BK channel pharmacology 
A wide range of endogenous, natural or synthetic compounds have been identified 
and/or developed to modulate the activity of BK channels. These compounds 
interact with BK channels and alter the activation state of the channel in various 
ways. The inhibitors for the channel have provided useful tools to investigate the 
functional roles, structure and electrophysiological properties of the channel (Yu et 
al., 2016). Also much attention has been focused to study the therapeutic potential 
of the BK modulators (Bentzen et al., 2014). Importantly the BK channel can be 
regulated by a number of endogenous signalling molecules (Hou et al., 2009). 
These molecules can be produced by immune cell, which may suggest a link 
between the inflammatory response and the BK channels. 
 
1.6.4.1 BK channel blockers 
BK channels are highly selective for K+ ions and the application of several cations 
have been shown to block K+ conductance by interacting with the conduction gate of 
BK channels (Carvacho et al., 2008). These cations are H+, Na+, Cs+ and Ba2+, and 
bind to the gates internally or externally with distinct affinity for each site. The 
blockade by these cations tends to be affected by membrane voltage, which affects 
the movement of K+ ions via the channel. These studies have been used to 
investigate the nature of pore region and selectivity filter of the channel. For instance, 
Cs+ entres the conduction gate regions to cause blockade of BK channels. This 
blockade has been suggested to be relieved by the large influx of K+ ions probably 
due to the higher affinity of the K+ ion for Cs+ to the conduction gate (Cecchi et al., 
1987). Ba2+ blocks BK channels from both external and internal sides but exhibits 
1000 fold difference in affinity between the two sides (Vergara et al., 1999). 
Tetraethylammonium chloride (TEA) is a non-selective potassium channel blockers 
but also known to effectively block the BK channel. TEA inhibits BK channels from 
both side but shows distant affinity with the dissociation constant 0.2 mM when 
applied internally and 30 mM for the external application (Kaczorowski and Garcia, 
1999). Including TEA, quaternary ammonium ions have been characterised to block 
Kv channels and also shown to block the BK channel with different kinetics. It was 
suggested that the results possibly reflected the structural similarlities as well as 
differences between these channels (Villarroel et al., 1988). BK channels are also 
blocked by Shaker ball peptide, which has been known for its blockade of Shaker K+ 
channels. 
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In addition to these non-selective BK channel blocking compounds, several scorpion 
toxins have been identified to block BK channels and a few of these toxins are 
highly selective to BK channels among other ion channels. These peptide toxins 
include charibdotoxin, slototoxin, martentoxin and iberiotoxin (IbTX). These 
polypeptide toxins inhibit BK channels by covering the pore region composed by the 
 subunit tetramer. These peptides are identified to have interaction sites with the  
subunits and the affinity and effectiveness are shown to be sensitive to the 
expression pattern of  subunits (Kaczorowski and Garcia, 1999). Most importantly, 
IbTX is highly selective to BK channel with the dissociation constant of 1.2 nM and 
used as the gold standard to inhibit the BK channel (Candia et al., 1992). 
A fungal indole alkaloid, paxilline is another selective BK channel inhibitor and 
alongside IbTX, it is widely used to study the property of the channel. The reagent is 
a small lipophilic molecule and considered to inhibit the channel at more than one 
site with distinct affinities (Knaus et al., 1994b; Li and Cheung, 1999; Zhou and 
Lingle, 2014). 
 
1.6.4.2 BK channel openers 
BK channels have been reported to open by several unsaturated cis fatty acid 
produced in cells. These fatty acids are arachidonic, palmitoleic, eicosapenanoic 
and eicosatetraynoic acids (Hercule et al., 2007). Also BK channels have been 
reported to increase opening in response to 17-estradiol depending on its 
coexpression with 1 subunit (Valverde et al., 1999). An anti-microbial peptide, -
defensin 2, produced by innate immune cells has also been reported to open the BK 
channel when the channel is coexpressed with the 1 subunit (Liu et al., 2013). A 
protecting effect of vasculature has been reported on the application of these BK 
channel activating molecules (Bentzen et al., 2014). 
 
There found several synthetic compounds to open the BK channel. An anti-estrogen 
agent, Tamoxifen has been reported to open BK channels which are coexpressed 
with the 1 subunit (Coiret et al., 2007). Various BK channel activators have been 
developed by drug companies. Benzimidaolone derivatives NS004 and NS1619 
have been used to study the physiological functions of BK channels and therapeutic 
effect (Olesen et al., 1994). Cym04 is another reported activator of the channel (G et 
al., 2012). However it also has been noticed that these drugs exhibit mitochondrial 
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toxicity and low specificity (Bentzen et al., 2014).  A newer benximidaxolone 
derivative, NS11021, is considered to have improved selectivity and effect on BK 
channel opening (Bentzen et al., 2007). Another activator, the GoSlo-SR family of 
activators are found to shift the voltage dependence of the BK channels (Roy et al., 
2012).It has been reported that compounds naturally found in plants and fungi 
activate BK channels. Examples of these are dihdrosoyasaponin and DHS-I. These 
materials have been used in medicines to treat asthma and smooth muscle 
disorders (Nardi et al., 2003).  
These openers for BK channels have been great interest of drug discovery to treat 
hypotension, vascular hyperactivity, erectile dysfunction, bladder instability, and 
inflammatory pain, and have studied in clinical trials (Bentzen et al., 2014). 
 
1.6.4.3 BK channel modulation by endogenous signalling molecule 
It has become apparent that various endogenous signalling molecules also regulate 
the opening of BK channels. Importantly in the context of this research, some of 
these molecules are produced by macrophages during the innate immune 
responses (Hou et al., 2009). The endogenous molecules which have been 
speculated to increase the opening of BK channels include protons, carbon 
monoxide (CO), arachidonic acid metabolites, such as hydroxyeicosatetranoic acids, 
epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids; the metabolites of 
cytochrome P540,  epoxygenases, lipoxygenases; the human--defensin 2; 17--
estradiol and unsaturated free fatty acids such as omega-3 docosahexaenoic acids 
(Baron et al., 1997; Bringmann et al., 1998; Hou et al., 2009; Bentzen et al., 2014). 
Indeed it has been suggested that the ability of these molecules to modulate BK 
channels may underlie their physiological and pathophysiological effects (Hercule et 
al., 2007). For instance, omega-3 docosahexaenoic acid has been demonstrated to 
lower the blood pressure in wild-type mice, while this was ineffective in BK knock 
out mice. 17, 18-epoxyeicosatetraenoic acid has been shown to achieve its 
vasodilator effect by acting on BK channels (Hercule et al., 2007). Heme has been 
reported to modulate the activity of the channels, however its effect is more complex. 
Heme binds to the cytoplasmic region of BK and increases the Po at negative 
voltage, however at positive voltages heme decreases Po (Horrigan et al., 2005). 
Finally ROS, such as hydrogen peroxide (H2O2), nitric oxide (NO), peroxynitrite 
(ONOO-) and super oxide (O2-) have been suggested to inhibit the channel activity 
via oxidation of Cys911 in the cytoplasmic region (Tang et al., 2004).  
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Interestingly many of these endogenous BK channel modulators have a role in 
inflammatory responses. For instance ROS, BK channel inhibitors, are released 
from macrophages during the early phase of inflammation and may contribute to 
pro-inflammatory signalling cascades (Tang et al., 2004). In contrast, CO, BK 
channel opener, has been shown to have anti-inflammatory effects in inflammation. 
In terms of cell signalling, CO is probably a more likely candidate as a modulator of 
the channel activity, as CO release is regulated by the enzyme heme oxygenase 
and the heme oxygenase 1 and 2 are involved in inflammation (Wallace et al., 2015). 
 
A second class of molecules, which have anti-inflammatory effects and also BK 
channel modulatory effects include arachidonic acid metabolites, including 
hydroxyeicosatetranoic acids, epoxyeicosatrienoic acid and dihydroxyeicosatrienoic 
acids. These molecules are associated with the later phase of inflammatory 
response and the resolution of inflammation (Perretti et al., 2015).  
 
1.6.5 BK channel expression in different cellular locations 
As stated above the BK channel can be found in many tissues and exist in many 
forms. Furthermore the BK channels are expressed in multiple subcellular locations 
and appear to have tissue and location specific properties/functions. The cellular 
location in which the BK are found include the plasma membrane, mitochondrial 
membrane and nuclear envelops (Xu et al., 2002; Douglas et al., 2006; Cui et al., 
2009; Li et al., 2014). However the roles for these intracellular BK channels are not 
completely understood. This may be related to the lack of specific reagents which 
are required to investigate their activity. 
 
BK channels have many important roles in cell biology, however its function in 
inflammation is not fully characterised. Interestingly several mediators of 
inflammation modulate the activity of the channels. The aim of this PhD is to 
investigate the role of the BK channels in cytokine production during the classical 
activation of macrophages via TLR4.  
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1.7 Aims 
The overall aim of this thesis is to investigate a role for BK channels in macrophage 
activation via TLR4. To date, relatively few studies have been carried out on ion 
channels in macrophages. References to suggest properties related to ion 
channel ,especially electrophysiology of these cells, are relatively sparse. Therefore 
this project was also aimed to structure the framework of ion channel research in 
macrophages. This included the development of methods to research ion channels 
such as patch clamp technique on macrophages. 
 
A mouse macrophage cell line, RAW264.7, was used throughout the thesis. This is 
because the cell line is often used in the studies of TLR4 signalling and cytokine 
production (Rutledge et al., 2012). Macrophages are known to be heterogenetic and 
plastic in nature. The cell line generally has more stable phenotype and is thought to 
be suitable for the method development, which aimed on this thesis. 
 
Previous research in the lab had established a role for heme oxygenases and CO in 
the regulator of inflammatory responses. One of proteins, which has been shown to 
be regulated by CO are BK channels. In addition, the activation of BK channels is 
the subject of many factors and importantly this include endogenous molecules 
which are produced during inflammatory responses. Especially the channels are 
regulated by CO, whose anti-inflammatory actions have been interest of the 
laboratory. It is hypothesised the channel may have involvement in inflammatory 
response. 
 
However the role of BK channel in macrophages had been under-researched. This 
thesis attempted to establish protocols by which the BK channel expression and 
activity could be measured in macrophages and carry out initial investigations into 
the role of the BK channel in macrophages. It was hoped that this research would 
elucidate the role of BK channel in macrophage activation and possibly indicate a 
mechanism by which CO regulates macrophage activation. 
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The release of inflammatory mediators is an important aspect of macrophage 
activation and has an impact on forming overall inflammatory responses (Medzhitov, 
2008; Stow et al., 2009; Arango Duque and Descoteaux, 2014). Therefore this 
project used the release of cytokines and a cytokine receptor as a measure of 
macrophage activation. 
 
The research questions to be addressed are following. 
1 Establish a model of macrophage activation by TLR4 activation in vitro 
To use cytokine release as a measure of inflammatory response, it was necessary 
to characterise the pattern of protein release during TLR4 activation in RAW264.7 
macrophages. These macrophages were stimulated with TLR4 ligand, LPS, and the 
released levels of cytokines were measured using enzyme-linked immunosorbent 
assay (ELISA). TNF-, IL-6 and IL-6R are considered to be important in 
inflammatory pathology and were analysed in this thesis. 
 
2 Do macrophages express BK channels? 
Little data is available on the ion channel expression in RAW264.7 macrophages. 
Especially the expression of BK channels in these cells had not been known. 
Therefore it was necessary to characterise their expression in RAW264.7 
macrophages. The channel expression was studied using 3 different method 
analysis, Western blot was carried out to assess the expression of the channel, 
immunofluorescence to visualise the channel location and electrophysiological 
recordings to determine the activity of the channel. Western blot analysis were 
carried out at whole cell level and other cellular fractions. As it has been reported 
that the activation of immune cells alter the expression of K+ channels (Feske et al., 
2015), this study was carried out in both resting LPS stimulated macrophages. 
 
3 Are BK channels expressed in macrophages involved in inflammatory response 
during TLR4 activation? 
To study the involvement of BK channels in macrophage activation, the effect of BK 
channel block by IbTX on cytokine and cytokine receptor release was studied. First 
whether IbTX has direct effect on cytokine and cytokine receptor release by 
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macrophages was tested to assess the suitability of this drug to use on 
macrophages. Once the effect was found, it was aimed to address the mechanism 
by which the channel inhibition altered the release of TNF-. This was investigated 
by different techniques; TNF- mRNA levels by real time quantitative PCR (RT-
qPCR), cellular retention of TNF- by Western blot.  
 
4 How ADAM17 important in release of cytokine and is BK channel involved in 
regulating it activity? 
 The results led the hypothesis that BK channels regulated the main membrane 
sheddase for TNF-, ADAM17 (Rose-John, 2013). To assess the effect of IbTX on 
ADAM17 activity, enzyme activity assay was carried out.  
 
5 Does the genetic inhibition of BK channel have the same effect as 
pharmacological inhibition? 
The results from this pharmacological modulation of channel were further elucidated 
by genetic inhibition of BK channels by BK silencing siRNA.It has been reported 
that macrophages are difficult to transfect siRNA (Forsbach et al., 2012). Therefore, 
the first experiment aimed to establish a protocol for effective BK silencing in 
RAW264.7 macrophages using several transfection reagents and siRNA sequences. 
The effect was assessed by measuring protein level by Western blot. The effect on 
the release of cytokines and a cytokine receptor by genetic inhibition of BK were 
analysed by ELISA, Western blot and ADAM17 enzyme activity assay. 
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 Chapter 2 Material and method 
2.1 Materials 
2.1.1 Drugs 
Sterile cell culture grade distilled water (diH2O: Thermo Fisher Scientific, U.S.) was 
used to reconstitute drugs. Sterile filtered cell culture grade dimethyl sulfoxide 
(DMSO: Sigma Aldrich, UK) was used to reconstitute drugs. Ultrapure LPS from 
E.coli 0111:B4 strain (Invivogen, U.S.) was reconstituted in diH2O and the stocks 
were made at the concentration of 5 mg/ml and aliquots were kept in -70oC freezer 
until required. A BK channel inhibitor, IbTX (Alomone Labs, Israel), was 
reconstituted in diH2O to the concentration of 10 M and aliquots were stored in -
20oC freezer. Another BK channel inhibitor, Paxilline (R & D Systems, U.S.), was 
prepared in DMSO at the concentrations of 100 mM and aliquots were stored in -
20oC freezer. A general inhibitor for membrane metalloproteases, GM6001 (Enzo 
Life Sciences, UK) was reconstituted in DMSO at the concentration of 6.75 mM, 
immediately diluted to 1 in 10 in diH2O to minimize DMSO concentrations and 
aliquots were stored in -20oC freezer. A selective inhibitor for ADAM17, TAPI-0 
(Enzo Life Sciences, UK), was prepared in DMSO at the concentration of 6.75 mM 
and aliquots were stored in -20oC freezer. NS11021 (Sigma Aldrich, UK) was 
dissolved in DMSO at the concentration of 100 mM and aliquots were stored in -
20oC freezer. Protease inhibitor cocktail (Sigma Aldrich, UK) was prepared in diH2O 
to 20 times concentrated than working concentrations and aliquots were stored in -
20oC freezer. The components of protease inhibitor cocktail and working 
concentrations are as following; 1 mM AEBSF, 0.8 M Aprotinin, 50 M Bestatin, 15 
M E-64, 5 mM EDTA, 20 M Leupeptin and 10 M Pepstatin A. TACE substrate II 
(fluorogenic) (BML-228; Enzo Life Science, UK) were reconstituted in DMSO at the 
concentration of 6.7 mM and was used in ADAM17 activity assay immediately after 
reconstitution. When DMSO was used for the reconstitution, the concentration of 
DMSO in the culture well never exceeded 0.015% in cytokine assays and 0.1% in 
the ADAM17 activity assays. Table 2-1 shows the summery of drug preparation 
used in the methods used in the thesis.  
 
 Chapter 2 Material and method 
 
56 
 
 
Compound Supplier Stock 
conc. 
Stock  
solvent 
Final conc. Range Methods 
IbTX Alomones labs, Israel 10 mM diH20 3-1000 nM ADAM, CA, E, 
IF, PCR & WB 
TEA Sigma, UK 0.5 M diH20 0.6-3 mM CA & E 
LPS Invivogen, U.S. 5 mg/ml diH20 3-1000 ng/ml ADAM, CA, E, 
IF, PCR & WB 
GM6001 Enzo Life Science, UK 6.75 mM DMSO 150 nM-15 M ADAM, CA & IF 
TAPI-0  Enzo Life Science, UK 6.8 mM DMSO 100 nM-600 nM ADAM, CA & IF 
TACE substrate  Enzo Life Science, UK 6.7 mM DMSO 5 M ADAM 
Paxilline R & D Systems, U.S. 25 mM  25 mM CA 
NS11021 Sigma, UK 100 mM DMSO 100 nM ADAM & CA  
Protease inhibitor 
cocktail 
Thermo Fisher Scientic 
U.S. 
X 20 diH2O 1 mM AEBSF, 0.8 M Aprotinin, 50 M Bestatin, 15 M E-64, 
5 mM EDTA, 20 M Leupeptin, 10 M Pepstatin A 
WB 
Table 2-1 Drugs 
Summary of drug preparation, names, sources, stock preparation, final concentration range and methods. IbTX: Iberiotoxin, TEA: Tetradoethyl ammonium, 
LPS: UltraPure LPS, diH2O: Distilled water, DMSO: Dimethyl sulfoxide. conc.: concentration. ADAM: ADAM17 activity assay, CA: cytokine assay, E: 
electropysiological recordings, IF: immunofluorescence imaging, PCR: real-time quantitative polymerase chain reaction, WB: Western blot. 
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2.1.2 Chemicals and reagents 
Dulbecco’s Modified Eagle Medium (DMEM) (Thermo Fisher Scientific, U.S.) and 
penicillin/streptomycin concentrate consisted of penicillin 10000 unit/ml and 10 
mg/ml streptomycin (Thermo Fisher Scientific, U.S.) were used for cell culture and 
DMEM was stored at 4oC and penicillin/streptomycin was at -20oC respectively. 
Molecular biology grade, bovine serum albumin (BSA; Sigma UK) was stored at 4oC. 
Sterile, cell cluture grade fetal bovine serum (FBS; Thermo Fisher Scientific, U.S.) 
and goat serum (Thermo Fisher Scientific, U.S.) was stored in -20oC. 30% 
acrylamide/Bis-acrylamide (Sigma, UK), sodium dodecyl sulfate (SDS; Pomega, UK), 
tetramethylethylenediamine (TEMED; Thermo Fisher Scientific, U.S.), and 
ammonium persulfate (APS; Sigma, UK) were used to make sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) gels. Pre-stained protein standards 
(New England Biolabs, UK) were used as a protein size indicator in Western blot. 
Other chemicals were purchased from Sigma, UK unless otherwise stated.  
 
2.1.3 Bioassay kits 
Mycoprobe (R&D Systems, U.S.) was used to monitor mycoplasma contaminations. 
Pierce Cell Surface Protein Isolation Kit (Thermo Fisher Scientific, U.S.) was used to 
isolate the plasma membrane from cells. Enzyme-linked immunosorbent assay 
(ELISA) kits for mouse TNF-, IL-6R and IL-6 (R & D Systems, U.S.) were used to 
quantify released cytokines from the cells. RNAsay mini-kit (Qiagen, UK) was used 
to isolate mRNA from cells. Superscript III Reverse transcriptase kit (Thermo Fisher 
Scientific, U.S.) was used to construct cDNA from mRNA. Taqman custom gene 
expression assay kit (Thermo Fisher Scientific, U.S.) for mouse TNF- and -actin 
were used for RT-QPCR. 
 
2.1.4 Buffers and solutions 
The formulations for the buffers and solutions used in experiments are summarized 
in Table 2-2. Chemicals were dissolved in diH2O unless specified. pH of the solution 
was normally adjusted with 12 N  HCl solution and/or 1-3 N NaOH solution. For 
phosphate buffer used in Rat brain preparation, 1N H2PO4 was used to adjust pH in 
place of HCl.  For electrophysiology solutions free Ca2+ concentration in the pipette 
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solution was estimated from a software, MAXCHELATOR (Stanford University, U.S.) 
and the osmolality of buffers was measured using an Osmometer (Loser 
Messetechnik, Germany) where required. 
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Name  Composition pH application 
Electrode buffer 192 mM Glycine, 25 mM Tris-Base, 0.1% (v/v) SDS  WB 
Phosphate buffered saline 
(PBS) 
137 mM NaCl, 2.7mM KCl, 10 mM Na2HPO4,  1.8 mM KH2PO4 7.2 ADAM, CA,CI, E, 
IF, PCR & WB 
Phosphate buffered saline 
with Tween (PBS-T) 
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4,  1.8 mM KH2PO4,  
0.1% (v/v) Tween-20 
7.2 CA 
SDS-PAGE sample buffer  
4 times concentrate  
62.5 mM Tris-HCl, 20% (v/v) Glycerol, 2% (w/v) SDS,  
5% (v/v)  -mercaptoethanol 
 WB 
Tris-buffered saline (TBS) 10 mM Tris (8.4 mM Tris-HCl, 1.6 mM Tris-Base), 100 mM NaCl  7.4 CI &WB 
Tris-buffered saline with 
Tween (TBS-T) 
10 mM Tris, 100 mM NaCl, 0.1% (v/v) Tween-20  7.4 CI &WB 
Transfer buffer 190 mM Glycine, 25 mM Tris-Base, 20% (v/v) Methanol  WB 
Citrate buffer (pH=5.0) 5 mM Citric Acid, 5 mM Tri-sodium citrate 5.0 CA 
Mild stripping buffer (pH=2.2)  200 mM Glycine, 1% (w/v) SDS, 1% (v/v) Tween-20, pH set to 2.2 with HCl 2.2 WB 
Lysis buffer for nuclei isolation 8 mM Tris-HCl, 2 mM Tris-Base, 10 mM NaCl, 3 mM MgCl2, 0.8% NP-40, 
Protease inhibitor cocktail 
7.5 CI 
Quenching solution for cell 
surface protein isolation 
PBS with 100 mM Glycine   CI 
Lysis buffer for cell surface 
protein isolation  
PBS with 1% IGEPAL-CA63, Protease inhibitor cocktail   CI 
Cell culture freezing solution  10% (v/v) Glycerol, 90% FBS  CC 
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Wash buffer for cell surface 
isolation 
PBS with 0.1% IGEPAL-CA630, Protease inhibitor cocktail  CI 
Kreb’s 125 mM NaCl, 26 mM NaHCO3, 2.5 mM KCl, NaH2PO4, 2 5mM D-glucose, 1 
mM CaCl2 
7.4 E 
Phosphate buffer for rat brain 
preparation 
153 M NaH2PO4,1.46 mM Na2HPO4, 320 mM Sucrose, Adjust pH with H2PO4 7.4 WB 
Pipette solution free Ca
2+
 
high(1.6 M) 
5 mM  EGTA, 20 mM HEPES, 10 mM KCl, 100 mM K-acetate, 1 mM MgCl2, 4 
mM CaCl2 
7.4 E 
Pipette solution free Ca
2+
 low 
(10 nM) 
5 mM  EGTA, 20 mM HEPES, 10 mM KCl, 100 mM K-acetate, 1 mM MgCl2, 50 
nM CaCl2 
7.4 E 
Table 2-2 Buffers 
Formulations, names, abbreviation, pH of the buffers and solutions and applied techniques. ADAM: ADAM17 activity assay, CA: cytokine assay, E: 
electrophysiological recordings, IF: immunofluorescence imaging, PCR: real-time quantitative polymerase chain reaction, SDS-PAGE: sodium dodecyl 
sulphate polyacrylamide gels, WB: Western blot, CI: isolation of cellular fractions. CC: cell culture.  
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2.1.5 Antibodies  
A mouse monoclonal anti-mouse BK mouse antibody (L6/60; Millipore, UK) and a 
rabbit polyclonal anti-mouse BK (APC-107; Almone labs, Israel) were used for 
BK identification in Western blot analysis. Both antibodies are designed to bind the 
intracellular, C-terminal, region of the BKprotein. Antibodies which are directed to 
the extracellular region of the subunit were avoided due to possible interference with 
the biotinylation procedure, 2.2.7. This is because the method for the plasma 
membrane isolation involves covalent modification of the cell surface protein, which 
could limit the binding of antibody to the extracellular region. L6/60 was used to 
visualise BK in immunofluorescence imaging. A rabbit polyclonal anti-ADAM17 
antibody (ab2051; abcam, U.S.) was used to assess ADAM17 expression in 
Western blot.  This antibody is designed to bind to the intracellular, C-terminal, 
region of ADAM17. For the validation of plasma membrane isolation technique, anti-
Akt rabbit polyclonal antibody was used. A rabbit monoclonal anti-mouse TNF- 
antibody (D2D4; Cell Signaling Technology, U.S.) was used to detect cellular TNF- 
in Western blot. A rabbit polyclonal anti--actin antibody (D6A8; Cell Signaling 
Technology, U.S.) was used as a loading control in Western blot. Goat anti-rabbit 
IgG horse radish peroxidase (HRP)-linked secondary antibody and horse anti-
mouse IgG HRP-linked secondary (Cell Signaling Technology, U.S.) were used to 
conjugate HRP to primary antibodies in Western blot. Non-specific binding of the 
secondary antibodies was tested by incubating the samples with the secondary 
antibodies alone, see 2.2.10.  
 
A mouse monoclonal anti-mouse BK antibody (L6/60; Millipore, UK) was used to 
visualize BK protein in immunofluorescence imaging. Before incubating with L6/60, 
F(ab)’ fragment-affinity purified unconjugated goat anti-mouse IgG (Thermo Fisher 
Scientific, U.S.) was applied at 1.25 g/ml to block the binding of the anti-mouse IgG 
secondary antibody to endogenous mouse Ig. Goat anti-mouse IgG (H&L) 
secondary antibody Alex Fluor® 488 conjugate (Thermo Fisher Scientific, U.S.) was 
used to conjugate fluorescence to primary antibody for immunofluorescence imaging. 
In order to achieve good signals, experimental conditions, such as antibody 
concentrations and incubation times were optimised. The optimised experimental 
conditions are summarised in Table 2-5. 
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2.2 Methods 
2.2.1 Cell culture 
RAW264.7 murine macrophage cell line and J774.1 murine macrophage cell line 
were obtained from the European Collection of Cell Culture. RAW264.7 and J774.1 
macrophages were cultured in DMEM containing 10% FBS, 100 unit/ml penicillin 
and 100 g/ml streptomycin, referred as culture media in text, in a humidified 
incubator at 37oC, 5% CO2. Cells were kept frozen in freezing media consisting of 
90% FBS (v/v) and 10% (v/v) glycerol, sterile filtered. The stocks of cells were kept 
in cryotubes. Each tube contained approximately 5x106 cells in liquid nitrogen. The 
cells were thawed in water bath at 37oC and immediately transferred to conical 
bottom tubes supplied with flesh media. To remove any freezing media, tubes were 
centrifuged at 210 x g, re-suspended in fresh culture media, transferred to the cell 
culture flasks and cultured in a incubator. The culture media was replaced at 4 hours 
and 24 hours after thawing to remove dead cells, released molecules and debris. 
When flasks reached approximately 80% confluency, the cells were passaged using 
a rubber scraper and a portion of cells were continuously cultured. The passage 
number did not exceed 16 times. Mycoplasma contamination was routinely tested as 
described in 2.2.2. Upon thawing and periodically, Nitrite assay, see 2.2.3, was 
carried out to assess the responsiveness to LPS.  
 
2.2.2 Mycoplasma detection 
The presence of mycoplasma contamination was tested using a mycoplasma 
detection kit, Mycoprobe (R&D Systems, U.S.) following the manufacturer’s 
instruction. To allow the detection of low level of contamination, cell culture media 
was sampled on day 1 and 3 to determine any increases in signal. The samples 
were mixed with supplied lysis buffer and hybridized to probes (biotin-labelled 
capture oligonucleotide probes and digoxigenin-labelled detection probes). Those 
probes are targeted to the 16S ribosomal RNA (rRNA) of common mycoplasmas. 
The hybridization solution is transferred to a streptavidin-coated microplate to 
capture the rRNA/probe hybrid. Following removal of unbound material by wash, an 
anti-digoxigenin alkaline phosphatase was added. An amplified solution was added 
and colour develops in proportion to the amount of mycoplasma rRNA. Colour 
development is stopped and the intensity of the colour is measured using a plate 
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reader at wavelength 490 nm with correction at 650 nm. An optical density greater 
than 0.1 indicated the presence of mycoplasma infection and density less than 0.05 
indicated the absence of mycoplasma contamination. Signals from day 0 sample 
and day 3 samples were compared to check change in mycoplasma level.  
 
Mean O.D. 
  positive ctrl 1.8163 
negative ctrl 0 
Day 1 0.0063 
Day 3 0.0038 
Table 2-3 Mycoplasma test on RAW264.7 cells. 
A typical result from mycoplasma test using culture media from RAW264.7 macrophages. 
Ctrl: control supplied with the kit. O.D.: Optical density. O.D.>0.1: presence mycoplasma 
infection, O.D. <0.05: absence of mycoplasma infection. Ctrl: control. 
 
2.2.3 Nitrite assay 
Macrophages are known to exhibit heterogeneity depending on the environmental 
cues and origin (Mosser and Edwards, 2008). Pervious work in the lab had found 
that sub-clones of macrophage cell lines can occur if high passage numbers, 25 
times or more, are used, or cells are not continually cultured under optimal 
conditions. These cells were usually associated with a decrease in their ability to be 
activated (lack of macrophage response to LPS can also be due to contamination). 
To use relatively consistent macrophage populations throughout the thesis, the 
nitrite assay was routinely carried out when each vial was thawed and to monitor the 
LPS responsiveness of the cells. Macrophages which showed a significant 
difference to a standard response was discarded and new culture was started. 
 
 Activation of macrophages with LPS and IFN leads to the generation of nitric oxide 
(NO) from L-arginine. Nitric oxide synthase 2 inducible derived NO is known to have 
an antimicrobial activity and possible participates in signal transduction pathways 
during the inflammatory response. Nitrite assay measures the amount of nitrite in 
cell culture media and is used to estimate the nitric oxide production. Typical data 
from experiments were displayed in Figure 2-1. The amount of nitrite in media were 
measured based on Greiss reaction. The Greiss reaction is a colorimetric assay, 
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resulting from the formation of pink coloured diazonium salt by addition of sulphate 
acid on the nitrite. The cells were plated at 1x105 per well on 96 well tissue culture 
plate and incubated overnight. Macrophages were stimulated with 10 or 1000 ng/ml 
LPS in presence or absence of 100 unit/ml IFN. After 24 hours, the media was 
collected. 50l of sample was transferred into 96 well plates in duplicate and 100l 
of Greiss solution, consisting of equal parts of 0.2% naphthylethylenediamine 
dihydrochloride, and 2% sulphanilamide in 5% phosphoric acid, added. The optical 
density was measured in microcell plate with a single wave length at 540 nm. 
Duplicates were averaged and the nitrite concentration in the samples was 
calculated against standard (0-100 M) composed of NaNO3 in diH2O.  
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Figure 2-1 Nitrite production from LPS and/or IFNactivated macrophages 
a) A typical nitrate standard plot and b) nitrate production from activated RAW264.7 cells 
using the Greiss assay. The cells were activated with various combinations of LPS and 
IFNfor 24 hours. At 24 hours the conditioned culture media was collected and the nitrite 
contents were analysed by Greiss reaction. Experiments were routinely carried out and data 
shown is one example. 
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2.2.4 MTT assay 
Methyl-thiazolyl-tetrazolium (MTT) assay was performed to estimate the effect of 
drug treatments on the cell viability. NAD(P)H-dependent cellular oxidoreductase 
enzymes present in mitochondria are capable of reducing yellow coloured 
tetrazolium salt and this results in the formation of purple coloured precipitated 
product, formazan. The change in colour is measured by optical density and used to 
estimate the activity of these enzymes. At the end of experiments, supernatant was 
removed and thiazolyl salt solution, 0.33 mg/ml Thiazolyl Blue Terazolium Bromide 
(Alfa Asar, U.S.) in PBS at 37oC was added to each wells. Plates were incubated on 
a shaker at room temperature until a purple precipitate was visible, typically for 10 
minutes.  Once the purple precipitate formed the MTT solution was removed, plates 
dried and the product dissolved in DMSO (Sigma, UK). The sample was pipetted 
into 96 well-plate wells in duplicate. Optical density of the samples was measured in 
a microplate reader, Spectra MAXPlus (Molecular Devices, U.S.) at single wave 
length 545 nm. The values averaged and were compared to non-treated controls.  
. 
2.2.5 Bradford assay 
Protein concentrations in samples were measured by Bradford assay. Bradford 
assay is a colormetric assay using the dye Comassie Brilliant Blue G-250.  When 
binding to protein, the product was read at 595 nm. The change in optical density 
was used to calculate the protein contents in the samples. Samples were diluted in 
PBS so as to fit the range of standard. Protein standard (0-2 mg/ml) was made with 
BSA in phosphate buffered saline (PBS). 2-5 l diluted sample and standard was 
pipetted in duplicates into a 96 well plate. Bradford reagent (Sigma, UK) was diluted 
1 in 2 in PBS and added to each well to give sample to reagent ratio of 1 to 50. 
Optical density was measured in a microplate reader, Spectra MAXPlus (Molecular 
Devices, U.S.) at single wave length 595 nm. The duplicates were averaged and 
background signal subtracted. Protein contents in the samples were calculated from 
the standard. 
 
2.2.6 Whole cell protein preparation for Western blot analysis 
After treatment procedures cell were prepared for Western blot analysis as follows. 
Cells were collected in conical bottom cryotubes with PBS supplied with protease 
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inhibitor cocktail at 4oC.  The tubes were centrifuged at 10000 x g for 7 minutes and 
supernatant was discarded. Cell pellets were snap frozen in liquid nitrogen and 
stored in -70 oC freezer until use. The cell pellet was lysed by sonication at 4oC in 
PBS containing protease inhibitor cocktail. The protein concentration in each sample 
was measured by Bradford assay, see 2.2.5. Four times concentrate SDS-PAGE 
sample buffer, 62.5 mM Tris-HCL, 20% (v/v) Glycerol, 2% (w/v) SDS, 5% (v/v) -
mercaptoethanol with trace amount of bromophenol blue was added 3 parts cell 
sample in PBS. The final protein concentration of the loading sample was 1 mg/ml 
protein. The following equation 2-1 was used to calculate the proportion of loading 
buffer, sample and PBS used, with FV being the final volume of sample prepared 
and FPC being the final protein concentration. The loading sample mixture was 
boiled in hot water bath for 2-3 minutes. Samples were used immediately or were 
stored at -20oC until loading. 
 
 
𝐹𝑉 = 𝐹𝑖𝑛𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 (𝑚𝑙) 
𝑆𝑃𝐶 = 𝑆𝑎𝑚𝑝𝑙𝑒 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (
𝑚𝑔
𝑚𝑙
) ; 𝑤ℎ𝑒𝑟𝑒 𝑆𝑃𝐶 ≥
1.333𝑚𝑔
𝑚𝑙
 
𝐹𝑃𝐶 = 𝐹𝑖𝑛𝑎𝑙 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 =
1𝑚𝑔
𝑚𝑙
 
𝐹𝑉
4
= 𝑺𝑫𝑺𝑷𝑨𝑮𝑬 𝒔𝒂𝒎𝒑𝒍𝒆 𝑳𝒐𝒂𝒅𝒊𝒏𝒈 𝒃𝒖𝒇𝒇𝒆𝒓 (𝒎𝒍) 
𝐹𝑉 ∗
𝐹𝑃𝐶
𝑆𝑃𝐶
= 𝒔𝒂𝒎𝒑𝒍𝒆 (𝒎𝒍) 
𝐹𝑉 − 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 𝑏𝑢𝑓𝑓𝑒𝑟 𝑣𝑜𝑙𝑢𝑚𝑒 − 𝑠𝑎𝑚𝑝𝑙𝑒 𝑣𝑜𝑙𝑢𝑚𝑒 = 𝑷𝑩𝑺 (𝒎𝒍) 
 
Equation 2-1 Calculation of Western blot sample volume 
This formulation is used to calculate the volume of SDS-PAGE (sodium dodecyl sulfate 
polyacrylamide gel electrophoresis) sample loading buffer, sample and PBS to prepare 
samples for Western blot. 
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2.2.7  Plasma membrane protein isolation 
Plasma membrane proteins were isolated using a protein biotinylation and capture 
method. Pierce Cell Surface Protein Isolation Kit (Thermo Fisher Scientific, U.S.) 
was used according to manufacturer’s guidelines. Isolation of the plasma membrane 
protein was carried out using 3 x 107 cells per sample. After cell surface proteins 
were labelled with 1 mg/ml sulfo-NHS-SS-Biotin (Thermo Fisher Scientific, U.S.), the 
cells were lysed in PBS containing protease inhibitor cocktail and 1% IGAL-CA60 by 
sonication at 4oC. The labelled proteins in post nuclear supernatants, separated by 
centrifugation, were captured with neutroavidn agarose. The captured protein was 
eluted with SDS-PAGE sample buffer, containing 50 mM 1,4-Dithiothreitol (DTT). 
The protein contents in elute were measured by Bradford assay. Samples were 
prepared for Western blot analysis as outlined in 2.2.6. As the total amount of 
plasma protein obtained is lower than total whole cell protein, the FPC of the loaded 
sample was 0.2 mg/ml. During the Western blot analysis the absence of the 
cytosolic protein, Akt, was used to validate plasma membrane isolation process 
Figure 2-2. 
 
 
Figure 2-2 Validation of the plasma membrane isolation  
Absence of the cytosolic protein Akt in the plasma membrane isolate (PM) and its presence 
in whole cell lysate (WC) from resting RAW264.7 macrophages. 7 g protein loaded per lane. 
Left indicates molecular weight in kDa. -action was used as a loading control.  
2.2.8 Nuclei isolation 
Nuclei from RAW264.7 macrophages were isolated using a detergent, NP-40, and 
low speed centrifugation as previously described (Antalis and Godbolt, 1991). 1x107 
cells were re-suspended at 4°C in lysis buffer composed of 8 mM Tris-HCl and 2 
mM Tris-Base, 10 mM NaCl, 3 mM MgCl2 and 0.8% NP-40 pH=7.5, Table 2-2, with 
protease inhibitor cocktail in small tubes with conical bottom. The tubes were 
-actin 
Akt 
80 
58 
46 
WC PM 
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centrifuged twice at 180 x g for 15 minutes. To prevent further lysis of nuclear 
membranes, NP-40 was washed from the cells by re-suspension with buffer 8 mM 
Tris-HCl and 2 mM Tris-Base, 10 mM NaCl, 3 mM MgCl2 pH=7.5, Table 2-2,   and 
centrifugation at 180 x g for 10 minutes at 4°C.  The obtained nuclei pellets were 
resuspended in buffer without NP-40. The nuclei integrity was checked using a 
confocal microscopy by visualizing DNA with DAPI staining. The isolated nuclei was 
lysed in PBS containing protease inhibitor cocktail by sonication at 4 oC and protein 
concentrations in the lysate was measured by Bradford assay. Samples were 
prepared for Western blot analysis as outlined in 2.2.6. 
 
2.2.9 Rat brain homogenise preparation 
Rat brain was used as a positive control for BK detection in Western blot. Rat brain 
tissue was kindly given by Professor Dickenson’s group at the department of 
Neuroscience, Physiology and Pharmacology in UCL. In his laboratory, all 
procedures associated with animals were approved by the UK Home Office. The rat 
brain was homogenised in 5 mM phosphate buffer supplemented with 320 mM 
sucrose and protease inhibitor cocktail using a glass squeezer. The homogenate 
was transferred to 1.5 ml conical bottom tubes and span at 800 x g for 5 minutes. 
The obtained pellet was suspended in the phosphate buffer and lysed in PBS 
containing protease inhibitor cocktail by sonication at 4oC and protein concentrations 
in the lysate were measured by Bradford assay. Samples were prepared for 
Western blot analysis as outlined in 2.2.6. 
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Figure 2-3 BK expression in rat brain lysate 
BKexpression in rat brain lysates was analysed by Western blot using anti-mouse BK 
antibodies, L6/60 and APC-107. 10 g protein was loaded each lane. Left indicates the 
molecular weight marker in kDa. Experiment was repeated for 5 times with L6/60 and twice 
with APC-107. 
2.2.10 Western blot analysis 
Gel casting, sample loading and transfer were performed using Mini-PROTEAN® 
Tetra Handcast Systems (Bio-rad, UK). SDS-PAGE gels were constructed by free 
radical polymerization of acrylamide and a monomer cross-linker bis-acrylamide. 
Pores between the polymers permit the movement of denatured protein in samples. 
SDS-PAGE gels were hand casted using the casting set in the Mini-PROTEAN® 
system. First Tris-HCl buffers, diH2O, acrylamide and bis-acrylamide solution were 
mixed and solution was degassed. Polymerization is initiated by adding APS with 
TEMED acting as a catalyst. Once the first layer of running gel has set, the second 
layer was poured. Pore sizes in polyacrylamide gels were determined by the 
percentage of acrylamide, APS and TEMED. To yield the best separation of the 
protein samples for the analysis, the composition of the running gel was changed 
depending on the molecular size of the target protein. For proteins, between 15 kDa 
and 60 kDa, 12.5% gels were used and for proteins larger than 60 kDa 7.5% gels 
were used. Stacking gel was made at 4.5%. Table 2-4 summarizes the formulation 
of the gels, which are total of 50 ml running gel solutions and 20 ml stacking gel 
L6/60 APC-107 
80 
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58 
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solution, typically used to make 4 gels. Gels were used immediately after pouring or 
stored in a fridge with hydration for up to one week before use. 
 
Gels are assembled in an electrophoresis chamber. 7 l pre-stained protein 
standard was load first lane of gel. Equal amount of sample protein, as prepared in 
2.2.6, was loaded on to gels. The amount of protein loaded per lane was typically 
between 1 to 10 g. Proteins were separated in the chamber filled with electrode 
buffer, Table 2-2. A constant voltage of 180 V applied until the protein sample 
reached the bottom of the gel and this was typically for 1 hour. The gel was 
assembled in transfer cassette and protein in the gels were transferred to 
nitrocellulose membranes (Thermo Fisher Scientific, U.S.) in transfer buffer by 
application of a constant voltage at 100 V for 1 hour. 
 
The membranes were blocked with 5% non-fat milk, 0.01% BSA and 0.1% Tween-
20 in tris-buffered saline (TBS) for 2 hours at room temperature with gentle shaking. 
Subsequently membranes were stained with primary antibodies overnight at 4oC 
with gentle shaking. The dilution factors and conditions for each primary antibody 
are summarized in Table 2-5. The membranes were washed with tris-buffered saline 
with tween-20 (TBS-T) for 10 minutes for 3 times on a shaker. The relevant 
secondary HRP-linked anti-mouse IgG or anti-rabbit IgG antibodies were applied to 
the nitrocellulose membranes. Non-specific binding of the secondary antibodies was 
tested by incubating the samples without primary antibody. Protein bands were 
visualized by chemiluminescence using Pierce ECL2 Western Blot Substrate 
(Thermo Fisher Scientific, U.S.) and scanned by a phosphor imager (Typhoon 9410 
variable made imager, GE Healthcare UK).  
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Reagent Stacking gel  
(20 ml total) 
7.5% running gel  
(50 ml total) 
12% running gel 
(50 ml total) 
30% Acrylamide/bis-
acrylamide 
2.6 ml 12.5 ml 20 ml 
0.5 M Tris-HCl 
pH 6.8 
5 ml - - 
1.5 M Tris-HCl 
pH 8.6 
- 12.5 ml 12.5 ml 
10% SDS 0.2 ml 0.5 ml 0.5 ml 
diH2O 12 ml 24.3 ml 16.8 ml 
TEMED 20 l 25 l 25 l 
10% (w/v) APS 0.1 ml 0.25 ml 0.25 ml 
Total volume 20 ml 50 ml 50 ml 
 
Table 2-4 Formulations for SDS-PAGE gel 
Formulation of sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels 
20 ml of stacking gel solution and 50 ml of running gels. This volume can make up 4 mini-
gels (8.6 cm x 6.7 cm). Ammonium persulfate (APS), prepared as 10% (W/W) solution in 
distilled water (diH2O). TEMED: tetramethylethylenediamin. 
2.2.10.1 Calibration of the molecular weight 
The molecular weight of protein bands was estimated using a pre-stained colour 
protein standard. This also confirms the samples on the gels were separated and 
transferred correctly. The marker is a visible colour (wavelength: 390 -700 nm) when 
transferred to the nitrocellulose but the colour does not appear when imaged with 
blue lazer (wavelength : 450 nm).  
To calibrate molecular weight, initially the left side of the membrane was cut at each 
colour indicator so that the marker is visible even under the phosphor-imager. 
However this process caused damage on the membrane and affected the quality of 
the image. Thus this calibration was done by matching the final image taken in the 
phosphor-imager and the photo taken in the same size prior to the application of 
chemiluminescence reagents as the colour marker fades immediately after the 
phosphoimage, Figure 2-4a. This analysis was followed in the Western blot and the 
calibrated molecular weight was indicated as bars, Figure 2-4a and b. These results 
were recorded in the form presented in Figure 2-4b not in the colour photo shown in 
Figure 2-4a. Molecular weights are marked as bars shown in Figure 2-4b when the 
antibody was first used and following blot, the bands at corresponding molecular 
weights were presented as in Figure 2-4c. 
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Figure 2-4 Calibration method for molecular weight in Western Blot analysis 
a) After sample transfer to nitrocellulose membrane a photograph was taken. After protein 
bands were developed in a phosphor imager, a) the two images were compared and the 
molecular weight were annotated on the image as bars. b) Western blot results were 
recorded with the annotations determined by process. These annotated images b) were 
used when an antibody was first applied. Subsequent experiments presented c) the bands at 
relevant molecular weight. 
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2.2.10.2 Densitometry analysis 
Densitometry analysis was carried out to semi-quantify the expression level of the 
protein bands of interest. The results are presented in order to show the relative 
expression in the treatment groups compared to control groups. Image Quant 5.2 
(Molecular Dynamics, USA) was used for these analyses. Boxes of equal size were 
drawn around each band. The local median background signals were excluded and 
band intensity normalized to-actin in samples prepared from whole cell lysates. 
Relative band intensities, mean+SEM (n=number of blots used for analysis) of 
treatment groups were expressed as a ratio of the mean intensity of control bands. 
The relative expression in treatment groups was presented as ratio to the relevant 
control group. Therefore statistical analysis has not been made in the densitometry 
analysis as no bench marking standards was available and only comparison within 
the same gel can be made. 
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Primary antibody Secondary antibody 
Antibody name ( Target 
protein) 
Manufacturer Host species Dilution Diluent Incubation  Antibody name  Manufacturer Host 
species 
Dilution Diluent Incubation 
L6/60 
(Mouse BK 
Milipore, UK Mouse 
monoclonal 
1 in 1000 TBS Overnight 4 
o
C Anti-mouse IgG HRP-linked 
Antibody 
Abcam, U.S. Horse 1 in 4000 TBS 50 min 
RT 
ab2051(Mouse  
ADAM17) 
Abcam, U.S. Rabbit 
polyclonal 
1 in 750 TBS Overnight 4 
o
C Anti-rabbit IgG HRP-linked 
Antibody 
Cell Signaling 
Technology, U.S. 
Goat 1 in 4000 TBS 50 min RT 
anti-Akt  rabbit 
polyclonal antibody 
(Mouse Akt) 
Cell Sigaling 
Technology, U.S. 
Rabbit 
polyclonal 
1 in 1500 TBS Overnight 4 
o
C Anti-rabbit IgG HRP-linked 
Antibody 
Cell Signaling 
Technology, U.S. 
Goat 1 in 4000 TBS 50 min RT 
APC-107 
(Mouse/Human BK  
Cell Sigaling 
Technology, U.S. 
Rabbit 
polyclonal 
1 in 1500 TBS 
0.1%BSA 
Overnight 4 
o
C Anti-rabbit IgG HRP-linked 
Antibody 
Cell Signaling 
Technology, U.S. 
Goat 1 in 4000 TBS 50 min RT 
D2D4 (Mouse TNF- Cell Sigaling 
Technology, U.S. 
Rabbit 
monoclonal 
1 in 1500 TBS Overnight 4 
o
C Anti-rabbit IgG HRP-linked 
Antibody 
Cell Signaling 
Technology, U.S. 
Goat 1 in 4000 TBS 50 min RT 
D6A8(Mouse/Human -
actin) 
Cell Sigaling 
Technology, U.S. 
Rabbit 
monoclonal 
1 in 2000 TBS Overnight 4 
o
C Anti-rabbit IgG HRP-linked 
Antibody 
Cell Signaling 
Technology, U.S. 
Goat 1 in 4000 TBS 50 min RT 
DM3568 (Mouse IL-
6R) 
2B Scientific, UK Rat 
monoclonal 
1 in 500 TBS Overnight 4 
o
C Anti-rat IgG HRP-linked 
Antibody 
Cell Signaling 
Technology, U.S. 
Goat 1 in 4000 TBS 50 min RT 
Table 2-5 Sources and experimental conditions for antibodies in Western blot 
Description of antibodies (antibody name, source and experimental conditions) used in Western blot analysis. BSA: bovine serum albumin, 
TBS: tris-buffered saline, RT: room temperature, HRP: horse radish peroxidase. 
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Figure 2-5 Blots stained with secondary antibodies without primary antibodies 
Protein samples from whole cell lysate of RAW264.7 macrophages and rat brain lysates. 
Proteins were loaded 10 g per each lane. Secondary antibodies, goat anti-rabbit IgG HRP-
linked secondary antibody and goat anti-mouse IgG HRP-linked antibody were used at 1 in 
4000 dilution. The experiments were repeated twice and blots show representative. 
2.2.11 Electrophysiology 
Whole cell voltage clamp recordings were performed at room temperature. 
Macrophages were plated on 13 mm glass coverslips chosen to fit the 
electrophysiology recording chamber. Pipettes were made using thin walled 
borosilicate glass (Harvard, Germany), heat-pulled and polished. When filled with 
pipette solution, the pipette had a resistance between 3.5 - 4 MΩ. Pipette solution 
was based on 120 mM K-acetate, 20 mM HEPES, 10 mM KCl, 5 mM EGTA, 1 mM 
MgCl2 and 4 mM CaCl2 with pH=7.2. Free Ca
2+ in the solution was estimated as 1.6 
M using a software, MAXCHELATOR (Stanford University, U.S.). For initial 
recordings, pipette solution with free Ca2+ at 10 nM was also used, Table 2-2. The 
extracellular solution was a modified Kreb’s; 125 mM NaCl, 26 mM NaHCO3, 2.5 
mM KCl, 1.26 mM NaH2PO4 H2O, 25 mM D-glucose and 1 mM CaCl2 with pH=7.4. 
The osmolality of the pipette solutions and extracellular solutions were maintained 
between 250-300 mOsmol. Currents were recorded using an Axopatch 200B 
amplifier (Axon Instruments, U.S.) at the sample rate of 5 kHz and filtered at 1kHz 
80 
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58 
46 
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Rat brain  RAW264.7  Rat brain  RAW264.7  
Anti-rabbit IgG Anti-mouse IgG  
 
 Chapter 2 Material and method 
 
77 
 
with Digitata 1332A (Molecular Devices, U.S.). Once a high resistance seal (>2 GΩ) 
was formed, a ramp protocol (25 second with 10 second sweep ranging from -40 to 
100 mV) was applied, Figure 2-6. 3 mM TEA and 30 nM IbTX were applied in 
extracellular solutions. pH of the extracellular solution was adjusted when TEA was 
used. For each treatment and control, ramp was repeated at least 5 times and the 
traces were averaged. There was 5-7 minutes interval between different drug 
applications. Both IbTX and TEA are reversible channel blockers and whole cell 
current are to recover during re-application of ramps in Kreb’s. Macrophage 
possesses pseudopodia on their cell surfaces, and the blockade of glass pipette 
electrode could easily occur. To test whether reduction in current was due to the 
channel blocking, control ramps were repeated several times to observe recovery 
and after the blocker application. TEA- and IbTX-sensitive currents were obtained by 
subtracting average traces in presence of TEA or IbTX from control traces. Net 
membrane currents were plotted against membrane voltage. Recordings were 
carried out at room temperature. pCLAMP software (Molecular Devices, U.S.) was 
used to monitor current magnitude and duration, establish voltage ramp protocols 
and analyze the data.  
 
Figure 2-6 Voltage ramp protocol for whole cell recordings 
A ramp protocol was established using pCLAMP software and applied in 35 second interval. 
Between 0 to 10 second voltage remained -60 mV. At 10 second, the membrane voltage 
was dropped to -100 mV and raised to 40 mV during 10 to 20 seconds. Between 20-35 
second voltage was kept -60 mV and the protocol was repeated. The ramp protocol was 
applied at least 5 times per treatment and the obtained traces were averaged. 
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2.2.12 Cytokine and cytokine receptor assays 
Macrophages were plated at 2.5x105 cells per well on 24 well plates and incubated 
overnight. The following day, the media was replaced and the cells received various 
drug treatments. After treatments, media was collected and kept in a -20°C freezer 
until analysis. Released cytokines and cytokine receptors, TNF-, IL-6R and IL-6, 
from macrophages were assessed using ELISA kits (R & D Systems, U.S.), 
according to the manufacturer’s protocol. All procedures were performed at room 
temperature. First the plate was coated with a relevant capture antibody in PBS 
overnight. Following day, the plates were washed with phosphate buffered saline 
with tween-20 (PBS-T) and blocked with 1% BSA in PBS for 1 hour. Cytokine/ 
cytokine receptor standards were prepared in a range between 0-1000 ng/ml in PBS 
containing 0.5% BSA. Samples were diluted in PBS containing 0.5% BSA, so as to 
achieve cytokine concentrations which fit with the standard curve of the kit. The 
standard and diluted samples were pipetted in duplicate. After 2 hours incubation, 
plates were washed with PBS-T and incubated with a secondary antibody, followed 
by wash and incubation with HRP. The color was developed using TMB substrate 
diluted in citrate buffer and optical density were measured in a microwell plate 
reader, Spectra MAXPlus (Molecular Devices, U.S.) at a wavelength 405 nm with 
650 nm corrections. The results were averaged and a cytokine concentration in the 
samples was calculated using the standard curve. The detection limits of kits are 
31.6 pg/ml for TNF- and IL-6, or 15.6 pg/ml for IL-6R. Figure 2-7 shows typical 
standard curves for TNF-, IL-6 and IL-6R. 
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Figure 2-7 ELISA standard plots for TNF-, IL-6 and IL-6R  
TNF-, IL-6 an IL-6R were prepared at the concentrations from 0-1000 pg/ml for TNF- 
and IL-6 or 0-500 pg/m for IL-6R in PBS containing 0.5% BSA and used as a standard for 
each plate in ELISA. Standard plots were fitted to curves using non-liner regression analysis 
using Graph pad prism software (Graphpad, U.S.). O.D.: Optical density.  
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2.2.13 RNA extraction and cDNA synthesis 
Total RNA was extracted from RAW264.7 macrophages using RNAsay mini-kit 
(Qiagen, UK) according to manufacturer’s instruction. The procedure extracts RNA 
molecules longer than 200 nucleotides. This feature provides relatively selective 
isolation of mRNA and exclusion of shorter RNAs, rRNA and tRNAs (<200 
nucleotides). Frozen cell pellets, containing 1x106 cells per group, were lysed and 
homogenized in a supplied lysis buffer supplied with 0.1% -metacaptoethanol 
(Sigma, UK) by votexing until participate clears. The lysates were centrifuged for 30 
seconds at 13000 x g in RNase free collection tubes with gDNA eliminator column.  
Total RNA in flow through was combined with 70% ethanol and salt and captured in 
the RNA binding column. RNA binding column washed twice with supplied washing 
buffers and centrifugations at 13000 x g for 15 seconds twice. RNA was eluted in 
water and stored in a -20 oC freezer.  The quality and purity of RNA were assessed 
by OD260/280 ratio, which is measured using a spectrophotometer (DU800; 
Beckman Coulter, U.S.). Complementary DNA (cDNA) was synthesized using the 
Superscript III Reverse transcriptase kit (Thermo Fisher Scientific, U.S.) with 
random primers (Thermo Fisher Scientific, U.S.) according to the manufacturer’s 
instructions. 2 g total RNA was mixed with 125 ng random primers, 10 ng dNTP 
Mix and RNase free DEPC treated water. The mixture was heated at 65°C for 5 
minutes to denature RNA. The mixture containing single stranded RNA was mixed 
with 4 l 5 x first stranded buffer, 200 units SuperScript™III RT, 1 nmol DTT and 1 
l RNaseOUT. After mixing, tubes were incubated at 25°C for 5 minutes for 
annealing. The mixture was heated at 50°C for 45 minutes to extend the strand. The 
reaction was inactivated by heating at 70°C for 15 minutes and cDNA for PCR 
template was obtained. 
 
2.2.14 Real time-quantitative PCR 
RT-QPCR was performed to assess mRNA level of TNF- from cDNA. Taqman 
custom gene expression assay (Thermo Fisher Scientific, U.S.) and the ABI Prism 
7900HT sequence detection system (Thermo Fisher Scientific, U.S.) were used. The 
probes for mouse TNF-(Mm00443260_g1, Thermo Fisher Scientific, U.S.) and 
mouse -actin (Mm00607939_s1, Thermo Fisher Scientific, U.S. ) were used. The 
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assay was set up in accordance with Taqman protocols. cDNA samples were diluted 
in DEPC treated RNase DNase free water. Master mixes for TNF- and -actin 
were made and sample dilution was added to each mix. The sample was loaded on 
the plates in triplicate and blank control was DEPC RNase and DNase free water. 
The PCR was performed. The background signal was subtracted and values were 
averaged. TNF- expression level was normalized to -actin. Experiments were 
repeated with n=3 per treatment group and shows representative data and is 
expressed as mean+SEM. 
 
2.2.15 Gene silencing 
Most effective BKsilencing in RAW264.7 macrophages in this thesis was observed 
when Lipofectamine® RNAiMAX reagent was used (Thermo Fisher Scientific, U.S.). 
Two silencing siRNAs for mouse BK Mm_Kcnma1_1 FlexiTube siRNA, termed 
sequence 1 (Catalogue number: SI00194369, Qiagen UK) and Mm_Kcnma1_5 
FlexiTube siRNA, termed sequence 5(Catalogue number: SI02670486 , Qiagen, 
UK) were used. Sequence 1 targets the sequence, CAC AAT GTC TAC AGT GGG 
TTA, and sequence 5 targets the sequence, CAG TTT CTG AAT ATC CTT AAA. 
These siRNAs were reconstituted in RNase free water to 10 M and stored at -20 oC. 
A non-silencing siRNA, Negative Control siRNA (Catalogue number: 1022076, 
Qiagen, UK) targeting sequence AAT TCT CCG AAC GTG TCA CGT was used. 
Stocks for non-silencing siRNA was made in RNase free water at the concentration 
of 20 M and stored at -20oC. RAW264.7 macrophages was plated in T25 cm2 cell 
culture flasks at 1.25 x 106 cells per flasks and each flask had and 6 ml of complete 
culture media supplied with 10% FBS, 100 unit/ml penicillin and 100 g/ml 
streptomycin. After overnight incubation, siRNAs and transfection reagents were 
diluted (siRNA 0.2 M, Lipofectamine® RNAiMAX 1 in 25) in OptiMEM (Thermo 
Fisher Scientific, U.S.). After 5 minutes, siRNA and transfection reagents were 
mixed and the mixture was incubated for further 20 minutes for the transfection 
complex to form. 90 pmol of total siRNA and 27 l of Lipofectamine® RNAiMAX 
were used per 25 cm2 flasks which were used for each transfection the final siRNA 
concentration was 15 nM during the transfection. Macrophages were incubated with 
the transfection complex for 72 hours. The effect of silencing was determined by 
Western blot analysis of BK. 
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In initial experiments, first GeneMute™ (SignaGen® Laboratories, U.S.) reagent 
was used in attempt to inhibit the expression of BK in RAW264.7 macrophages. 
GeneMute™ regent was used following the manufacturer’s instructions. Briefly, 
RAW264.7 macrophages were plated at 5 x 105 cells per well in 6 well plate and 
each well contained 1.5 ml complete media. siRNAs were diluted into 10 M in 150 
l GeneMute™ reagent. The siRNA-transfection mixture was incubated for 15 
minutes to form transfection complex. The complex was added to each well and the 
cells were incubated for 48 hours.   
 
Second, Viromer® Blue (Lipocalyx, Germany) reagent was used in attempt to inhibit 
BK expression in RAW264.7 macrophages. The reagent was used following the 
manufacture’s instruction. Briefly RAW264.7 macrophages were plated at 5 X 105 
cells per well in 6 well plate and each well contained 1.5 ml culture media. 15 pmol 
siRNA was diluted in Blue Buffer, supplied, and Viromer® transfection reagent was 
mixed.  The mixture was incubated for 15 minutes at room temperature to allow 
transfection complex to form. 150 l transfection complex was added to each well 
and after 48 hours of incubation. The cells were analyzed for the expression of BK. 
See chapter 7 for the validation of silencing protocols. 
 
2.2.16 ADAM17 activity assay 
Proteolytic activity of ADAM17 was assessed by monitoring cleavage of TACE 
substrate II (fluorogenic) in living macrophages. The method was adapted from a 
paper by Alvarez-Iglesias et al (Alvarez-Iglesias et al., 2005). The enzyme substrate 
was added directly on to cells in culture and this configuration enabled the 
assessment of the plasma membrane expressed ADAM17 activity in living cells. 
RAW264.7 macrophages were plated at 4.8 x 104 cells per well on a 96 well 
fluorescence plate with complete DMEM and received relevant treatment. As the 
phenol red contained in normal DMEM interfered with fluorescence signal, the 
media was replaced with phenol red free DMEM supplemented with 4 mM L-
glutamine (Thermo Fisher Scientific, U.S.) on the day of the activity assay. Three 
hours before the assay, the macrophages were activated with 150 ng/ml LPS. TACE 
substrate II fluorogenic (BML-P228, Enzo Life Sciences, UK) reconstituted in DMSO, 
directly dissolved in the assay media and applied to the cells at the final 
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concentration of 5 M. Immediately, fluorescence signals were measured for 60 
minutes using a fluorescence plate reader (Mithras LB 940, Thermo Fisher Scientific, 
U.S.) in 15 minutes interval. Samples containing no TACE substrate acted as 
negative control. A general inhibitor for membrane metalloproteases, 4.5 M 
GM6001, and a selective inhibitor for ADAM17, 0.6 M TAPI-0, were used to 
confirm that the fluorescence signal was due to the ADAM17 activity. Activity was 
calculated as change in fluorescence per minute in each well, this is expressed as 
fluorescence/minute for clarity. Results state per minute increase of fluorescence 
signal as mean+/-SEM and stated in text. Each experiment was repeated with n=3 
or 4 per treatment group. Figure 2-8 shows the data from 150 ng/ml LPS stimulated 
RAW264.7 macrophages with or without 4.5 M GM6001 or 0.3 M TAPI-0. 
 
 
Figure 2-8 ADAM17 activity in macrophages and the effect of GM6001 and 
TAPI-0 
RAW264.7 macrophages were stimulated with 150 ng/ml LPS for 3 hours and TACE II 
substrate was applied at 5 M with/without inhibitors for ADAM17, 4.5 M GM6001 or 0.3 M 
TAPI-0. Control wells received DMSO and all wells had 0.15 % DMSO during assay. 
Fluorescence signals were monitored in 10 minutes interval for 60 minutes and the rate of 
change in fluorescence between 10 to 50 minutes was expressed as ADAM activity 
(fluorescence/minute). The graph shows results from n=3 repeated experiments. 
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2.2.17 Immune fluorescence imaging 
RAW264.7 macrophages were plated at 1.3 x 104 cells per 13 mm circular glass 
coverslips. Macrophages were treated with 10 ng/ml LPS for up to 24 hours and 
fixed by incubation with 4% paraformaldehyde in PBS for 5 minutes and washed 
with PBS twice. The coverslips were blocked for one hour at room temperature on a 
shaker with 10% goat serum and 4% BSA in PBS. For staining of BK, mouse 
monoclonal anti-moue BK antibody, L6/60 (Millipore, UK), was used. RAW264.7 
macrophage is a mouse cell line, and it was predicted that specific binding of Alex 
Fluor® 488 anti-mouse IgG secondary antibody (Thermo Fisher Scientific, U.S.) to 
the endogenous cellular like Ig molecules could result in high background. To avoid 
this problem, 1.25 g/ml anti-mouse IgG was added to the block solution and 
incubated for 2 hours prior to the primary antibodies to mask endogenous Ig. The 
coverslip was washed twice with PBS. The coverslips were then incubated with 
L6/60 diluted to 1 in 750 in 5% goat serum and 2% BSA in PBS at 4oC overnight. 
The coverslips were washed twice for 5 minutes with PBS. Alex Fluor® 488 anti-
mouse IgG secondary antibody was used to conjugate fluorescence dye to the 
primary antibody bind the cells. The secondary antibodies were diluted to 1 in 4000 
in 5% goat serum and 2% BSA in PBS for 2 hours at room temperature. The 
coverslips were washed for 5 minutes twice. To visualize nuclei of macrophages, 
DAPI diluted 1 in 10000 in PBS, was applied for 5 minutes. The coverslips were 
washed for 5 minutes twice. The coverslips were mounted on glass slides with 
Vectashield (Vector Laboratories, U.S.). Fluorescence was visualized using a 
confocal microscopy (Zeiss LSM510 Meta, Carl Zeiss, Germany). Coverslips without 
primary antibody incubation were also prepared and the gain of microscope was 
adjusted so that no fluorescence signal was seen in these secondary antibody only 
control samples. This allowed to record the fluorescence signal due to the primary 
antibody binding and not resulting from non-specific binding of the secondary 
antibody to the cell to be recorded, 8. Images were taken from an area with 15-20 
cells with the size indicated in the image. Experiments were repeated at least 3 
times and resentative images are shown in figures.  
  
 
 Chapter 2 Material and method 
 
85 
 
 
 
 
Figure 2-9 Immunofluorescence imaging of macrophages 
RAW264.7 macrophages were paraformaldehyde fixed and stained with antibodies (Ab) and 
DAPI. Left panel shows a cell stained with anti-BK (L6/60) following incubation with a 
secondary antibody and DAPI.  The right panel shows a cell incubated with a secondary 
antibody and DAPI without primary antibody staining. Scale bar: 5 m.  
2.2.18 Statistical analysis 
Statistical significance among treatment groups were tested using one-way ANOVA 
and the significance between control group and treatment group was tested by 
Dunnet’s test following one-way ANOVA. Alternatively paired t-test was performed 
where there were only two groups. The name of test performed was indicated in 
each figure legend. Graphpad Prism (Graphpad Software, U.S.) was used to 
perform these tests. A p-value less than 0.05 was considered to be significant and 
expressed as *p<0.05, **p<0.01 and ***p<0.001 in figures. 
 
Value stated in the text is from one example from repeated experiments. Figures in 
this thesis present both data from one experiment, which are quoted in text as well 
as combined data from all repeated experiments. Comments were made in the end 
of each result section to discuss these data from single experiment and aggregate 
data. The number of biological replicates, blots or cells for each experiment (n) is 
indicated in the figure legend.  
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 Chapter 3 How macrophages change TNF-, IL-6 and IL-6R 
release during TLR4 activation? 
3.1 Introduction 
Inflammatory stimuli are recognised by receptors expressed on immune cells and 
this recognition leads to the activation of inflammatory responses from the cell. 
Activated immune cells release a variety of inflammatory mediators which have 
important roles in controlling immune responses. Monocytes and macrophages are 
known to be the major source of these mediators during inflammation.  
The aim of this short chapter is to characterise cytokine release from macrophages 
in response to TLR4 activation. Three proteins released from macrophages, TNF-, 
IL-6 and IL-6Rwere studied. LPS, a classical TLR4 activator, was used to activate 
macrophages at doses ranging from 3 to 1000 ng/ml. After 4 or 24 hours of LPS 
treatment, the concentration of these proteins in culture media was analysed. 
 
3.2 Results 
Stimulation of macrophages with LPS, 1 to 100 ng/ml, increased the release of TNF-
 in dose-dependent manner. The maximum TNF- release occurred with 100 
ng/ml LPS and was 32.6+/-1.0 ng/ml at 4 hours and 41.7+/-3.0 ng/ml at 24 hours, 
Figure 3-1 a and b. LPS stimulation also induced the release of IL-6 in dose 
dependant manner at doses from 10 to 1000 ng/ml. The maximum IL-6 release 
occurred at LPS dose of 1000 ng/ml with 0.63+/-0.02 ng/ml at 4 hours and 2.3+/-
0.08 ng/ml at 24 hours, Figure 3-2 a and b. IL-6Rwas constitutively released from 
macrophages and was 66.4+/-3.9 pg/ml at 4 hours and 328+/-14.8 pg/ml at 24 hours, 
Figure 3-3 a and b. LPS did not alter IL-6Rrelease from macrophages during the 
first 4 hours of incubation and was 65.8+/-4.1 pg/ml with 100 ng/ml LPS, however 
after 24 hours, LPS dose-dependently inhibited IL-6R release with the minimum IL-
6R release at 24 hours was occurring at 100 ng/ml LPS and was 104+/-10.3 pg/ml, 
Figure 3-3 a and b.  Additional increases in the dose of LPS had no further effect, 
Figure 3-3 a and b. MTT assays indicated that LPS doses had no significant effect 
on cell viability at either 4 hours or 24 hours, Figure 3-4 a and b.  The combined 
data, from repeated (≥ 3 times) experiments, for protein release and MTT was in line 
with the described results from individual experiments. These combined data were 
presented in Figure 3-1, 3-2, 3-3 and 3-4. 
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Figure 3-1 TNF- release from LPS activated macrophages 
RAW264.7 macrophages were treated with 0-1000 ng/ml LPS for a) & c) 4 hours or b) & d) 
24 hours. TNF- in conditioned was media measured by ELISA. Bars show mean+SEM 
(n≥3). a) & b) shows result from one experiment with n=4. c) & d) show combined data from 
3 experiments. 
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Figure 3-2 IL-6 release from LPS activated macrophages 
RAW264.7 macrophages were treated with 0-1000 ng/ml LPS for a) & c) 4 hours or b) & d) 
24 hours. IL-6 in conditioned was media measured by ELISA. Bars show mean+SEM (n≥3). 
a) & b) shows result from one experiment with n=3. c) & d) show combined data from 3 
experiments. 
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Figure 3-3 IL-6R release from LPS activated macrophages 
RAW264.7 macrophages were treated with 0-1000 ng/ml LPS for a) & c) 4 hours or b) & d) 
24 hours. IL-6R in conditioned was media measured by ELISA. Bars show mean+SEM 
(n≥3). a) & b) shows result from one experiment with n=3. c) & d) show combined data from 
3 experiments. 
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Figure 3-4  Effect of LPS treatment on macrophage cell viability  
RAW264.7 macrophages were treated with 0-1000 ng/ml LPS for a) & c) 4 hours or b) & d) 
24 hours. Cell viability was assessed by MTT. Bars show mean+SEM (n≥3). a) & b) show 
the result from one experiment with n=4 and c) & d) show combined data from 3 experiments.   
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3.3 Discussion 
Ligation of LPS to TLR4 initiates inflammatory signalling cascades via intercellular 
adaptor proteins, MyD88 and/or TRIF, leading to the activation of transcription 
factors and the initiation of gene transcription. The transcription factors activated 
after LPS treatment include NF-B, AP-1 and IRFs (Kawai and Akira, 2006; Watters 
et al., 2007). The activation of these transcription factors leads to the induction of 
inflammatory molecules including TNF- and IL-6. RAW264.7 macrophages are 
known to express TLR4 (He et al., 2016). In agreement with previous observations, 
the results demonstrated that macrophages released increasing amounts of TNF- 
and IL-6, upon the activation of TLR4. 
 
TNF-is a potent pro-inflammatory cytokine and the elevated levels of this cytokine 
are associated with much inflammatory pathology. TNF- binds to TNFR1 and 
TNFR2 expressed on the plasma membrane of cells. Ligation of these TNF- 
receptors ultimately causes the activation of NF-B which results in the activation of 
further inflammation i.e. a positive feedback loop is established. TNF- also acts 
directly on the hypothalamus, stimulates the release of corticotrophic releasing 
hormone and induces fever (Aggarwal et al., 2012; Croft et al., 2013).  
 
TNF- release was increased in a dose dependant manner up to 100 ng/ml LPS 
and began to decrease above 100 ng/ml LPS in RAW264.7 macrophages. However 
LPS did not affect the viability within the dose range, 1-1000 ng/ml, over 24 hours. 
Therefore the reduction in TNF- release was unlikely to be due to the toxicity of 
LPS but possibly by other mechanisms. It is known that there are negative 
regulators of TNF- production. For example, IL-10 released from macrophages is 
known to down-regulate the release of proinflammatory cytokines including TNF-. 
Synaptotagmin XI (SytXI) is a specific inhibitor of TNF-. SytXI has been shown to 
inhibit the fusion of TNF- with the plasma membrane therefore decreasing the 
expression of the cytokine on the membrane. This, in turn, results in the decreased 
release of TNF- from the cell (Duque et al., 2013).  It is possible that the decrease 
in TNF- release at high concentration of LPS which has been observed in this 
section could be due to the activation of negative regulators rather than cell death. 
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IL-6 is known to exhibit both pro-inflammatory and anti-inflammatory effects. IL-6 
signals through a receptor consisting of IL-6R in combination with gp130. IL-6R 
can be found as both soluble and membrane bound form with IL-6 being able to bind 
to either forms. The binding of IL-6 to either the soluble or membrane bound form of 
the receptor can leads to the activation of distinct signalling pathways which exert 
different biological responses. Signalling via soluble IL-6R, termed trans-signalling, 
elicits pro-inflammatory effects such as the increase in fever and induction of acute 
phase proteins. The trans-signalling is known to be important in the maintenance of 
T cells by inhibiting apoptosis of T helper 17 cells and promoting the development of 
regulatory T cells. Signalling via membrane bound IL-6R, is termed classical 
signalling, and known to be regenerative, mediating tissue remodelling (Hunter and 
Jones, 2015). IL-6 release from RAW264.7 macrophages continued to increase at 
the highest dose of LPS, which differed from TNF- release. This phenomenon 
suggested that TNF- and IL-6 have distinct mechanisms for controlling their 
release the downstream of TLR4 activation.  
 
A previous report using RAW264.7 macrophages showed that IL-6 and TNF- have 
differing production kinetics on their release, due to the segregation of TNF- and 
IL-6 into different vesicles (Manderson et al., 2007). The results in this chapter 
supported this idea of different kinetic in the release of TNF- and IL-6. With 100 
ng/ml LPS stimulation, the concentration of released TNF- in media at 4 hours was 
32.6 ng/ml, and 41.7 ng/ml at 24 hours. This result showed that the first 4 hours of 
activation accounts for 75% of total TNF- release over 24 hours. IL-6 level was 
0.63 ng/ml at 4 hours and 2.3 ng/ml at 24 hours suggesting that 27% of total IL-6 
release in 24 hours was occurred during the first 4 hours i.e. suggesting a linear 
production of the cytokine over 24 hours. However, this analysis does not take into 
account the possible breakdown of these cytokines in the culture. Although the 
breakdown of cytokines has been poorly investigated, it is possible that TNF- may 
have a faster decay rate than IL-6 in the system, although in this instance the decay 
of TNF- would not be the same rate throughout the 24 hours. 
 
It is known that IL-6R, a receptor for IL-6, is constantly released from macrophages 
and found at nM level in normal human serum (Jones et al., 2001). In line with this, 
culture media from resting RAW264.7 macrophages contained IL-6R. However, 
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LPS treatment appeared to inhibit the release of IL-6R at 24 hours in dose 
dependant manner and this inhibition in IL-6R release by LPS appeared at only 
later time point at 24 hours. It must be noted that there are few studies which 
characterized the release of IL-6R in macrophages. One possible explanation for 
the observed reduction in IL-6Rrelease at later time point could be due to the 
binding of IL-6 to the IL-6R, which sharply increased after 24 hours of LPS 
stimulation. In this scenario the IL-6/IL-6R complex could not recognised by ELISA. 
This was tested in the laboratory and found that the addition of 3 ng/ml IL-6 only 
reduces the measurement in pg/ml range for IL-6R by 5%. Therefore the 
interference with IL-6 was not likely to be the cause of the reduction in IL-
6Rmeasurement, but suggests this reduction may be due to another biological 
effect. The control of IL-6 trans-signalling is of great interest in the treatment of 
autoimmune diseases and it is important to investigate further.  
 
This chapter characterised the release of TNF-, IL-6 and IL-6R from RAW264.7 
macrophages during TLR4 activation. Next chapter investigated the BK channel 
expression in RAW264.7 macrophages.  
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 Chapter 4  Do macrophages express BK channels and does 
TLR4 activation affect the channel expression? 
4.1 Introduction 
The aim of this chapter is to characterise the expression of BK channels in 
RAW264.7 macrophages. The expression, sub-cellular location of BK channels, the 
expression level and functionality were studied using immunofluorescence imaging, 
Western blot analysis and electrophysiological recordings. Macrophages are known 
to be plastic in nature with immune stimuli dramatically alter their phenotypes 
(Mosser and Edwards, 2008). It was hypothesised that immune activation may alter 
the expression of ion channels in macrophages. The BK channel expression was 
therefore characterised in LPS activated macrophages as well as in resting 
macrophages. 
 
4.2 Results 
4.2.1 BK channel expression in resting macrophages 
Western blot analysis 
Two antibodies against mouse BK subunit, a rabbit polyclonal antibody, APC-107, 
and mouse monoclonal antibody, L6/60, were used in Western blot analysis of BK 
in RAW264.7 macrophages. Both antibodies are designed to bind to the C-terminal 
region of BK. Both primary antibodies detected the presence of protein bands at 
approximately 120 kDa in whole cell lysate from resting RAW264.7 macrophages, 
Figure 4-1 and Figure 4-2. Using the L6/60 antibody resulted in the appearance of 
doublet bands at 110 to 120 kDa, Figure 4-2. Protein bands at approximately 
120kDa also appeared in rat brain lysates, Figure 4-2.  For both APC-107 and L6/60 
protein bands appeared at 100, 80, 60, 46, 32, and 25 kDa in whole cell lysates of 
RAW264.7 macrophages. However the lower band intensity appeared less than the 
band at 120 kDa when L6/60 was used. APC-107 gave less clear cut discrimination 
in signal intensities between the higher and lower molecular weight band, Figure 4-1 
and Figure 4-2. In rat brain lysate, major bands appeared between 120-140 kDa. 
Lower protein bands at 110, 80, 45, 32 and 25 kDa were also appeared against both 
APC-107 and L6/60, Figure 4-1 and Figure 4-2. 
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When APC-107 was removed and the anti-rabbit IgG HRP-linked secondary 
antibody was applied on the membrane alone, most of the protein bands 
disappeared, although some faint bands could still be seen, Figure 4-1. When L6/60 
was removed and anti-mouse IgG HRP-linked secondary antibody was applied 
alone, doublet bands between 110 to 120 kDa disappeared, Figure 4-2.  Due to the 
specificity of L6/60 antibody for the 120 kDa band, which is predicted to be the 
complete BK subunit, it was decided to use L6/60 to characterise BK expression 
in following experiments. 
 
 
Figure 4-1 BK expression in resting macrophages using a rabbit polyclonal 
anti-mouse BK antibody, APC-107 
BKexpression in the whole cell lysate of resting RAW264.7 macrophages (left) and rat 
brain (right) was analysed by Western blot using APC-107. No primary blot was made by 
omitting the primary antibody. Molecular marker in kDa is indicated in far left. 10 g protein 
was loaded each lane. The experiment was repeated twice. 
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Figure 4-2 BK expression in resting macrophages using a mouse 
monoclonal anti-mouse BKantibody, L6/60 
BKexpression in whole cell lysate of resting RAW264.7 macrophages (left) and rat brain 
(right) was analysed by Western blot using L6/60. No primary blot was made by omitting the 
primary antibody. Molecular marker in kDa is indicated in far left. 10 g protein was loaded 
each lane. The experiment was repeated 5 times. 
 
Immunolocalisation 
The subcellular location of BK channels in resting RAW264.7 macrophages was 
analysed by immunofluorescence imaging techniques. BK in the cells was 
analysed using L6/60. DAPI staining displayed nuclei in resting RAW264.7 cells, 
and positive staining for BK were found in the nucleus, nuclear membrane and 
cytoplasm in resting macrophages, Figure 4-3. The plasma membrane appeared to 
be relatively free of BK protein with only faint diffuse staining was seen, Figure 4-3. 
BK was found to be associated with the nuclei BK in approximately 90% of resting 
macrophages, Figure 4-3.  
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Figure 4-3 Localisation of BK in resting macrophages 
Resting RAW264.7 macrophages were paraformaldehyde fixed and stained for with DAPI 
(blue) and anti-BKwith L6/60 (green); merged DAPI+L6/60 and control in which there was 
no primary antibody but DAPI was present. a) single cell images (n=4, n: the number of 
cells) or b) area (n=11). Scale bar, 5m. The experiment was repeated 4 times and images 
shown are representative. Pictures are taken from area containing approximately 15 cells. 
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Nuclei isolation 
Nuclei from resting macrophages were isolated and analysed for BK expression by 
Western blot. The blot indicated bands at 120 kDa and 80 kDa using L6/60 in 
samples of whole cell lysate and nuclei isolate. The protein band at 80 kDa in nuclei 
isolate appeared stronger than whole cell lysate, Figure 4-4. 
 
Figure 4-4 BK expression in nuclei isolate of resting macrophages 
BK expression in nuclei (N) and whole cell (WC) lysates from resting RAW264.7 
macrophages. 10 g protein was loaded each lane. Left shows molecular weight marker in 
kDa. The experiment was repeated 3 times. 
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4.2.2 BK channels in TLR4 activated macrophages 
In order to investigate if TLR4 activation changes the BK channel expression, 
macrophages were stimulated with LPS for up to 24 hours and the expression of 
BK was analysed. In preliminary experiments, LPS was applied at the maximal 
dose, 150 ng/ml, however this resulted in a significant increase in membrane 
dynamics, see 4.2.3. Therefore 10 ng/ml LPS was selected to use to investigate the 
effect of TLR4 activation on the channel expression. This does of LPS, 10 ng/ml, 
had been shown to increase TNF- and IL-6 release and decrease the release of IL-
6R from RAW264.7 macrophages at 24 hours in chapter 3. 
 
Immunolocalisation 
In immunolocalisation studies, the major effect of stimulating RAW264.7 
macrophage with LPS was the appearance of clusters of positive staining on some 
parts of the cell plasma membrane at 18 hours and 24 hours, the lack of DAPI 
staining at these clusters suggest it was not nuclei material. However the intensity of 
nuclei staining appeared to decrease after 24 hours of LPS treatment, while the 
proportion of cells showing nuclei staining remained approximately the same (83%; 
10/12), Figure 4-5 and Figure 4-6.    
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Figure 4-5 Localisation of BK in LPS activated macrophages 
RAW264.7 macrophages were activated with 10 ng/ml LPS and at indicated times cells were 
paraformaldehyde fixed and stained for nuclei with DAPI (blue) and anti-BKwith L6/60 
(green); merged DAPI+L6/60 and control in which there was no primary antibody but DAPI 
was present. Scale bar, 5m. Arrows indicate BK staining on the plasma membrane. The 
experiment was repeated 3 times.  
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Figure 4-6 Localisation of BK in LPS activated macrophages at population 
level 
RAW264.7 macrophages were stimulated with 10 ng/ml LPS for 24 hours. Then the cells 
were paraformaldehyde fixed and stained for nuclei with DAPI (blue) and anti-BKwith 
L6/60 (green). Scale bar, 5m. The experiment was repeated 4 times and image shown is 
representative. Pictures are taken from area containing approximately 12 cells. 
Western blot analysis 
To confirm the appearance of BK channel expression on the plasma membrane 
during TLR4 activation, whole cell protein and plasma membrane isolate from LPS 
activated RAW264.7 macrophages were analysed for BK expression by Western 
blot. At whole cell level, BK showed a small increase in expression after LPS 
treatment. Densitometry analysis showed that at whole cell level, the amount of 
BK was increased by 25 % after 24 hours of LPS activation, N.S., Figure 4-7a and 
Figure 4-7c. In contrast, BK was hardly detectable in isolated plasma membrane 
from resting RAW264.7 cells using the protocol described in 2.2.7. The expression 
of BK on the plasma membrane increased during LPS treatment peaking around 
18 hours, Figure 4-7b. The relative expression of plasma membrane associated 
BKwas 2.5 fold higher at 24 hour compared to that at 0 hour, p<0.05, Figure 4-7c.  
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Figure 4-7 BK expression in the plasma membrane isolate and whole cell 
lysate from RAW264.7 macrophages during LPS treatment 
RAW264.7 macrophages were treated with 10 ng/ml LPS for up to 24 hours and a) whole 
cell (WC) and b) plasma membrane (PM) were collected. BK expression, -actin and Akt 
was analysed by Western blot. c) Densitometry analysis of relative BK expression at 24 
hours compared to at 0 hours. Bars represent mean+SEM, n=3, where n represents the 
number of blots used for analysis. The experiment was repeated 3 times. 
4.2.3 Electrophysiological recording of resting and LPS treated macrophages 
Whole cell voltage clamp experiments were performed to test for the functional BK 
channel expression on the plasma membrane of resting macrophages and 
macrophages activated with 10 ng/ml LPS for 24 hours. The following 
pharmacological reagents were used in electrophysiological recordings to study BK 
channel expression; 3 mM TEA, non-selective K+ channel blocker, and 30 nM IbTX, 
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a BK channel selective inhibitor. Both reagents were applied in extracellular 
solutions for the justification of doses, see 4.3. 
 
As mentioned in section 4.2.2, LPS was initially applied at the maximal dose at 150 
ng/ml, however, at this maximal dose of LPS, macrophages were highly activated 
and became very difficult to make recordings from. This was due to an inability to 
make a stable seal with the electrode possibly because of the change in the 
membrane property. Therefore the submaximal dose of LPS was selected. Even 
after lowering LPS doses, it was to complete the cycle of drug treatments in 
macrophages and this limited the number of cells recorded in this thesis.  
 
During the first series of experiments, the membrane properties of macrophages, 
probably the presence of pseudopodia prevented the formation of seal. To 
overcome this problem, a gentle air pressure applied into pipette using 1ml syringe 
when approaching cells. This is to repeal these pseudopodia and make relatively 
clean surface. This improved the formation of seal in the subsequent experiments. 
 
Initially pipette solutions were prepared with 640 nM free Ca2+ in K+-gluconate based 
solution, however, it was found that it was found difficult to determine free K+ ions in 
the solution and this interfered with the data analysis. It was also suggested to 
increase the concentration of free Ca2+ for the activation of the channel. Therefore 
the pipette solution was changed to K+-acetate based pipette solution, see Table 2-2, 
with 1.6 M. free Ca2+. Pipettes with various resistances from 2 to 4.5 MΩ were 
tested in RAW264.7 macrophages and it was decided to use pipette with the 
resistance between 3.5 and 4 MΩ. 
 
3 mM TEA did not affect the whole cell current during voltage clamp (-100 mV to 40 
mV, duration 10 s, Figure 2-5) in the majority of resting macrophages. In separate 
experiments, only 8.7% of resting macrophages had a K+ current which was 
sensitive to 30 nM IbTX. After 24 hours of LPS treatment, the proportion of cells 
expressing TEA sensitive current increased. Importantly 30 nM IbTX blocked K+ 
current in 41.5% macrophages. The 0 current potential of the I-V plot indicated both 
TEA and IbTX sensitive currents were carried via K+ ions, Figure 4-8 and Figure 4-9.  
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Figure 4-8 I-V plot of whole cell TEA-sensitive current in macrophages 
Representative traces of TEA-sensitive current obtained by whole cell recordings from 
resting RAW264.7 macrophage or RAW264.7 macrophage stimulated for 24 hours with 10 
ng/ml LPS. Voltage ramp (-100 mV to +40 mV, duration 10 s) was applied in presence or 
absence of 3 mM TEA in the extracellular solution. Representative graphs of TEA-sensitive 
current. The ramp protocol was run in individual cells at least 6 times per drug treatment and 
these traces were averaged. Sensitive currents were obtained by subtraction of traces with 
drug treatment from control traces and plotted against membrane voltage.   
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Figure 4-9 I-V plot for whole cell IbTX sensitive current in macrophages 
Representative traces of IbTX-sensitive current obtained by whole cell recordings from 
resting RAW264.7 macrophages or RAW264.7 macrophages treated for 24 hours with 10 
ng/ml LPS. Voltage ramp (-100 mV to +40 mV, duration 10 s) was applied in presence or 
absence of 30 nM IbTX in the extracellular solution. Representative graphs of IbTX-sensitive 
current. The ramp protocol was run in individual cells at least 6 times per drug treatment and 
these traces were averaged. Sensitive currents were obtained by subtraction of traces with 
drug treatment from control traces and plotted against membrane voltage.   
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LPS treatment BK current present Resting potential 
Current amplitude of 
BK current at 
0 mV  
 none 8.7%(2/23) 
-60 to -50 mV (11 cells) 
-30 to -40 mV ( 7 cells) 
0 to +10 mV ( 4 cells) 
50 to 100 pA ( 1 cell) 
150 to 200 pA (1 cell) 
24 hrs 41.2% (7/17) 
-60 to -50 mV ( 9 cells) 
-30 to -40 mV (4 cells) 
0 to +10 mV ( 4 cells) 
50 to 100 pA (2 cells) 
100 to 150 pA (2 cells) 
150 to 200 pA (3 cells) 
 
Table 4-1 Summery of whole cell recordings in resting and LPS treated 
RAW264.7 macrophages  
RAW264.7 macrophages received no treatment or received 10 ng/ml LPS for 24 hours prior 
to patch-clamp experiments. The percentage and the number of cells which expressed 30 
nM IbTX-sensitive whole cell K
+
 current /the total numbers of cells recorded are described. 
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4.3 Discussion 
BK channels are expressed in various cellular locations including the plasma 
membrane, mitochondrial membrane and nuclear membrane. These channels are 
known to have location specific roles in cell biology (Xu et al., 2002; Hoshi et al., 
2013; Li et al., 2014; Balderas et al., 2015). In addition, the gating properties of the 
BK channel are altered by tissue specific expression of accessory - and/or -
subunits or BK gene splicing (Yan & Aldrich, 2010; Orio, et al., 2002).  
Endogenous molecules, such as proton, Heme, carbon monoxide and arachidonic 
acid also affect activation states of the channels (Hou, et al., 2009). Due to the 
variations in the localisation and differing opening properties of the BK channel, their 
expression pattern must be carefully examined before studying their biological roles. 
 
The aim of this chapter was to characterise the expression of BK channel in resting 
and TLR4 activated RAW264.7 macrophages. This was investigated using three 
different techniques. Immunofluorescence imaging was used to visualise the 
subcellular location of BK protein. Western blot analysis of the cellular fractions 
semi-quantified the BK expression levels, indicated any possible splice variants 
and also confirmed the pattern of the cellular localisation observed in the 
immunofluorescence staining. Because of the various forms of post-translational 
regulation of the ion channels (Kyle and Braun, 2014), the mere existence of 
channel protein does not confirm that the channel is functional as an ion channel. 
Therefore, the whole cell voltage clamp experiment was performed to test the 
expression of the plasma membrane located channels.  
 
In electrophysiological recordings, the assessment of the channel expression was 
mainly determined by its pharmacological properties. Two types of K+ channel 
blockers were used, TEA and IbTX. TEA blocks most types of K+ channels from 
both sides of lipid bilayer membranes in a voltage dependent manner and is known 
to exhibit higher affinity for BK channels compared to other types of K+ channels (Yu 
et al., 2016).  IbTX is a peptide toxin of 37 amino acid in length and is highly 
selective for BK channel. This toxin is membrane impermeable and blocks the 
channel pore from the outside. This drug is selective for BK channels located on the 
plasma membrane at concentrations at 100 nM and below (Galvez, et al., 1990).   
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The results from immunofluorescence imaging and Western blot analysis of cellular 
fractions consistently indicated the presence of BK protein in resting RAW264.7 
macrophages. Immunofluorescence images showed that BK was predominantly 
associated with the nucleus and its surrounding region of cytoplasm. The BK 
positive staining was hardly detectable on the plasma membrane in resting 
macrophages. This expression pattern was confirmed by Western blot analysis of 
the cellular fraction of the plasma membrane and nuclei. The expression of BK 
channels on nuclear membrane has been reported in neurons (Li et al., 2014), 
however, this is the first time the expression of nuclear BK channels in macrophages 
has been reported to my knowledge. Consistent with the biochemical analysis, the 
electrophysiological recordings with TEA and IbTX also showed that few resting 
macrophages express functional BK channels on the plasma membrane. 
 
However, there was a noticeable change in the expression of plasma membrane BK 
channel during LPS activation. BK positive staining of distinct areas of the plasma 
membrane was observed in the immunofluorescence image between 18-24 hours of 
LPS stimulation. BK staining pattern on the plasma membrane of macrophages 
resembled the channel clustering, which has been reported in central principal 
neurons of rats and mice (Kaufmann et al., 2010). Western blot analysis also 
showed an increased expression of BK protein in the plasma membrane isolate 
after LPS activation, with the relative expression at 24 hours was 2.5 fold higher 
than that of resting macrophages. An increase BK expression was also observed 
at whole cell level; however, the magnitude of increase was 25%, which was 10 
times smaller than that seen for the plasma membrane. 
 
It was noted by a number of experienced electrophysiologists in the department that 
RAW264.7 macrophages were a particularly difficult cell to path-clamp.  First, it was 
difficult to form GΩ seals. This may be due to the fact that the plasma membrane of 
macrophages is comparatively dynamic in nature. This property is important in the 
process of phagocytosis, however may have resulted in the difficulty in forming 
stable seal between the electrode and the membrane. Secondly the tip of electrode 
was often blocked by fine pseudopodia on macrophages. On the other hand, it was 
required to use a thin walled grass electrode in order to achieve effective dilation of 
cytoplasm, however this may have increased a chance of pseudopodia to slip into 
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the electrode. This condition was slightly improved by applying gentle air pressure to 
the pipette electrode when approaching a cell, to repeal the uneven structure of 
macrophage membrane such as pseudopodia. Even though, the percentage of cells, 
which completed the recording cycle, composed of approximately 20 ramps, was 
estimated to be approximately 3% of the total cells attempted. This highlights 
possible sampling problems when conducting electrophysiological studies of 
macrophages and their phenotypes. This problem became even more evident in 
LPS stimulated cells. The activation of cells is known to alter the cell surface 
molecule expression and membrane properties. It is possible that the plasma 
membrane of macrophages became more fluid and dynamic after TLR4 activation. It 
would be important to develop technique to achieve stable recordings in these cells.  
Possible experiments would be resting the cells in normal culture media for 1 hour 
after LPS activation to make them less active before carrying out recordings. It was 
also noticed that the cells which succeeded to record tended to share morphological 
characteristics. The macrophages existed in many shapes including spindly shape 
or round shape with various sizes. In this thesis, it was noticed that the recordings of 
macrophages with round shape were relatively successful compared to the cells 
with spindly shape. However as macrophages are heterogenic, the interpretation 
could be limited to these particular population. Again it would be important to 
develop techniques to consistently record these cells. 
  
While technically challenging electrophysiological recordings did provide some 
evidence that the BK channel was upregulated on the plasma membrane in 
activated macrophages. The population of cells with TEA sensitive K+ channel 
increased among macrophages treated with LPS for 24 hours. In line with this, the 
number of macrophages, which expressed IbTX sensitive K+ current, increased 5 
fold in LPS treated macrophages. Taken together, these results indicated that LPS 
activation led to an increase in the expression of functional BK channels on the cell 
surface in RAW264.7 macrophages. However it is important to note that not all 
macrophages upregulated BK channels on the plasma membrane during LPS 
activation. The upregulation of K+ channels during immune cell activation has been 
observed in previous studies, suggesting a positive correlation between the immune 
cell activation and K+ channel expression. The expression of Kir currents was 
reported to increase after Phorbol 12-myristate 13-acetate (PMA) treatment in a 
mouse macrophage cell line J774.1 (Gallin and Sheehy, 1985) and mouse bone 
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marrow derived macrophages have been shown to induce the expression of Kv1 type 
channel subunits after treatment with TNF-(Vicente et al., 2005). 
 
Using two different BK antibodies a protein band was detected in RAW264.7 
macrophages at 120 kDa. This is close to the predicted molecule weight for mouse 
BK protein of 130 kDa. However, it is important to note that studies often report the 
BK being detected as a 120 kDa by Western blot analysis. When whole cell lysate 
is analysed, 120 kDa protein bands were observed as doublets in RAW264.7 
macrophages. This doublet has been reported when using anti-BK antibodies with 
rat brain tissue (Misonou et al., 2006). However when plasma membrane isolates 
are analysed, the 120 kDa band is appeared in single band. It is possible that the 
doublet may result from various modifications of the channel, including mRNA 
splicing and glycosylation (Kyle and Braun, 2014). The absence of double band but 
repeated appearance of signal band in plasma membrane isolate could lead to 
assume that such modification occurs at different rate depending on channel cellular 
location. Further analysis with different cellular fractions may help to investigate the 
reason for doublet in whole cells and absence in plasma membrane isolate. 
Additional protein bands also appeared at smaller sizes, 110, 80, 60, 46, 32 and 25 
kDa when using L6/60. Blots were the primary antibody was omitted indicated that 
these bands were likely due to non-specific binding of the secondary antibody. 
However, it cannot be totally exclude that a smaller sized BK protein, possibly 
spliced variant, exists in the cell. To test this BK mRNA expression could be 
analysed. When APC-107 was used bands at smaller sizes 60, 46, 32 and 25 kDa 
were also detected. Again removal of the primary antibody could not totally exclude 
the possibility that these where specific lower molecular weight BK protein. Lower 
weights of BK proteins have been reported in previous research. It is proposed that 
proteolysis of the C-terminal region of BKoccurs during the process of sample 
preparations and resulted in smaller fragments of 55 kDa and 25 kDa BK (Knaus, 
et al., 1995) by a methodological effect. It is possible that this phenomenon occurred 
during the process of sample preparation in this thesis. However it is possible to say 
that both antibodies recognised a protein band at 120 kDa which appeared to be the 
regular form of the BK protein.  
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It has been well appreciated that the co-expression of accessory subunits can alter 
the voltage dependence and Ca2+ sensitivity of BK channels (Hoshi, et al., 2013). In 
this study, the electrophysiological studies were limited to their pharmacological 
properties in RAW264.7 macrophages at whole cell level. I-V relation of the IbTX 
sensitive currents from macrophages described shallower I-V relationship, indicating 
the possibility that the BK channels on macrophages may have less voltage 
dependency compared to other cells. However this needs further investigation.  It 
will be interesting to address the subunit expression in these cells by molecular and 
biochemical analysis and to characterise the electrophysiological properties of the 
channels in macrophages at the single channel level in the future. 
 
In conclusion, BK channels are present in RAW264.7 macrophages. In the resting 
macrophages the channel are predominantly intracellular but sparse on the cell 
surface. TLR4 activation by LPS led to the upregulation of functional BK channels 
on the plasma membrane of these cells. In next chapter, the involvement of these 
plasma membrane located BK channels in the release of cytokine and cytokine 
receptors from TLR4 activated macrophages were studied. 
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 Chapter 5 Does the plasma membrane BK channel have a 
role in TNF-, IL-6 or IL-6Rrelease from 
macrophages? 
5.1 Introduction 
Chapter 4 demonstrated that RAW264.7 macrophages express BK channels. In the 
resting condition or early time point of LPS activation, these channels are 
predominantly associated with intracellular sites with functional BK channels 
appearing sparse on the plasma membrane. However LPS treatment over 24 hours 
led to the appearance of the channels on the plasma membrane.  
Functional BK channels have been described in different subcellular locations, 
including the mitochondrial membrane, nuclear membrane and plasma membrane 
and these studies have suggested the location specific roles for the channel (Xu et 
al., 2002; Singh et al., 2012; Hoshi et al., 2013; Li et al., 2014). The aim of this 
chapter was to investigate whether the plasma membrane expressed BK channels 
are involved in the release of TNF-, IL-6 and IL-6R. These molecules were 
selected as they have been shown to be involved in the pathogenesis of a number 
of diseases, see chapter 1 and are current therapeutic targets for chronic 
inflammatory diseases. 
First, the effect of BK channel blocking drugs, IbTX and paxilline on the release of 
these proteins from macrophages was investigated at a time when the expression of 
plasma membrane BK channels appeared low. This was done by applying these 
drugs on resting macrophages or during at the early time points, 0 to 4 hours of LPS 
stimulation. Second, the involvement of the plasma membrane BK channels in the 
release of these proteins was studied. This was done by treating macrophages with 
a low level of LPS for 24 hours prior to simulating with a higher dose of LPS. This 
protocol allows the investigation of the effect of BK channel blocking drugs on 
macrophage activation when the plasma membrane form of the BK channel is 
present.  
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5.2 Results 
5.2.1 Effect of IbTX on TNF-, IL-6 and IL-6R  
IbTX is a water soluble peptide and is highly selective for BK channels. Previous 
studies have demonstrated that IbTX works at concentrations in nM range. Chapter 
4 showed that 30 nM IbTX blocked BK-like currents and this concentration did not 
have any effect on cell viability. Therefore, this drug was applied at the 
concentrations from 3 to 30 nM. The macrophages were left unstimulated or 
stimulated with 10 or 150 ng/ml LPS for 4 hours with or without IbTX. This dose 
range was selected based on the results from chapter 3 & 4, which demonstrated 
that 10 ng/ml LPS caused the increase of BK channels on the plasma membrane. 
150 ng/ml LPS caused maximal production of TNF-. Proteins release from LPS 
stimulated macrophages was measured after 4 hours stimulation. The reasoning for 
this was that it had been shown that this time point was the optimum for TNF- 
production in chapter 3. In addition, the expression of the plasma membrane BK 
channels was shown to be sparse at this time point after LPS stimulation, see 
chapter 4. 
 
4 hours with IbTX, 3, 10 and 30 nM, did not induce the release of TNF- or IL-6 nor 
alter the release of IL-6R from resting macrophages. The induction of TNF- and 
IL-6 was below detection limit of ELISA kits, see section 2.2.11, and the level of IL-
6R was 302+/-5.6 pg/ml in non-treated group and 304+/-12.7 pg/ml in the group 
treated with IbTX 30nM, Figure 5-1a. This indicated that the drug does not have a 
direct effect on the release of these proteins from macrophages. IbTX did not also 
change the release of TNF-, IL-6 or IL-6R from macrophages activated with 10 
ng/ml LPS. The level of TNF- was 8.4+/-1.2 ng/ml from the group received 10 
ng/ml LPS only and 8.1+/-1.6 ng/ml from the group received 10 ng/ml LPS and 30 
nM IbTX, N.S., Figure 5-2a. The level of IL-6 was 0.44+/-0.45 ng/ml from the group 
received 10 ng/ml LPS only and 0.50+/-0.11 ng/ml from the group received 10 ng/ml 
LPS and 30 nM IbTX, N.S., Figure 5-2a. IL-6R was at 38.1+/-7.9 pg/ml from the 
group received 10 ng/ml LPS only and 44.0+/-11.4 ng/ml from the group received 10 
ng/ml LPS and 30 nM IbTX, N.S., Figure 5-2a. Consistently, at 150 ng/ml LPS, IbTX 
did not alter the release of TNF-, IL-6 or IL-6R. The level of TNF- was 15.0+/-2.4 
ng/ml from the group received 150 ng/ml LPS only and 15.6+/-1.2 ng/ml from the 
group received 150 ng/ml LPS and 30 nM IbTX, N.S., Figure 5-3a. IL-6 was at 
0.62+/-0.017 ng/ml from the group received 150 ng/ml LPS only and 0.69+/-0.16 
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ng/ml from the group received 150 ng/ml LPS and 30 nM IbTX, N.S., Figure 5-3a. 
IL-6R was 32.9+/-5.7 pg/ml from the group received 150 ng/ml LPS only and 
33.6+/-5.1 pg/ml from the group received 150 ng/ml LPS and 30 nM IbTX, N.S., 
Figure 5-3a.  MTT assay indicated no effect on cell viability when it was applied 
alone or with either dose LPS, Figure 5-4a. 
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Figure 5-1 Effect of IbTX on TNF-IL-6 and IL-6R release from resting 
macrophages  
RAW264.7 macrophages received 3-30 nM IbTX, shaded bars, or medium control, clear bar. 
After 4 hours culture media was collected. TNF-IL-6 and IL-6R in media was measured 
by ELISA. Bars represent mean+SEM (n≥3). a) shows results from one experiment with n=3. 
b) shows combined data from 3 experiments. N.T.: no treatment controls. Statistical 
significance of drug treatments against control (ctrl) was tested by one-way ANOVA followed 
by Dunnett’s test. 
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Figure 5-2 Effect of IbTX on TNF-IL-6 and IL-6R release from macrophages 
activated with a submaximal dose of LPS 
RAW264.7 macrophages received 3-30 nM IbTX, shaded bars, or medium control, clear 
bars, during stimulation with 10 ng/ml LPS. After 4 hours, culture media was collected. TNF-
IL-6 and IL-6R in media were measured by ELISA. Bars represent mean+SEM, (n≥3). 
N.T.: no treatment controls. a) shows results from one experiment with n=4. b) shows 
combined data from 3 experiments. Statistical significance of drug treatments against control 
(ctrl) was tested by one-way ANOVA followed by Dunnett’s test.  
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Figure 5-3 Effect of IbTX on TNF-IL-6 and IL-6R release from macrophages 
activated with a maximal dose of LPS 
RAW264.7 macrophages received 3-30 nM IbTX, shaded bars, or medium control, clear 
bars, during stimulation with 150 ng/ml LPS. After 4 hours, culture media was collected. 
TNF-IL-6 and IL-6R in media were measured by ELISA. Bars represent mean+SEM, 
(n≥3). N.T.: no treatment controls. a) shows results from one experiment with n=4. b) shows 
combined data from 3 experiments. Statistical significance of drug treatments against control 
(ctrl) was tested by one-way ANOVA followed by Dunnett’s test.  
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Figure 5-4 Cell viability of macrophages treated with IbTX and LPS 
RAW264.7 macrophages received no treatment, 10 or 150 ng/ml LPS for 4 hours with, 
shaded bars or without, clear bars, 3-30 nM IbTX and cell vitality was assessed by MTT. Cell 
viability was measured by MTT. Bars represent mean+SEM, n≥3. N.T.: no treatment controls. 
a) shows data from one experiment with n=3 and b) shows combined data from 3 repeated 
experiments. Statistical significance of drug treatments against no treatment control was 
tested by one-way ANOVA followed by Dunnett’s test. 
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5.2.2 Effect of paxilline on TNF- release from early time point of TLR4 activation 
of macrophages 
A second reported BK channel selective blocker, paxilline, was investigated. Due to 
the complexity of how paxilline blocks the channel, it was difficult to estimate the 
IC50 for this drug in this experiment. Therefore an initial cell culture experiment with 
paxilline was carried out to find the maximal tolerable dose of the drug in RAW264.7 
macrophages. Paxilline, at 3 M, significantly increased the release of TNF-from 
resting macrophages, 601+/-225 pg/ml compared to vehicle control, which had no 
detectable production of TNF-, p<0.05, Figure 5-5a. However, above 1 M 
paxilline decreased MTT result, with measurements of 0.17+/-0.008 O.D. in vehicle 
control and 0.13+/-0.05 O.D. in 3 M paxilline treatment group, p<0.05, Figure 5-5b. 
Therefore the maximum dose of paxilline used was set as 1 M. The lower does 
was selected by estimating from the literature, which has been reported to 
selectively block closed BK channels and this is at 20 nM. Due to its poor solubility 
in aqueous solutions, paxilline was first dissolved in DMSO. The final concentration 
of DMSO used in culture wells was 0.015%. Initial experiments showed that this 
concentration of DMSO did not have an effect on TNF- release.  
Paxilline treatment for up to 24 hours at 0 to 1 M did not induce TNF- from resting 
macrophages, Figure 5-5a. In comparison, 20 nM paxilline enhanced TNF- release  
from macrophages stimulated for 4 hours with 10 ng/ml LPS by 54% compared to 
vehicle control group, 4.8+/-0.34 ng/ml with 20 nM paxilline compared to 3.1+/-0.99 
ng/ml DMSO vehicle control, p<0.05, Figure 5-6. 1 M paxilline also significantly 
increased, p<0.05, TNF- release by 61%, 5.0+/-1.2 ng/ml compared to the DMSO 
vehicle control, Figure 5-6a.  Paxilline did not affect TNF- release when 150 ng/ml 
LPS was used on the macrophages. MTT assay showed that 4 hours of incubation 
with paxilline did not affect the viability of the cells, Figure 5-6.  
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Figure 5-5 Preliminary data. Effect of paxilline on TNF- release and cell 
viability in resting macrophages 
RAW264.7 macrophages received no treatment (N.T.) or 3-3000 nM paxilline (Pax.), shaded 
bars, for 4 hours. Vehicle control (DMSO Veh.), clear bars, was made with DMSO. The final 
concentration of DMSO was 0.015% in controls, clear bars, and drug treatments, shaded 
bars. a) Concentration of TNF- in conditioned media was measured by ELISA. b) Cell 
viability was assessed by MTT assay. Bars represent mean+SEM  and shows result from 
one preliminary experiment with n=5. O.D.: optical density. Statistical significance of vehicle 
control (DMSO Veh) against drug treatments was tested by one–way ANOVA followed by 
Dunnett’s t-test.* p<0.05. 
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Figure 5-6 Preliminary data. Effect of paxilline on TNF-release from LPS 
activated macrophages 
 RAW264.7 macrophages received no treatment (N.T.), 10 or 150 ng/ml LPS with/without 20 
or 1000 nM paxilline (Pax.) for 4 hours. Vehicle control (DMSO Veh.), clear bars, was DMSO. 
The final concentration of DMSO 0.015% in controls, clear bars, and drugs treatments, 
shaded bars. TNF- in conditioned media was measured by ELISA. Bars represent 
mean+SEM with n=4. The experiment was repeated twice and graph shows result from one 
experiment with n=4. Statistical significance of vehicle control (DMSO Veh) against drug 
treatments was tested by one–way ANOVA followed by Dunnett’s test.* p<0.05.  
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5.2.3 LPS conditioning protocol and its effect on TNF-, IL-6 and IL6R release 
from macrophages 
The results from the previous section demonstrated that IbTX did not have any 
effect on the release of TNF-, IL-6 and IL-6R during first 4 hours of LPS 
stimulation. However the results from chapter 4 demonstrated that this was not the 
optimum time for the expression of BK channels on the plasma membrane, but 
would suggest that the active BK channels only occurred on the plasma membrane 
of the RAW264.7 cells after 18-24 hours of stimulation with 10 ng/ml LPS. Therefore, 
to investigate the effect of IbTX on the release of these proteins at a time when BK 
channels were expressed on the plasma membrane, the following protocol was 
developed, Figure 5-7. First RAW264.7 macrophages were stimulated with 10 ng/ml 
LPS for 24 hours. After 24 hours, the culture media was changed and these 
‘conditioned macrophages’ were treated with 150 ng/ml LPS for 4 hours in the 
presence or absence of 30 nM IbTX, Figure 5-7. The protocol is called ‘LPS 
conditioning’ protocol.  
 
 
            
Figure 5-7 Protocol for investigating the effect of plasma membrane BK 
channel block by macrophages 
RAW264.7 macrophages were treated with 10 ng/ml LPS for 24 hours. The media was 
replaced at 24 hours and subsequently, macrophages were activated with 150 ng/ml LPS 
with/without 30 nM IbTX. At 4 hours, cells and media were collected for analysis. 
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As described in chapter 1, TNF- release can be regulated at the plasma 
membrane and it was decided to investigate the amount of cellular mTNF- in the 
following experiments. mTNF- was detected using a rabbit monoclonal anti-mouse 
TNF-antibody, D2D4. D2D4 detected a protein band at 26 kDa in LPS stimulated 
cells and this protein band was absent in whole cell lysate from resting 
macrophages. Weaker bands also appeared between 30-40 kDa. The 26kDa band 
corresponded to the molecular weight of mTNF-. 
 
 
Figure 5-8 TNF- expression in resting and LPS activated macrophages using 
a rabbit monoclonal anti-mouse TNF- antibody, D2D4 
RAW264.7 macrophages received no treatment or 150 ng/ml LPS for 4 hours. mTNF- 
expression was assessed by Western blot. 10 g protein was loaded per lane. Left indicates 
molecular weight marker in kDa. The experiment was repeated 5 times. 
Before investigating the effect of the IbTX in this model, the effect of preconditioning 
the RAW264.7 macrophages with low dose LPS on the subsequent activation of the 
macrophages with 150ng/ml LPS was evaluated. LPS conditioning of macrophages 
resulted in approximately 38% reduction in TNF- secretion in response to 150 
ng/ml LPS for 4 hours compared to non-conditioned macrophages, 2.4+/-0.32 ng/ml 
and 3.9+/-0.64 ng/ml respectively, p<0.05, Figure 5-9a. 
 
LPS conditioning also reduced the expression of the 26 kDa cellular mTNF- LPS 
stimulation with 150 ng/ml LPS by 70%, Figure 5-9b.  In contrast, release of IL-6 
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was potentiated in LPS conditioned group by 280%, non-conditioned group 0.34+/-
0.08 ng/ml  compared to condition group 1.3 +/-0.11 ng/ml, p<0.05, Figure 5-10a. IL-
6R release was also increased by 25%, 14.0+/-0.54 pg/ml to 19.1 +/- 2.1 pg/ml, 
p<0.05, Figure 5-10a. 
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Figure 5-9 Effect of LPS conditioning on TNF- release and mTNF- 
expression in macrophages  
RAW264.7 macrophages were incubated with 10 ng/ml LPS for 24 hours to produce LPS 
conditioned macrophages. Non conditioned macrophage (ctrl) did not receive this 
preconditioning.  Subsequently the media was replaced and the conditioned and ctrl cells 
were activated with 150 ng/ml LPS for 4 hours. a) TNF- release was measured by ELISA. 
Bars represent mean+SEM (n≥3). a) shows result from one experiment and c) shows 
combined data from 3 repeated experiments. b) Western blot analysis of mTNF-and -
actin expression. Densitometry analysis shows relative mTNF- expression in groups 
received LPS conditioning compared to the control groups without LPS conditioning (ctrl) 
and expressed. Bars represent mean+SEM with n=3, where n is number of blots used for the 
analysis. The experiment was repeated 3 times. Statistical significance was tested using 
paired t-test *p<0.05, **p<0.01, ***p<0.0001 
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Figure 5-10 Effect of LPS conditioning on IL-6 and IL-6R release from 
macrophages 
RAW264.7 macrophages were incubated with 10 ng/ml LPS for 24 hours to produce LPS 
conditioned macrophages. Non conditioned macrophage (ctrl) did not receive this 
preconditioning.  Subsequently the media was replaced and the conditioned and ctrl cells 
were activated with 150 ng/ml LPS for 4 hours. IL-6 and IL-6R release was measured by 
ELISA. Bars represent mean+SEM (n≥3). a) shows results from one experiment with n=4. b) 
shows combined data from 3 repeated experiments. Statistical significance was tested using 
paired t-test *p<0.05. **p<0.01, ***p<0.0001. 
 150 ng/ml LPS    
0
5
10
15
20
25
IL
-6
R

(
n
g
/m
l)
 
0
0.4
0.8
1.2
1.6
IL
-6
 (
n
g
/m
l)
 
 150 ng/ml LPS 
 LPS  
conditioned 
ctrl 
 LPS  
conditioned 
ctrl 
 150ng/ml LPS 
 LPS  
conditioned ctrl 
0
2
4
6
8
10
IL
-6
(n
g
/m
l)
 
*** 
b 
* 
* 
a 
     Chapter 5 Effect of BK channel blockers 
136 
 
5.2.4 Effect of IbTX on TNF-, IL-6 and IL-6R release from LPS conditioned 
macrophages  
In conditioned macrophages, the application of 30 nM IbTX significantly enhanced 
TNF- release during 150 ng/ml LPS treatment compared to macrophages which 
did not receive the drug.  Release was increased by approximately 65%, 2.4+/-0.32 
ng/ml in LPS only group compared to 3.8+/-0.12 ng/ml in LPS with IbTX group, 
p<0.05, Figure 5-11a. IL-6R release from LPS stimulated conditioned 
macrophages was also shown to increase with IbTX treatment by approximately 
80%, 30.1+/-3.1 pg/ml from the group received LPS only and 54.5+/-7.5 pg/ml from 
the group received LPS with IbTX, p<0.05, Figure 5-11a. In comparison, IL-6 
release was not altered by IbTX treatment, showing 1.2+/-0.11 ng/ml in the group 
received LPS only and 1.3+/-0.24 ng/ml in the group received LPS with IbTX, Figure 
5-11a. IbTX treatment did not affect the viability of the cells, Figure 5-11a. 
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Figure 5-11 Effect of IbTX on the plasma membrane BK channels in TNF-and 
IL-6R from LPS activated macrophages. 
RAW264.7 macrophages were incubated with 10 ng/ml LPS for 24 hours to produce LPS 
conditioned macrophages. Subsequently the media was replaced and conditioned cells were 
activated with 150 ng/ml LPS with/without 30 nM IbTX. After 4 hours, culture media was 
collected and analysed by ELISA for TNF-IL-6R and IL-6.  Cell viability was assessed by 
MTT. Bars show mean+SEM (n≥3). a) shows results from one experiment with n=3 and b) 
shows combined data from 3 repeated experiments. Statistical significance was tested by 
paired t-test. O.D.: optical density.*p<0.05, **p<0.01. 
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5.2.5  Regulation of TNF- by IbTX 
Previous section, 5.2.4, demonstrated that IbTX increases the release of TNF- and 
IL-6Rfrom the conditioned macrophages during LPS activation. TNF-production 
is regulated at multiple levels including gene transcription, protein translation and 
membrane release. The increase in the release of TNF- by IbTX could involve any 
or all these mechanisms. To identify at which step of TNF- production IbTX 
modulated, TNF- mRNA was analysed by RT-qPCR and the cellular contents of 
the cytokine protein was analysed by Western blot.  
 
mRNA samples were collected from conditioned RAW264.7 macrophages after 4 
hours LPS treatment with or without 30 nM IbTX and cDNA synthesised. The levels 
of TNF- mRNA were subsequently analysed by RT-qPCR with levels normalised to 
-actin, an internal control, Figure 5-12a. GAPDH had previously been shown not be 
a reliable internal control in this experiment. In spite of a significant increase in the 
levels of released TNF- by IbTX, no significant difference in TNF- mRNA 
expression was observed with IbTX, Figure 5-12a. In comparison, cellular levels of 
mTNF- decreased with IbTX, Figure 5-12b and 5-12c. Taken together these results 
suggested that IbTX modulated the release of the cytokine and not gene 
transcription or translation. 
 
To further investigate the role of BK channels in the system, a BK channel opener, 
100 nM NS11021 was applied to LPS stimulated conditioned macrophages as a 
preliminary experiment. 100 nM NS11021 caused a significant decrease in TNF- 
release, 9.8+/-0.22 ng/ml from LPS only group and 6.2+/-0.98 ng/ml from LPS with 
NS11021 group, p<0.05, Figure 5-13. This result supports the role of BK channels in 
negatively regulating the release of the cytokine. However, it has to be noted that 
similar to paxilline, NS11021 is a small lipophilic molecule. Therefore the possibility 
that this drug caused the activation of other cytoplasmic BK channels as well as the 
activation of the plasma membrane BK channels cannot be excluded. 
 
Initially it was attempted to study the expression of IL-6R in RAW264.7 
macrophages and the effect of IbTX on the cellular expression of IL-6R. However 
only one available antibody, a rat monoclonal anti-mouse IL-6R antibody, DM3568, 
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was not able to detect any protein bands even after a series of optimization. 
Therefore, this study focused on the regulation of TNF- 
The combined data, from repeated (≥ 3 times) experiments, for protein release and 
MTT was in line with the described results from individual experiments. These 
combined data were presented in Figure 5-1, 5-2, 5-3, 5-4, 5-9 and 5-10. Statistical 
analysis of combined data and individual experimental data demonstrated a similar 
pattern of significance between treatment groups. It was noted combined data 
reached higher degree of significance. 
 
 
Figure 5-12 Effect of IbTX on TNF- mRNA and mTNF- expression  
RAW264.7 macrophages were incubated with 10 ng/ml LPS for 24 hours to produce LPS 
conditioned macrophages. Subsequently the media was replaced and conditioned cells were 
activated with 150 ng/ml LPS with/without 30 nM IbTX. After 4 hours, cells were collected 
and analysed for a) TNF- mRNA expression normalised to an internal control, -actin. Bars 
represent mRNA signal ratio as mean+SEM, n=3 independent experiments. b) mTNF 
expression was analysed by Western blot. c) Densitometry analysis of TNF- expression. 
Bars represent protein expression mean+SEM, n=3. 
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Figure 5-13 Preliminary data. Effect of NS11021 on TNF- release from LPS 
conditioned macrophages. 
RAW264.7 macrophages were incubated with 10 ng/ml LPS for 24 hours to produce LPS 
conditioned macrophages. Subsequently the media was replaced and conditioned cells were 
activated with 150 ng/ml LPS with/without 100 nM NS11021. After 4 hours, culture media 
was collected and analysed by ELISA for TNF-Graph show mean+ SEM from one 
experiment with n=4. Statistical significance was tested by paired t-test. O.D.:optical 
density.*p<0.05 
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5.3 Discussion 
The first aim of this chapter was to investigate the effect of BK channel blockers, 
IbTX and paxilline, on the release of TNF-, IL-6 and IL-6R. IbTX is a 37 amino 
acids peptide toxin isolated from scorpion venom. IbTX achieves a half maximum 
block of BK channels within the nM range and is highly selective for BK channels at 
30 nM. This drug is impermeable to the lipid bilayer membranes and blocks the pore 
region of the channels from the outside (Galvez et al., 1990; Yu et al., 2016). 
Through PRRs, macrophages are known to respond to various microbial toxins. 
Therefore it was important to establish if IbTX lead to the direct activation of 
macrophages at the concentrations which the drug blocks BK channels. It was found 
that IbTX did not stimulate TNF-, IL-6 release or alter IL-6R release from resting 
macrophages. The IbTX was not toxic to the cells over 4 hours. Taken together 
these results suggested that IbTX itself does not stimulate inflammatory cascades in 
macrophages. 
 
The tremorgenic mycotoxin, paxilline is another selective blocker for BK channels. 
The size of  paxilline is 435 Da and is highly lipophilic in nature (Knaus et al., 1994b). 
Previous research has demonstrated that the paxilline blocks BK channels 
differently depending on the channels activation state. The affinity of this blocker to 
the channels has been reported to be inversely proportional to the open probability 
(Po) of the channel. The IC50 of this drug ranges from 10 nM, when the channels are 
closed, to 10 M ,when the channels are opening at maximum rate (Zhou and Lingle, 
2014). In this thesis, the paxilline doses above 1 M appeared to affect the viability 
of the cells. Paxilline also significantly enhanced TNF- secretion from 
macrophages, activated with submaximal dose of LPS. However this effect was lost 
when macrophages were stimulated with the optimal dose for TNF-release. The 
result showed that paxilline modulated cytokine secretion from macrophages. If IbTX 
and paxilline are selective to BK channels how could they elicit differing effects? 
From chapter 4, it was demonstrated that RAW264.7 macrophages had low 
expression of BK channels on the plasma membrane in resting conditions and 4 
hours after LPS activation. BK channels were abundant at intracellularly sites in 
resting RAW264.7 macrophages and at early time points of LPS activation. Owing to 
its lipophilic nature, it is possible that the paxilline entered cells and blocked 
intercellular BK channels whereas IbTX does not. Alternatively paxilline may 
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enhance TNF- release by the off-target effect which is in addition to BK channel 
block. Additional targets for paxilline have been reported. At M levels, paxilline 
inhibits Ca2+ ATPase and IP3 receptors (Longland et al., 2000; Bilmen et al., 2002). 
As this drug is widely used to study the BK channel, it would be worth investigating 
the mechanisms of how paxilline causes the activation of macrophages.  
 
IbTX is considered to be a gold standard for the BK channel inhibition. Importantly, it 
only blocks BK channels located on the plasma membrane, thus provides a unique 
tool to selectively investigate plasma membrane located BK channels without 
affecting the intercellular pool of BK channels. For this reason, IbTX was used to 
block the plasma membrane located BK channel.  
 
To investigate the effect of the plasma membrane BK channel block it was 
necessary for the cells to express functional BK channels on their plasma 
membrane. Results from chapter 4 have demonstrated that BK channels are 
upregulated on the plasma membrane 24 hours after stimulation with 10 ng/ml LPS, 
using this observation, a protocol was developed to investigate the role of the BK 
channel in activated macrophages. In this protocol, macrophages were stimulated 
for 24 hours with a sub-optimal dose of LPS to induce BK expression on the plasma 
membrane. These macrophages were termed ‘LPS conditioned’ macrophages.  
These cells were then activated with 150 ng/ml LPS for 4 hours and the drug could 
be applied during the activation to investigate BK channels role.   
 
This protocol of low dose followed by high dose treatment with LPS is reminiscent of 
LPS/endotoxin tolerance, which is a well-appreciated immunological phenomenon 
(Morris et al., 2015). In this response, a first challenge of cells, usually macrophages, 
with a low dose of LPS causes macrophages to become less responsive to 
subsequent challenge with a higher dose of LPS. In the tolerant state, immune cells 
have been reported to down-regulate the release of pro-inflammatory cytokines in 
response to the second challenge (Biswas and Lopez-Collazo, 2009). LPS tolerance 
is not only seen at cellular level, but also may be important in clinical settings where 
the immune system becomes unresponsive to a subsequent bacterial infections. To 
date multiple mechanisms have been implicated in the establishment/maintenance 
of endotoxin tolerance. Among these mechanisms, the downregulation of 
     Chapter 5 Effect of BK channel blockers 
144 
 
proinflammatory cytokine transcription is considered to be most prominent. However, 
it is likely the multiple mechanisms are involved in tolerance. As expected, 
stimulation of macrophages with 10 ng/ml LPS generated the tolerance state and 
reduced the release of TNF- form macrophages in response to secondary 
stimulation with 150 ng/ml. mTNF- expression was also decreased in LPS 
conditioned RAW264.7 macrophages. However, in comparison to TNF-, it was 
noted that IL-6 was significantly increased in LPS conditioned macrophages by 3 
fold. There was also a significant increase in IL-6R release. This opposing effect 
on IL-6 release may rather represent the priming effect of immune cells. It has been 
known that low dose of LPS application could dramatically enhance the 
inflammatory response to subsequent LPS application (Morris et al., 2015). 
 
30 nM IbTX significantly increased TNF- release by 55%. Indeed it appeared to 
reverse the effect of endotoxin tolerance in TNF- release. However this was not 
associated with an increase in TNF-mRNA, but at the post transcriptional site.  To 
investigate the cellular contents of mTNF- expression in these cells, Western blot 
was performed using a rabbit monoclonal anti-mouse TNF- antibody D2D4. Firstly, 
in non-treated resting cells no protein band appeared, in LPS activated 
macrophages, the major band at 26 kDa and minor bands approximately at 30 kDa 
appeared indicating the production of TNF- in response to TLR4 activation. The 
major band possibly corresponds to 26 kDa membrane anchored form TNF- and 
minor bands to glycosylated form. In the LPS conditioned macrophages IbTX 
decreased the expression of mTNF- by 44% which negatively correlated with the 
increase in the secretion of TNF- from IbTX treated LPS conditioned cells. These 
results suggest that BK channels regulate TNF- at the secretion from the cells and 
not earlier protein synthesis. In support of this, IbTX treatment did not affect the 
mRNA for TNF-In deed the most likely explanation is that the BK channel 
negatively regulates the release of TNF- from the plasma membrane. In support of 
the negative effect of BK channel in the release of TNF-, an application of 100 nM 
BK opener, NS11021, at the dose selective for BK channels resulted in a significant 
decrease in TNF- release. However it is noted that NS11021 is lipophilic in nature 
and the interpretation of the results from this activator may not be limited in the 
activation of the plasma membrane BK channel.  
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TNF- is initially expressed as its transmembrane form of 26 kDa mTNF-. 
Membrane metalloproteases cleave mTNF- to release the soluble 17 kDa TNF-. 
ADAM17 is the primary enzyme to facilitate TNF- ecotodomain shedding. This 
enzyme also cleaves IL-6R and is known to increase IL-6R in the circulation 
(Khokha et al., 2013). It is noted that IL-6R is also reported as a substrate for a 
membrane metalloprotease, ADAM10 (Giebeler and Zigrino, 2016). IbTX further 
increased IL-6R release observed in LPS treated conditioned macrophages. 
Collectively, the data indicated possible interaction between the plasma membrane 
BK channel and the ADAMs.  
 
IL-6, by contrast, is not expressed in a transmembrane form and is not subjected to 
cleavage by ADAM17 or other members of membrane metalloproteases family 
(Arango Duque and Descoteaux, 2014). IL-6 is produced in the endoplasmic 
reticulum and directed to Golgi. Accumulation has been reported to occur after 4 
hours of LPS stimulation in RAW264.7 macrophages (Manderson et al., 2007). IL-6 
then exits from the Golgi, in vesicles and is secreted from the membrane via 
SNARE-mediated fusion with plasma membrane without processing as a 
transmembrane form. The block of the plasma membrane BK channels had no 
effect on IL-6 release during LPS stimulation of conditioned macrophages. Again 
this observation also supports the plasma membrane BK channels are working on 
the substrates of ADAM17. Therefore it was important to establish the role of 
ADAM17 in our system and interaction between its proteolytic activity and BK 
channels.  
 
This chapter demonstrated that IbTX increased the release of TNF-at the 
secretion in LPS conditioned macrophages. The release of IL-6R is also enhanced 
by IbTX however IL-6 was not affected. This opened up the hypothesis that BK 
channels located on the plasma membrane may be involved in the regulation of 
ADAM17 activity. 
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 Chapter 6 Does ADAM17 have a role in TNF- and/or IL-6R 
release in macrophages and does the plasma membrane 
BK channel regulate ADAM17 activity? 
6.1 Introduction 
Chapter 5 indicated a possible interaction between the plasma membrane BK 
channel and the release TNF- and IL-6R. The release of TNF- and IL-6R is 
mediated by ADAM17. It was hypothesised that the plasma membrane located BK 
channel may regulate ADAM17 activity. The aim of this chapter was to first 
investigate the expression and function of ADAM17 protein in RAW264.7 
macrophages and secondly to study the effect of IbTX on the activity of ADAM17.   
 
6.2 Results 
6.2.1 ADAM17 expression in TLR4 activated macrophages 
A rabbit polyclonal antibody for ADAM17, ab2051, which designed to bind the C-
terminal region of the enzyme protein, was used to characterise the expression of 
ADAM17 in RAW264.7 macrophages. Figure 6-1 and Figure 6-2 show blots of 
ADAM17 in whole cell and plasma membrane isolate from RAW264.7 macrophages 
during treatment with 10 ng/ml LPS for up to 24 hours. ADAM17 has been reported 
to exist in a full length precursor 130 kDa and active 85 kDa forms. Ab2051 detected 
the presence of 85 and 130 kDa protein bands from whole cell lysates of RAW264.7 
macrophages, Figure 6-1.  In whole cell lysate, 10 ng/ml LPS treatment caused an 
increase in the expression level of 85 kDa protein bands, peaking around 24 hours 
of LPS stimulation, Figure 6-1.  By contrast, protein bands at 130 kDa in whole cell 
lysate stayed relatively constant during the time course of LPS treatment except at 
24 hours where the protein band appeared weaker, Figure 6-1. A cytosolic protein, 
Akt, which was used to validate isolation process, was present in whole cell lysate 
and absent in plasma membrane isolate indicating that the cell surface isolation 
appeared not to have the contamination of cytosolic contents, Figure 6-1 and Figure 
6-2. 
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Figure 6-1 ADAM17 expression in whole cell lysate from LPS activated 
macrophages  
RAW264.7 macrophages were treated with 10 ng/ml LPS for 0-24 hours. ADAM17, Akt and 
-actin expression in whole cell lysate (WC) were analysed by Western blot. -actin acted as 
a loading control. The experiment was repeated 3 times. 
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Western blot analysis of the plasma membrane isolates using an anti-ADAM17 
antibody demonstrated the presence of protein bands at 85 and 130 kDa in plasma 
membrane isolate, Figure 6-2. It appeared that the level of 85 kDa form and the 
level of 130 kDa from ADAM17 stayed relatively constant during LPS treatment 
except that the expression level of 85 kDa form appeared highest at 12 hours of 
LPS treatment, Figure 6-2.    
 
 
Figure 6-2 ADAM17 expression in plasma membrane isolate from LPS 
activated macrophages 
RAW264.7 macrophages were treated with 10 ng/ml LPS for 0-24 hours. ADAM17, AkT and 
-actin expression in plasma membrane isolate (PM) were analysed by Western blot. -actin 
acted as a loading control. Absence of cytosolic protein AkT was used to check the 
contamination of cytosolic contents in isolation process. The experiment was repeated 4 
times.  
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6.2.2 ADAM17 activity in TLR4 activated macrophages  
The ultimate aim of this chapter was to investigate if the plasma membrane BK 
channel regulates the activity of ADAM17. To test this, it was required that ADAM17 
activity was measured in the system which allowed the physical interaction between 
plasma membrane BK channel and ADAM17 to be maintained. Therefore, although 
the majority of ADAM17 assays have been done in cell-free systems, it was 
important that this assay was performed in live cells. Reported protocols were used 
and adapted to meet the requirement of the experiment (Alvarez-Iglesias et al., 
2005). After initial experiments, using fluorogenic TACE substrate II, a substrate for 
ADAM17 in this assay, it was found that the phenol red formulated in the media 
used and FBS lead to a high background by interfering with the fluorescence signal 
resulting from TACE substrate cleavage. Therefore enzyme activity assays were 
carried out with phenol red-free DMEM and FBS free DMEM.  
 
The cells received LPS conditioning for 24 hours, as described in chapter 5, Figure 
5-7. This protocol was demonstrated to upregulate the plasma membrane BK 
channels in macrophages in chapter 4. At 24 hours, the media was replaced with 
FBS and phenol red free DMEM during the macrophages activation with 150 ng/ml 
LPS for 3 hours, the substrate was added for the final hour. To preserve the spatial 
configuration of cellular components in the macrophages, the enzyme assay was 
carried out on plated live cells. As described in 2.15, the wells without TACE II 
substrate were prepared in order to eliminate the interference with the data from 
endogenous fluorescence of the cells. Per minute change in fluoresce signal in wells 
with TACE II substrate after the subtraction of the control measurement was 
estimated as ADAM17 membrane sheddase activity. ADAM17 activity data was 
reported as the rate of fluorescence signal increase per minute. In all experiments, 
ADAM17 inhibitors were used to confirm that increase in fluorescence was due to 
the enzyme activity of ADAM17. 
 
The ADAM17 activity in the group which received LPS conditioning showed 
significantly higher activity compared to the group which did not receive LPS 
conditioning, 1718+/-261fluorescence/minute without LPS conditioning and 2459+/-
119 fluorescence/minute in LPS conditioned cells, p<0.05, Figure 6-3.   
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Application of 4.5 M GM6001, a general inhibitor for membrane metalloproteases, 
diminished fluorescence signal by 86% in groups without LPS conditioning. The 
activity in DMSO control was 1718+/-261 fluorescence/minute and 235+/-344 
fluorescence/minute in GM6001 treatment group, p<0.05, Figure 6-3. A  reduction of 
93% was also observed with GM6001 treatment in LPS conditioned macrophages, 
where DMSO control groups showed 2459+/-119 fluorescence/minute and GM6001 
treatment group showed 183+/-96.4 fluorescence/minute, p<0.001, Figure 6-3. 
Treatment with 0.6 M TAPI-0, a specific inhibitor for ADAM17, also significantly 
reduced the signal but at lesser degree compared to GM6001. The reduction in 
fluorescence signal was 70% in groups without conditioning, where DMSO control 
groups had 1718+/-26 fluorescence/minute and TAPI-0 treatment group had 528+/- 
13 fluorescence/minute, p<0.05, Figure 6-3. TAPI-0 also reduced ADAM17 activity 
by 59% in LPS conditioned groups, where DMSO control group had 2459+/-119 
fluorescence/minute and TAPI-0 treatment group had 1019+/-232 
fluorescence/minute, p<0.05, Figure 6-3.  
 
The results demonstrated the presence of enzymatically active ADAM17 in TLR4 
activated RAW264.7 macrophages. This section also showed that inhibitors for 
ADAM17, significantly down-regulated the substrate cleavage. Utilizing these 
inhibitors the next section was aimed to investigate its effect of ADAM17 inhibitors 
on the release of TNF-, IL-6 and IL-6R. 
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Figure 6-3 ADAM17 activity in LPS activated macrophages and the effect of 
LPS conditioning, GM6001 and TAPI-0 
RAW264.7 macrophages were incubated with 10 ng/ml LPS for 24 hours to produce LPS 
conditioned macrophages. Non conditioned macrophages (ctrl) did not receive this 
preconditioning.  Subsequently the media was replaced and the cells were stimulated with 
150 ng/ml LPS for 3 hours and TACE II substrate was applied at 5 M with/without inhibitors 
for ADAM17, 4.5 M GM6001, light grey bars, or 0.3 M TAPI-0, dark grey bars, for the final 
hour. Control wells received DMSO, clear bars, and the final concentration of DMSO in all 
wells was 0.15%. Fluorescence signals were monitored every 10 minutes for 60 minutes 
after the addition of the enzyme substrate and the rate of change in fluorescence between 
10 to 50 minutes was expressed as ADAM activity (fluorescence/minute). Bars represent 
mean+SEM, n=4, repeated experiments. Statistical significance within groups received no 
LPS conditioning or within the groups received LPS conditioning was tested using one-way 
ANOVA followed by Dunnett’s test. Statistical significance between non conditioned and LPS 
conditioned groups were tested using paired t-test. *p<0.05, ***p<0.001.  
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6.2.3 Effect of a general inhibitor for membrane metalloproteases, GM6001 and 
ADAM17 specific inhibitor, TAPI-0, on TNF-and/or IL-6R release from 
TLR4 activated macrophages 
GM6001 doses at 0.45-4.5 M was applied during 150 ng/ml LPS activation of 
macrophages for 4 hours and its effect on TNF- and IL-6R release was assessed. 
GM6001 dose dependently inhibited TNF-release with the maximum decrease in 
TNF- secretion by 86% at 4.5 M GM6001. The level of TNF- was 12.9+/-4.2 
ng/ml in DMSO control and 1.8+/-0.48 ng/ml in the 4.5 M GM6001 treatment group, 
p<0.001 Figure 6-4a. IL-6Rrelease was also inhibited by GM6001 with the 
maximum reduction of 49% occurring at 1.5 M GM6001. The level of IL-6R was 
81.6+/-6.2 pg/ml in DMSO control group and 32.6+/-0.5 pg/ml in the group with 1.5 
M GM6001 treatment, p<0.05, Figure 6-4a. 
 
TAPI-0 0.1- 0.6 M was applied to RAW264.7 macrophages during 150 ng/ml LPS 
activation for 4 hours. TAPI-0 inhibited the release of TNF- with the maximum 
reduction by 70% at 0.3 M TAPI-0. The level of TNF- was 13.0+/-2.2 ng/ml in 
DMSO control group and 3.9+/-0.24 ng/ml in the 0.3 M TAPI-0 p<0.05, Figure 6-5a. 
TAPI-0 inhibited IL-6R release and with a maximum inhibition of 49% in the groups 
treated with 0.3 M TAPI-0. The level of IL-6R was 79.2+/-8.7 pg/ml in DMSO 
control group and 41.3+/-12.8 pg/ml in 0.3 M TAPI-0 group, Figure 6-5a. 
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Figure 6-4  Effect of GM6001 on TNF-and IL-6R release from LPS activated 
macrophages  
RAW264.7 macrophages were treated with 150 ng/ml LPS with/without 0.45, 1.5 or 4.5 M 
GM6001, grey bars, or vehicle control, clear bars. At 4 hours culture media was collected. 
The amount of TNF-and IL-6R in conditioned media was measured by ELISA. Bars show 
mean+SEM (n≥3). a) shows results from one experiment with n=3 and b) shows combined 
data from 3 repeated experiments. Controls received DMSO vehicle (DMSO Veh.) and all 
wells had 0.015 % DMSO. Statistical significance of treatment groups compared to DMSO 
control group was tested using one-way ANOVA followed by Dunnett’s test.*p<0.05, 
**p<0.001.   
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Figure 6-5 Effect of an ADAM17 inhibitor, TAPI-0, on TNF-and IL-6R release 
from LPS activated macrophages  
RAW264.7 macrophages were treated with 150 ng/ml LPS with/without 0.1, 0.3 or 0.6 M 
TAPI-0, grey bars, or vehicle control, clear bars. At 4 hours culture media was collected. The 
amount of TNF-and IL-6R in conditioned media was measured by ELISA. Bars represent 
mean+SEM (n≥3).a) shows result from one experiment with n=3 and b) shows combined 
data from 3 repeated experiments. Controls contained 0.015 % DMSO. Statistical 
significance of treatment groups compared to DMSO control group was tested using one-
way ANOVA followed by Dunnett’s test.*p<0.05, **p<0.01, ***p<0.0001. 
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6.2.4 Effect of GM6001 and TAPI-0 on IL-6 release from TLR4 activated 
macrophages 
Application of GM6001 did not affect the release of IL-6. The level of IL-6 was 
recorded as 0.65+/-0.059 ng/ml from DMSO control group and 0.62+/-0.045 from 
4.5 M GM6001 treatment group, Figure 6-6a. TAPI-0 treatment did not affect the 
release of IL-6 and was 0.35+/-0.017 ng/ml in the DMSO control group and 0.32+/-
0.0072 ng/ml in the group received 0.6 M TAPI-0, Figure 6-6a. MTT assay showed 
that GM6001 and TAPI-0 treatments had no effect on the viability of cells, Figure 6-
7a. 
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Figure 6-6  Effect of GM6001 and TAPI-0 on IL-6 release from LPS activated 
macrophages  
RAW264.7 macrophages were treated with 150 ng/ml LPS with 0.45, 1.5 or 4.5 M GM6001 
or 0.1, 0.3 or 0.6 M TAPI-0 grey bars, or vehicle control, clear bars. At 4 hours culture 
media was collected. The amount of IL-6 in conditioned media was measured by ELISA. 
Bars represent mean+SEM (n≥3). a) shows result from one experiment and b) shows 
combined data from 3 repeated experiments. Controls groups received DMSO vehicle 
(DMSO Veh.) and all wells contained 0.015 % DMSO. Statistical significance of treatment 
groups compared to DMSO control group was tested using one-way ANOVA followed by 
Dunnett’s test.    
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Figure 6-7  Effect of LPS, GM6001 or TAPI-0 treatments on cell viability 
RAW264.7 macrophages were treated with 150 ng/ml LPS with 0.45, 1.5 or 4.5 M GM6001 
or 0.1, 0.3 or 0.6 M TAPI-0, grey bars, or vehicle control, clear bars. At 4 hours cell viability 
was assessed by MTT assay and expressed as mean+SEM (n≥3). a) shows results from 
one experiment and b) shows combined data from 3 repeated experiments. O.D.: optical 
density. Controls groups received DMSO vehicle (DMSO Veh.) and all wells contained 
0.015 % DMSO. Statistical significance of control group compared to treatment groups was 
tested using one-way ANOVA followed by Dunnet’s test.   
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6.2.5 Effect of IbTX on ADAM17 activity in macrophages 
 IbTX had no effect on the activity of ADAM17 during 4 hours of LPS activation with 
activity being 1545+/-42 fluorescence/minute in LPS only group and 1457+/-108 
fluorescence/minute in LPS with IbTX group, N.S., Figure 6-8. Next RAW264.7 
macrophages received LPS conditioning to upregulate the plasma membrane BK 
channel. 30 nM IbTX was applied to these macrophages and its effect on ADAM17 
activity was compared to conditioned macrophages which did not receive IbTX. In 
LPS conditioned cells, IbTX treatment dramatically increased ADAM17 activity by 
150%. The activity was at 2560+/-228 fluorescence/minute in control LPS group and 
at 7095+/-1485 fluorescence/minute in IbTX treatment group, p<0.05, Figure 6-9 . In 
all treatment groups, the increase in fluorescence was inhibited by 4.5 M GM6001. 
The activity was 166+/-111 fluorescence/minute in the group received LPS and 
GM6001, p<0.01 compared to LPS with DMSO control group, and at 394+/-99 
fluorescence/minute in the group received LPS, IbTX and GM6001, p<0.001 
compared to control. This indicated that fluorescence signals were due to the activity 
of membrane bound metalloproteases. In LPS conditioned groups, application of 0.3 
M TAPI-0 also inhibited activity of ADAM17 but to a lesser degree than GM6001. 
The activity was 1515+/-216 fluorescence/minute in the group received LPS with 
TAPI-0, p<0.05 compared to LPS with DMSO control group and was at 1008+/-453 
fluorescence/minutes in the group received LPS, IbTX and TAPI-0, p<0.05 
compared to the group with LPS, IbTX and DMSO control, Figure 6-9. 
 
The combined data, from repeated (≥ 3 times) experiments, for protein release and 
MTT was in line with the described results from individual experiments. These 
combined data were presented in Figure 6-3, 6-4, 6-5, 6-6 and 6-7. Statistical 
analysis of combined data and individual experimental data demonstrated a similar 
pattern of significance between treatment groups. It was higher degree of 
significance was seen in combined data compared to individual experimental data. 
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Figure 6-8 Effect of IbTX on ADAM17 activity of LPS activated of macrophages  
RAW264.7 macrophages were stimulated with 150 ng/ml LPS with/without 30 nM IbTX for 3 
hours and TACE II substrate was applied at 5 M during the first 1 hour. Fluorescence 
signals were monitored in 10 minutes interval for 60 minutes and signals between 10 to 50 
minutes used for analysis. The concentration of DMSO in all wells was at 0.15%. ADAM17 
activity was measured as per minutes increase in fluorescence signal. Bars show 
mean+SEM with n=3 repeated experiments. Statistical significance was tested by paired t-
test.   
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Figure 6-9 Effect of IbTX on ADAM17 activity in LPS conditioned macrophages  
RAW264.7 macrophages were incubated with 10 ng/ml LPS for 24 hours to produce LPS 
conditioned macrophages. Subsequently these macrophages were stimulated with 150 
ng/ml LPS for 3 hours and TACE II substrate was applied at 5 M for the final hour. Cells 
recived IbTX, grey bars, or media alone, clear bars, with/without inhibitors for ADAM17, 4.5 
M GM6001 or 0.6 M TAPI-0. The final DMSO concentration was 0.15 % and DMSO acted 
as the vehicle control (DMSO Veh.) Fluorescence signals were monitored in 10 minutes 
interval for 60 minutes and the rate of change in fluorescence between 10 to 50 minutes was 
used to assess ADAM activity (fluorescence/minute). Bars show mean+SEM with n=3 
repeated experiments. Statistical significance between the treatment groups of interest 
versus the relevant control group is indicated by horizontal lines and tested using paired t-
test. *p<0.05,**p<0.01,***p<0.0001.  
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6.2.6 Effect of IbTX on  ADAM17 expression 
The effect of IbTX on the expression of ADAM17 during LPS activation of 
conditioned macrophages was analysed by Western blot in a single preliminary 
study. It was difficult to obtain clean blot from this experiment. However at whole cell 
level there was 51% increase in the expression of 85 kDa protein band with IbTX 
treatment, while the level of 130 kDa  protein was not affected, Figure 6-10.  
  
 
     
Figure 6-10 Preliminary data. Effect of IbTX on ADAM17 expression  
RAW264.7 macrophages were incubated with 10 ng/ml LPS for 24 hours to produce LPS 
conditioned macrophages. Subsequently the media was replaced and the conditioned cells 
were activated with 150 ng/ml LPS for 4 hours with, grey bars, or without, clear bars, 30nM 
IbTX. a) ADAM17 expression was analysed by Western blot and -actin acted as a loading 
control. Densitometry analysis shows relative expression of b) 85 kDa band or c) 130 kDa in 
IbTX treatment group compared to activated macrophage containing no IbTX only group. 
Blots were obtained from a single preliminary experiment. 
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6.3 Discussion 
ADAM17 was first identified in 1997 as a membrane bound enzyme which release 
mTNF- from the cell surface (Black et al., 1997; Moss et al., 1997). Since its 
discovery, a diverse range of molecules, including cytokines, growth factors, 
receptors and adhesion molecules have been found to be the targets for ADAM17. 
76 proteins have been identified as substrates for the enzyme (Scheller et al., 2011; 
Giebeler and Zigrino, 2016). Many of the substrates for ADAM17 are involved in the 
inflammatory responses as well as in other intercellular signalling mechanisms. 
Examples include the regulation of TNF- signalling by the cleavage of TNF- and 
its receptors, the initiation of epidermal growth factor receptor (EGFR)-mediated 
proliferation by ecotodomain shedding of heparin-binding EGF-like growth factor 
(HB-EGF) and the modulation of regulated intramembrane proteolysis by cleavage 
of Notch receptor. Taken together ADAM17 regulates a wide range of biological 
responses, including the immune response, cell survival and growth (Scheller et al., 
2011). However an essential question is how ADAM17 selectively regulates the 
release of these substrate molecules in a special manner to initiate specific cellular 
signalling pathways? 
 
Due to its important role in biology, ADAM17 is one of the best characterised 
members of membrane metalloproteases family. While global ADAM17 knock-out 
animals are not viable, the significance of this enzyme is seen in the studies using a 
cell specific gene deletion, for example, mice deficient in myeloid ADAM17 are 
resistant to septic shock (Horiuchi et al., 2007). The enzyme has been also shown to 
mediate key roles in the regeneration and resolution of inflammation. Using a novel 
transgenic technique termed exon-induced translational stop, it was demonstrated 
that epithelial cells with an approximately 95% reduction in ADAM17 expression had 
deficiencies in intestinal barrier function and poor recovery after intestine 
inflammation. This was due to insufficient TGFand EGFR signalling (Chalaris et al., 
2010). 
   
Perhaps reflecting its important role, the expression and activity of the protease is 
highly regulated, with the protein undergoing a series of maturation processes to 
become an active enzyme on the plasma membrane. It has been reported that 
ADAM17 is initially translated as a catalytically inactive form with pro-domain 
masking the catalytic site of this enzyme. At late Golgi compartment, the pro-domain 
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is cleaved by furin convertases, which is thought to be essential for ADAM17 
protease activity. Due to this maturation process, the cellular ADAM17 is likely to 
appear at two distinct molecular weights, a 133 kDa full length precursor and 90 kDa 
matured enzyme without pro-domain peptide (Schlöndorff et al., 2000). The enzyme 
is then transported to the plasma membrane by iRhom2. Research has reported that 
this translocation by iRhom2 is essential for the expression and function of ADAM17 
at the plasma membrane (Adrain et al., 2012; McIlwain et al., 2012; Siggs et al., 
2012). Phosphorylation of cytoplasmic tail of ADAM17 by p38 at thereonine 735 has 
also been reported to increase the trafficking of ADAM17 to the cell surface (Soond 
et al., 2005). At the cell surface, ADAM17 is thought to exist as a homo-dimer in 
association with tissue inhibitor of metalloproteinases-3 (TIMP-3) (Xu et al., 2012b). 
Inflammatory signalling is believed to cause the dissociation of this dimer into an 
active monomer enzyme and the release of TIMP-3. Yet, the precise mechanism by 
which ADAM17 becomes activated is still controversial. A study has suggested that 
early in an inflammatory response, the release of TNF- and L-selectin by ADAM17 
does not require the removal of pro-domain of the enzyme nor TIMP-3 dissociation 
suggesting a more rapid and reversible activation of this enzyme. These authors 
speculated that early ADAM17 activation was determined by the local lipid bilayer 
microenvironment, composition and charge (Schwarz et al., 2013). In another study 
it was demonstrated that the enzyme does not require the phosphorylation of C-
terminal, but that the transmembrane region of the ADAM17 is essential in the 
control of substrate cleavage (Li et al., 2007). However the majority of these studies 
are carried out in cell expression systems which may not contain all relevant 
regulatory mechanisms found for ADAM17 activation in other cells and 
interpretations of these results could be limited.  
 
This chapter characterised the expression and function of ADAM17 and tested the 
hypothesis that BK channel on the plasma membrane regulated the activity of this 
enzyme. ADAM17 is expressed 85 kDa and 130 kDa protein in whole cell lysate and 
plasma membranes isolates from RAW264.7 macrophages. Protein bands at 130 
kDa are believed to represent its precursor form with the 85 kDa form indicating the 
matured form of the enzyme. Previous research demonstrated that the sheddase 
activity of this enzyme is positively correlate with the mature form of the enzyme 
(Black et al., 1997).   
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Interestingly, the expressions of ADAM17 followed a distinct pattern between whole 
cell and plasma membrane during LPS activation of RAW264.7 macrophages. At 
whole cell level, 130 kDa ADAM17 appeared to be present under resting condition 
and remained at similar level thought the time course of LPS activation. Taking this 
into account, it appeared that there was an increase in the mature form of ADAM17 
at 85 kDa, 12 to 18 hours after LPS treatment. In this thesis the ADAM17 at 85 kDa 
did not appear as a distinct band, but appeared as smear. The existence of full-
length ADAM17 on the plasma membrane of RAW264.7 macrophages contrasted 
with the conclusion from a study using human COS-7 cells, where full length form 
ADAM17 was hardly detected in the cell surface protein (Schlöndorff et al., 2000). 
Possible explanations for this phenomenon may include differences in the cell 
surface protein isolation process, different mode of cell activation and/or species 
specific regulation of ADAM17 localisation. While the above measurement of 
ADAM17 protein in cell preparation is important, ADAM17 activity in living cells 
general gives a better insight into control mechanism for an enzyme. 
 
The use of a fluorogenic substrate for ADAM17 indicated the presence of membrane 
sheddase activity of ADAM17 in RAW264.7 macrophages. The use of the general 
metalloproteases inhibitor, GM6001, also confirmed that the activity assay was 
measuring the membrane metalloproteases activity in RAW264.7 macrophages. 
The enzyme activity in these macrophages seemed to increase after LPS treatment. 
The data could indicate that LPS may have caused the upregulation of this enzymes 
activity in these cells. Importantly a selective inhibitor for ADAM17, TAPI-0 also 
inhibited the increased activity. This data support a role for ADAM17 in this assay 
and demonstrate the presence of ADAM17 on the plasma membrane on RAW264.7 
macrophages. Comparing the degree of inhibition between GM6001 and TAPI-0, it 
appeared that the ADAM17 was the dominant metalloprotease responsible for the 
breakdown of TACE II substrate.   
 
Cells release cytokines by a variety of mechanisms, such as membrane fusion of 
secretary granules and ecoto-domain shedding of transmembrane anchored 
cytokines by membrane bound proteases (Stow et al., 2009). Macrophages release 
TNF- via the latter mechanisms (Arango Duque and Descoteaux, 2014). In line 
with this, the inhibition of membrane metalloproteases by GM6001 significantly 
reduced the amount of TNF-release from LPS activated RAW264.7 macrophages. 
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The release of TNF- was also significantly reduced by the application of TAPI-0, a 
selective inhibitor of ADAM17. The maximum inhibition of TNF- release achieved 
with this drug was approximately 70%, as compared with 90% with GM6001. The 
discrepancy in the inhibitory effects between GM6001 and TAPI-0 could suggest the 
involvement of other membrane metalloproteases such as ADAM10 in TNF-
release, with the greater effect of GM6001 being due to the inhibition of both 
ADAM10 and ADAM17. However the difference also may due to the potency and/or 
half-lives of the two drugs. In this thesis, TAPI-0 was found to have a maximal effect 
on TNF- inhibition at 0.3 M. It must be noted that at concentrations above 2 M, 
TAPI-0 has been shown to inhibit other metalloproteinases. To further investigate 
the release of TNF- in the system, it would be necessary to silence ADAM17 by 
gene silencing. However, it is difficult to achieve an effective silencing of protein 
expression in RAW264.7 cells as it will be discussed in chapter 7.  
 
The inhibition of membrane metalloproteases by GM6001 and the inhibition of 
ADAM17 by TAPI-0 also effectively inhibited the release of IL-6R. It has been 
known that ADAM10 and ADAM17 are involved in the release of IL-6RAnother 
study has suggested that ADAM10 and ADAM17 may work on different regions for 
cleavage. ADAM17 requires its stalk region, a triple serine (3S) motif (Ser-359 to 
Ser-361) adjacent to the cleavage site for IL-6R in human, while ADAM10 does not 
(Riethmueller et al., 2016). The result with TAPI-0 suggested the involvement of 
ADAM17 in releasing IL-6R.  To clarify involvement and relative contribution of 
ADAM10 and ADAM17 in RAW264.7 macrophages, the application of selective 
inhibitors for ADAM10 and gene silencing of individual enzyme, especially ADAM17, 
would be suggested. 
 
While GM6001 and TAPI-0 inhibited the release of IL-6R release, the inhibition of 
this receptor was to lesser degree compared to the inhibition observed in TNF- 
release. In addition to membrane shedding by membrane metalloproteases, 
alternative splicing of IL-6R mRNA also leads to the soluble/circulating form of IL-
6R, which is independent of membrane metalloproteases (Rose-John and Heinrich, 
1994). It is believed that the contribution of mRNA splicing pathway to IL-6R 
production is relatively minor compared to the membrane metalloprotease mediated 
shedding. Collectively the results demonstrated that ADAM17 protein is expressed 
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in RAW264.7 macrophages and functions as a membrane sheddase for mTNF- 
and IL-6R.  Therefore although other metalloproteases than ADAM17 also cause 
the release of TNF- and IL-6R, the data from this chapter would suggest that 
ADAM17 mediated sheddase activity is the major mechanism by which TNF- is 
released from RAW264.7 macrophages.  
 
Pharmacological inhibition of plasma membrane located BK channels in RAW264.7 
macrophages by IbTX dramatically enhanced the activity of ADAM17. This result 
was in line with the observation from chapter 5, where IbTX significantly enhanced 
TNF- and IL-6R release and reduced cellular mTNF-. Importantly IbTX only 
increased ADAM17 in conditioned macrophages. The LPS pre-conditioning is 
required to increase the expression of the BK channel on the plasma membrane, 
and therefore the data is in line with a role for the channel in regulating ADAM17 
activity. The results suggest that BK channels on the plasmas membrane of 
macrophages negatively regulate the activity of ADAM17. As a preliminary study, it 
was tested if IbTX changed in ADAM17 expression. IbTX appeared to increase the 
expression of 85 kDa ADAM17 in LPS stimulated RAW264.7 macrophages. 
However it should be noted that this data is from a single preliminary experiment 
and this interpretation is limited in the case that the level of 85 kDa ADAM17 
expressions and its activity is directly proportional to each other. To confirm this 
phenomenon, further experiments is required. The experiments could be suggested 
would be first to investigate the correlation between 85 kDa form enzyme and the 
activity of ADAM17 in RAW264.7 cells and this experiment also need to be further 
repeat with plasma membrane isolate.  
 
The data suggested a role for BK channels in regulating TNF- and IL-6R from 
macrophages via activity of ADAM17. This links an ion channel activity to protein 
secretory mechanisms and suggests a novel regulatory process for ADAM17. 
However this analysis relays on the selectivity of IbTX for BK channels. Therefore in 
next chapter an alternative method to inhibit BK channels, gene silencing, was used. 
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 Chapter 7 Does BK channel silencing upregulate ADAM17 
activity in macrophages? 
7.1 Introduction 
Chapter 6 showed that a pharmacological inhibition of the plasma membrane BK 
channel increased the activity of ADAM17, suggesting a role for BK channels in 
regulating the activity of ADAM17. The aim of this chapter is to study the effect of 
genetic inhibition of BK channels on ADAM17 to validate the results using IbTX. 
The introduction of genetic materials into macrophages is known to be problematic 
as transfection reagents/vectors themselves can lead to the activation of 
macrophages. In addition stably transfected macrophages can lead to the 
generation of sub-clones from a heterogenic macrophage population which may 
show different activities compared to the original population. Therefore it was 
decided to use transient transfection with siRNA to knock-down BKin RAW264.7 
macrophages. The first part of this chapter attempted to optimize the transfection 
protocol to inhibit BK expression in RAW264.7 macrophages. Secondly, the effect 
of BK silencing on the release of TNF- and IL-6R and the activity of ADAM17 
was investigated. 
 
7.2 Results 
7.2.1 Optimization of siRNA protocol in macrophages  
7.2.1.1 Transfection reagents for the inhibition of BK protein expression 
First objective of this chapter was to develop a protocol which silenced BK channels 
in RAW264.7 macrophages; two sequences for BK silencing siRNA were acquired 
from Qiagen. These sequences were predesigned to be selective against 
BKThese two sequences were named sequence 1 and sequence 5. siRNAs were 
used at the recommended concentration of 10 nM in the first set of experiments, 
which investigated different transfection reagents, namely GeneMute™, Viromer® 
and lipofectamine® RNAiMAX with transfection protocols followed as described in 
2.2.15. Cells received either no treatment, transfection reagent alone, transfection 
reagent containing non-silencing siRNA and BK silencing siRNAs, sequence 1 and 
5. BK expression was analysed by Western blot analysis using a mouse 
monoclonal anti-mouse BK, L6/60. 
GeneMute™ transfection reagent was applied to RAW264.7 macrophages at the 
concentration of 10 nM. This reagent utilises a liposome mediated delivery of siRNA. 
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In line with results from chapter 4, Western blot displayed the presence of protein 
bands at 120 kDa as a doublet. The application of GeneMute™ reagent by itself 
down regulated the expression of BK and there was no apparent difference in the 
expression of BKbetween the non-silencing siRNA and BK silencing siRNA 
treatment groups. This suggested that GeneMute™ reagent had a non-specific 
inhibitory effect on the expression of the protein RAW264.7 cells, Figure 7-1a. The 
application of higher concentrations of siRNA with GeneMute™ caused the 
significant proportion of cell death. Secondly BK silencing sequence was applied to 
macrophages using Viromer® Blue reagent at the concentration of 10 nM. This 
transfection reagent uses viral vector mediated delivery of siRNA. With Viromer® 
Blue, the addition of non-silencing or silencing siRNA did not alter the expression of 
BK in RAW264.7 macrophages, Figure 7-1b. Similar results were obtained 
Lipofectamine® RNAiMAX, where BK silencing siRNA had only a minor effect in 
the group treated with siRNA sequence 5, Figure 7-1c. Higher concentration of 
siRNA with Veromer® Blue resulted in a significant proportion of cell death during 
the incubation with siRNA. As a minor silencing effect was seen with 
Lipofectamine® RNAiMAX, further optimization was carried out with Lipofectamine® 
RNAiMAX. 
 
Figure 7-1 Effect of BK silencing siRNA treatment on BK expression using 
GeneMute™, Viromer ® Blue or lipofectamine® RNAiMAX reagents 
RAW264.7 macrophages were not treated (N.T.) or treated with transection reagent only 
(Reagent), non-silencing siRNA (Ns), BK silencing siRNA sequence 1 (sBK1), sequence 5 
(sBK5). The transfection reagents used was a) GeneMute™, b) Viromer® Blue or c) 
lipofectamine® RNAiMAX.  siRNA concentration was 10 nM. The expression of BK was 
analysed by Western blot. The experiment was performed 1-2 times. Blots shown are 
representative of all experiments.  
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Due to the lack of the effect on BK silencing by the siRNA at 10 nM, a second 
series of experiments were carried out using 15 nM siRNA. An additional group 
which contained both sequence 1 and sequence 5 (7.5 nM each) was included. 
Using Genemute® and Viromer® Blue as transfection reagents in this experiment 
resulted in cell death after 48 hours. In comparison, Lipofectamine® RNAiMAX in 
combination with non-silencing or silencing siRNA did not cause a noticeable 
change in cell morphology or adherence to the culture flasks for at least 72 hours. 
Using these conditions, a combination of silencing siRNA sequences 1 and 5 
achieved the most effective silencing. However, the overall decrease in BK 
expression was still limited to approximately 25% at whole cell lysates compared to 
the control which is non-silencing siRNA group, Figure 7-2. The concentration of 
siRNA used in subsequent experiments was 15 nM and incubation time was 72 
hours.  
 
 
Figure 7-2 Effect of silencing siRNA on BKexpression at the whole cell in 
macrophages 
RAW264.7 macrophages were not treated (N.T.) or treated with non-silencing siRNA (Ns) or 
BK silencing siRNA (sBK), RNAiMAX was used as the transfection reagent. BK, -actin 
and Akt expression in whole cell lysate (WC) was assessed by Western blot. Densitometry 
analysis of relative BK was normalised to -actin. The amount of BK expression in the no 
treatment group and BK silencing siRNA treated group was compared to non-silencing 
siRNA control group. Bars represent mean+SEM with n=3 where n is number of blots used 
for analysis. The experiment was repeated 4 times. 
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7.2.2 Effect of BK silencing siRNA on BKexpression on the plasma membrane 
isolate  
As discussed in chapter 4, BK channels were found on the plasma membrane of 
RAW264.7 macrophages and at intracellular sites. As chapter 4, 5 and 6 suggested 
that it was the plasma membrane BK channel which was important in the regulation 
of ADAM17, the effect of siRNA treatment on the plasma membrane BK channel 
was assessed. BK was almost undetected in plasma membrane lysate from non-
treated cells, Figure 7-3a. These results were consistent with the observations made 
in chapter 4.  Notably, BK was detected at 120 kDa in the plasma membrane 
isolate of the groups which received non-silencing siRNA, Figure 7-3a. Densitometry 
analysis indicated that there was approximately 5 fold increase in BK expression 
on the plasma membrane in the non-silencing siRNA groups compared to the non-
treated control groups, Figure 7-3b. BK silencing siRNA reduced this expression 
on the plasma membrane with a 65% reduction when compared to non-silencing 
siRNA groups, Figure 7-3b. MTT assay was carried out to assess if the siRNA 
treatment affected the viability of the cells.  
 
Figure 7-3 Effect of BK silencing siRNA on BK expression at the plasma 
membrane in macrophages  
RAW264.7 macrophages were not treated (N.T.) or treated with non-silencing siRNA (Ns) or 
BK silencing siRNA (sBK) using lipofectamine® RNAiMAX. BK, -actin and Akt 
expression in plasma membrane isolates (PM) was assessed by Western blot. Densitometry 
analysis of relative BK was normalised to -actin. The amount of BK expression in the no 
treatment group and BK silencing siRNA treated group was compared to non-silencing 
siRNA control group. Bars represent mean+SEM with n=3 where n is number of blots used 
for analysis. The experiment was repeated 3 times. 
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7.2.3 Effect of BK silencing siRNA on TNF- release and mTNF- expression 
during TLR4 activation 
The application of non-silencing siRNA caused the upregulation of BK channel on 
the plasma membranes, Figure 7-3. As this was the reason for using the 
conditioning protocol in chapter 5, which was applied to the cells in order to 
upregulate the BK channel on the plasma membrane, was no longer required in this 
chapter. siRNA treated cells were stimulated with 150 ng/ml LPS. BK silencing 
significantly increased the release of TNF- by 107%. The level of TNF- was 8.1+/-
0.15 ng/ml in non-silencing siRNA treatment group and 16.9+/-1.9 ng/ml in BK 
silencing siRNA treatment group, p<0.05, Figure 7-4a.  BK silencing siRNA also 
resulted in the reduction in mTNF-expression and densitometry analysis indicated 
that BK silencing caused a 66% reduction in mTNF- relative to the expression 
seen in the non-silencing siRNA treated group, Figure 7-5. BK silencing siRNA 
also significantly increased IL-6R release from RAW264.7 macrophages by 50% 
with 103+/-30 pg/ml and 159+/-7.3 pg/ml measured in the no-silencing and  BK 
silencing siRNA treatment group respectively, p<0.05, Figure 7-6a. 
 
The combined data, from repeated experiments over 3 times, for protein release and 
MTT was in line with the described results from individual experiments. These 
combined data were presented in Figure 7-4 c and d, and 7-6b. Statistical analysis 
of combined data and individual experimental data demonstrated a similar pattern of 
significance between treatment groups in TNF- and IL-6R release. It was noted 
combined data from repeated experiments reached higher degree of significance in 
these molecules release. However the cell viability was shown to be affected by the 
siRNA application in combined data with approximately 40% degrease, Figure 7-4d. 
This may be due to reported off target effect of siRNA transfection to immune cells 
(De Arras et al., 2014), which will be discussed in 7.3 discussion. However the 
decrease was equivalent in non-silencing siRNA, which is the control group and 
BK silencing siRNA groups, which is the treatment group in the experiment. 
Therefore this did not affect the analysis nor interpretation of the effect of BK 
channel inhibition. 
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Figure 7-4 TNF- release and cell viability in macrophages after treatment with 
BK silencing siRNA  
RAW264.7 macrophages were not treated (N.T), clear bar, or treated with non-silencing 
siRNA (Ns), black bars, or BK silencing siRNA (sBK), grey bar followed by stimulation with 
150 ng/ml LPS. After 4 hours cell culture media were collected. The level of TNF- in 
conditioned media was measured by ELISA. Cell viability was assessed by MTT assay. Bars 
represent mean+SEM (n≥4). a) & b) shows result from one experiment with n=4 and c) & d) 
shows combined data from 3 repeated experiments. 
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Figure 7-5 Effect of BK silencing siRNA on mTNF- expression in 
macrophages  
RAW264.7 macrophages were treated with non-silencing siRNA (Ns), black bar, or BK 
silencing siRNA (sBK), grey bar followed by stimulation with 150 ng/ml LPS. After 4 hours 
cell were collected for Western blot analysis a) mTNF- and -actin. b) Densitometry 
analysis shows relative mTNF- expression in the BK silencing siRNA treated group 
compared to non-silencing siRNA treated group. Bars represent mean+SEM (n=3), where n 
is the number of blots used for analysis. The experiment was repeated 4 times. 
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Figure 7-6  Effect of BK silencing siRNA on IL-6Rrelease from 
macrophages  
RAW264.7 macrophages were treated with non-silencing siRNA (Ns), black bar, or BK 
silencing siRNA (sBK), grey bars, followed by stimulation with 150 ng/ml LPS. After 4 hours 
medium was collected for IL-6R measurement by ELISA. Bars represent mean+SEM (n≥4). 
a) shows result from one experiment with n=4 and b) shows combined data from 3 repeated 
experiments. Statistical significance between the two treatment groups was tested using 
paired t-test. *p<0.05, **p<0.01.  
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7.2.4 Effect of BK silencing siRNA on and ADAM17 activity 
ADAM17 activity was assessed in BK silenced and non-silenced RAW264.7 
macrophages. As previously described, silenced or non-silenced macrophages were 
counted on the day of the assay in the suspended in phenol red free DMEM and 
directly plated onto the wells. The cells were stimulated with 150 ng/ml LPS and 
after 3 hours, TACE substrate II was directly added. Fluorescence signal was 
monitored for 1 hour duration. The groups treated with BK silencing siRNA had 
doubled the activity of ADAM17 compared to non-silencing siRNA treatment. The 
activity was 10294+/-2704 fluorescence/minute in non-silencing siRNA and 20565+/-
4723 fluorescence/minute in BK silencing siRNA treated group, p<0.05, Figure 7-7. 
Treatment with GM6001 significantly reduced activity and with 2304+/-1430 
fluorescence in non-silencing siRNA group and 4597+/-3981 fluorescence/minute in 
BK silencing siRNA group being recorded, Figure 7-7. A preliminary experiment 
with Western blot analysis of 85 kDa ADAM17, which are considered to be biological 
active form of the enzyme, see 6-3 discussion, showed that there was 43% increase 
in the level of 85 kDa ADAM17 protein in the groups receiving BK silencing siRNA 
compared to the non-silencing siRNA control groups, Figure 7-8 a and b. 
  
Figure 7-7 Effect of BK silencing siRNA on ADAM17 activity in macrophages 
RAW264.7 macrophages were treated with non-silencing siRNA (Ns), black bar, or BK 
silencing siRNA (sBK), grey bars, and stimulated with 150 ng/ml LPS. After 3 hours, TACE 
substrate was applied. Control wells received DMSO (DMSO Veh.) with a final concentration 
of 0.15%. Per minute change in fluorescence signals (ADAM17 activity) were monitored in 
10 minutes interval for 60 minutes and signals between 10 to 50 minutes used for analysis. 
Bars represent mean+SEM with n=4 repeated experiments. Horizontal lines represent 
statistical significance between groups and were tested by paired t-test. *p<0.05.  
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Figure 7-8 Preliminary data. Effect of BK silencing on ADAM17 expression 
RAW264.7 macrophages were treated with non-silencing siRNA (Ns), black bar, or BK 
silencing siRNA (sBK), grey bars, followed by the stimulation with 150 ng/ml LPS. After 4 
hours the cells were collected for Western blot analysis for a) ADAM17 and -actin. b) 
Densitometry analysis shows relative mTNF- expression in BK silencing siRNA treated 
group compared to non-silencing siRNA treated group. Blots shown are from a single 
preliminary experiment.  
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7.3 Discussion 
Gene silencing is mediated by the sequence specific degradation of RNA resulting 
from the insertion of a short double stranded RNA (small interference RNA: siRNA) 
(Hohjoh, 2004). While this technique provides a powerful tool to investigate the roles 
of the protein of interest, the effectiveness of silencing is known to vary significantly 
between the cell types. In addition, the application of siRNA may cause toxicity or 
cellular activation depending on the cellular system investigated. RAW264.7 
macrophages and macrophages in general, are regarded as difficult cells to carry 
out genetic manipulation of protein expression in vitro (De Arras et al., 2014). In this 
chapter, it was found the most efficient transfection protocol developed only resulted 
in 25% reduction in whole cell BK expression in these macrophages. This is in line 
with a previous observation of RAW264.7 macrophages in which proteins have been 
attempted to be silenced (Thompson et al., 1999). 
Previous research has showed that siRNA can activate immune responses by TLR3, 
TLR7 and/or TLR8. These TLRs recognises double stranded RNA including siRNA 
and/or delivery vehicles used for siRNA transfection (Sioud, 2005). TLR3 is 
activated in a sequence independent manner and has been suggested to take a 
comparatively minor role in siRNA induced inflammation compared to that of TLR7 
and TLR8. It has been suggested that the TLR7 and TLR8 preferentially recognise 
certain sequences of siRNA, which results in the release of TNF-IL-6 and or 
IFN(Karikó et al., 2004; Sioud, 2005; Forsbach et al., 2012). Unlike these 
observations, in the protocol used in the transfection did not stimulate TNF- 
release from resting RAW264.7 macrophages. Although combined data showed a 
decrease in cell viability after non-silencing or silencing siRNA, the decrease in cell 
viability between non-silencing control group and silencing siRNA group were 
equivalent. Therefore this protocol was used to analyse the role of BK channels in 
these cells. Importantly it was noted that a purpose of this protocol was the 
upregulation of the plasma membrane BK channels in non-silencing siRNA controls. 
The silencing of BK resulted in much lower level of expression of the plasma 
membrane BK channels, while not completely inhibiting it. It therefore appears that 
the reagent used in protocol, most likely upregulated the expression of BK channels 
on the plasma membrane. Fortuitously, this mimicked the effect of LPS conditioning 
which was used to upregulate the BK channel on the plasma membrane in chapter 4 
and 5. Therefore the direct effect of BK silencing on TLR4 activation of 
macrophages was possible without conditioning the macrophages.   
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The reason why BK silencing was 3 times more effective on the plasma membrane 
than at whole cells is not known. No literature could be found which investigated the 
difference in the effectiveness of siRNA silencing siRNA among cellular locations. 
However BK channels appeared on the plasma membranes of the macrophages 
after the transfection. It is possible to speculate that the BK silencing siRNA 
preferentially inhibited the translation of the newly synthesised BK which were 
directed to the cell surface. It would be important to test if the plasma membrane BK 
channel came from the pre-existing pool of BK channel protein, i.e. the intracellular 
pool, or was newly synthesized. To test this, it would be suggested to activate 
macrophages with 10 ng/ml LPS for 4 hours or the non-silencing siRNA to induce 
BK the appearance of the channel on the membrane in the presence or absence of 
transcription inhibitors and analyse the effect on the channel expression pattern. 
However, it must be noted that these experiments may be difficult to interpret. In 
addition, the silencing appeared to have less effect on intracellular sources of the 
BK channel. This result suggests that the effect which is seen in this chapter with BK 
channel silencing is likely to be due to the inhibition of the plasma membrane 
located BK channel and rather than the intracellular BK channel. The result also 
highlights a problem encountered when using other knockout technologies which 
prevent the expression of the channel globally i.e. all cellular location. This makes it 
important not only in the relation of a cellular function to the presence of protein, but 
also to its cellular location. 
 
BK channel protein knock down increased the activity of the ADAM17 showing a 2.5 
fold higher compared to non-silencing siRNA controls. These changes in TNF-and 
IL-6R release profiles, mTNF-expression and ADAM17 activity shown in BK 
silenced cells were comparable to the effects seen with IbTX, a pharmacological 
inhibition of the plasma membrane BK channel, shown in chapter 5 and 6.  Although 
the data was from a single preliminary experiment, the matured form ADAM17 at 85 
kDa appeared upregulated by BK silencing. It would be important to elucidate the 
connection between BK channel and ADAM17 activation processes. 
 
In conclusion, non-silencing siRNA treatment led to the upregulation of BK channels 
on the plasma membrane in macrophages and BK silencing siRNA significantly 
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down regulated this. Data from this chapter, using gene silencing, support the 
hypothesis that the plasma membrane located BK channel negatively regulates 
ADAM17 activity and enhances the release of TNF- and IL-6R. 
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 Chapter 8 General discussion 
Inflammatory cytokines are important in facilitating acute inflammatory responses 
and essential in host defence. At the same time, prolonged and/or deregulated 
production of cytokines is associated with major diseases. Drugs which target 
cytokines and their receptors are used to treat many inflammatory diseases e.g. 
Remicade©, an anti-TNF- drug, and Actemra©, an anti-IL-6R drug in rheumatoid 
arthritis.  While many cytokines have been implicated in the inflammatory response 
TNF- is considered the archetype pro-inflammatory cytokine. Macrophages are 
known to be the major source of TNF- along with a diverse array of other 
inflammatory mediators (Arango Duque and Descoteaux, 2014). It is therefore not 
surprising that a significant amount of research has investigated the cellular 
mechanisms which regulate the production of this cytokine from macrophages. 
However, the involvement of one class of plasma membrane protein, namely ion 
channels, in macrophage activation has received relatively little attention. 
 
The general aim of this thesis was to use a variety of techniques to investigate the 
role of ion channels in the activation of macrophages in vitro. Specifically, the 
expression and role of BK channels in TNF- production from macrophages during 
TLR4 activation was investigated. 
 
BK channels are highly selective for K+ ions and characterised by a large voltage 
conductance. The channel has important roles in regulating the membrane voltage 
and Ca2+ signalling. Their functions and biophysical properties have been 
extensively studied in excitable tissues such as in neurons and smooth muscle cells. 
Research has also revealed that BK channels are widely expressed in the body, in 
many different cell types and at different cellular locations. The BK channel is 
regulated by a diverse range of endogenous ligands. Importantly, many of the 
regulator ligands for BK channels opening have been hypothesised to have roles in 
inflammation e.g. CO. Previous work in the lab had suggested a role for CO 
producing enzyme, heme oxygenase, in regulating macrophage functions; however 
the precise mechanism by which this enzyme elicits its anti-inflammatory effect is 
yet to be elucidated. Finally, while not directly related to this thesis but of importance 
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in any possible follow-up research in vivo, BK channels had been conclusively 
shown to have no role in neutrophils in the innate immune response (Essin et al., 
2007). 
 
It was therefore hypothesised that the BK channel may be involved in macrophage 
inflammatory responses. However not many studies had been carried out to 
characterise the expression of BK channels in these cells and the presence or 
absence of the channel in macrophages had not been determined and the technical 
approach to study ion channels in these cells had not been established. The 
challenge of this thesis was to first optimise the experiment to study ion channel in 
macrophages. Therefore a macrophage cell line, which tends to give more 
reproducibility to the experiments, was considered to be better for this study than 
primary cells. Furthermore literatures suggested that cultures of macrophages while 
expressing BK like channels did not show a homogenous expression across the 
populations (Gallin, 1991). This was probably because macrophages are highly 
heterogenic in nature (Gordon and Taylor, 2005). Human cell lines are not used 
predominately monocytic in nature and require to be differentiated before they 
become macrophages. The differentiation step adds another level of variability into a 
cellular system and produces macrophages which unlikely to be conducive for 
electrophysiological techniques. For these reasons, it was decided that a mouse 
macrophage cell line, RAW264.7 macrophage is suitable for this study. In addition, 
these cells are readily activated by the TLR4 ligand, LPS and TLR4 signalling has 
been well characterised in these cells. Therefore it was expected that these cells are 
clearer to investigate the effect of BK channel modulation on the TLR4.  
 
The research progressed as follows; 
1  The release of TNF-, IL-6 and IL-6R, important proteins in inflammatory 
response, from RAW264.7 macrophages during activation of TLR4 was 
characterised. The effect of BK channel modulation drugs on the cytokine 
release was tested. 
2 The expression of BK protein in resting macrophages was investigated by 
biochemical analysis, and the channel functionality on the plasma membrane 
was tested by electrophysiological recordings. 
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3 BK proteins were found in resting macrophages, therefore the effect of 
TLR4 activation on the BK channel expression pattern was investigated. 
4 TLR4 activation led to upregulation of BK channels on the plasma membrane 
at later time point. The involvement of the plasma membrane expressed BK 
channels on the secretion of TNF-, IL-6 and IL-6R was studied using a 
selective pharmacological inhibitor for BK channels, IbTX. 
5 TNF- release was found to be elevated by IbTX. Next the research proceed 
to identify at which steps of TNF- production was affected by the channel 
inhibition; mRNA transcription, cellular protein synthesis or release was 
investigated.   
6 BK channel inhibitor was found to alter the release and retention of mTNF-.  
It was hypothesised that BK channels may interact with a TNF- releasing 
enzyme, ADAM17. The functions of ADAM17, in macrophages were 
characterised. Subsequently the effect of IbTX on the activity of ADAM17 
was studied. 
7 As IbTX treatment enhanced ADAM17 activity, next BK channel was 
inhibited by gene silencing siRNA to verify the results from the 
pharmacological inhibition of BK channels. 
 
 These research objectives were investigated and the results were presented and 
analysed in chapter 3-7. In terms of the general aim of the thesis, if positive data on 
BK channel involvement in these cells had not be collected by objective 2, the role 
of other ions channels in these cells would have been investigated. This discussion 
chapter is aimed to integrate the results chapters, interpret the data in the light of the 
current literature and suggest further work arising from this thesis. This chapter also 
discusses the importance of this finding in inflammation and other physiological 
and/or pathological processes.  
 
The main finding of this thesis is that the plasma membrane expressed BK channel 
regulates the activity of ADAM17 in TLR4 activated RAW264.7 macrophages, 
chapter 6 and 7. This was demonstrated using both a pharmacological approach 
and gene silencing approach. ADAM17 is a membrane sheddase which causes the 
release of TNF- from the plasma membrane along with a number of other proteins, 
Table 8-1. Data in chapter 6 confirmed the role of this enzyme in the release TNF- 
from RAW264.7 macrophages. ADAM17 also appeared to regulate the release of 
     Chapter 8  General discussion 
186 
 
IL-6Rfrom macrophages. However the results indicated that the contribution of 
ADAM17 in overall IL-6R release is slightly less than that for TNF-. An alternative 
mechanism by which IL-6R is released could include ADAM10, however the data 
with the pan metalloproteinase inhibiter, GM6001, would suggest this is not the case 
here. Instead, the result suggested the contribution of other mechanisms which are 
independent of membrane metalloproteinases. IL-6R is also released by the 
alternative splicing of the IL-6R gene (Horiuchi et al., 1994) and this mechanism 
may account for the release of IL-6R from RAW264.7 macrophages. Nevertheless, 
the BK channel inhibition caused a significant enhancement in IL-6R release. 
 
The analysis of the enzyme protein expression and the effect of membrane 
metalloprotease inhibitors supported the hypothesis that it was ADAM17, which is 
most likely to be regulated by BK channels, chapter 6 and 7. However the limitation 
of this analysis is that the specificity of the membrane metalloprotease inhibitors is 
not absolute due to the similarity of the cleavage sites recognised by these enzymes. 
Therefore there have been difficulties in synthesising selective inhibitors for each 
enzyme. In addition, the members of membrane metalloproteases family can have 
overlapping substrate specificities and different members can act on the same 
substrate (Khokha et al., 2013). This means that the absence of one 
metalloproteinase can be compensates by the other members. A possibility that the 
BK channel regulated the activity of other member of ADAMs cannot be excluded. In 
particular ADAM10 can act as a sheddase for TNF- and IL-6R Additional 
experiments with inhibitors of other metalloproteases and gene silencing may help 
to determine the relative contribution of various metalloproteinase to these proteins 
release. 
 
Two previous papers (Papavlassopoulos et al., 2006; Essin et al., 2009) have 
investigated the role of BK channels in the production of TNF- from macrophages. 
Essentially these papers reported that BK channels facilitated TNF- production 
(Papavlassopoulos et al., 2006) or had no role (Essin et al., 2009). These results 
appear to oppose the finding from this thesis. This difference may due to various 
factors. This may include the use of different drugs in the paper, paxilline, instead of 
IbTX used in this thesis and the general knock-down of BK channels in these papers, 
while in this thesis, the experiments were designed to selectively inhibit plasma 
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membrane expressed BK channels without affecting intracellular BK channels. In 
the paper by Papavlassopoulos et al, paxilline, a different reagent from IbTX used in 
this thesis, was used as a BK channel blocker at 20 M to confirm the involvement 
of the channel. However, in this thesis, paxilline at the concentrations of 3 M and 
higher concentrations resulted in a toxic effect of paxilline. It is also noted that the 
IC50 for BK channel block with paxilline can be relatively high. Paxilline was not 
extensively studied in these thesis because i) the above noted toxicity, ii) the 
possible effect on intracellular BK channels due to the lipid nature of the drug, iii) 
reported off-target effects of paxilline (Longland et al., 2000; Bilmen et al., 2002). In 
the second paper (Essin et al., 2009), TNF- function was investigated from 
macrophages isolated from BK knockout mice. Interestingly these researchers 
found no effect of knocking out BK channel on TNF- release from macrophages 
stimulated for 24 hours with LPS.  This thesis showed that only when BK channel 
appeared on the plasma membrane did IbTX have an effect and BK channel like 
current was sparse in resting macrophages. These authors also found a sparsity of 
IbTX sensitive currents in electrophysiological recordings from macrophages 
isolated from wildtype animals, which may have had similar phenotype to resting 
macrophages. Therefore this data on the BK channel expression in resting 
macrophages is also in line with this thesis. 
 
An ELISA assay was used to measure release of TNF-, IL-6 and IL-6R in the 
samples which were taken from repeated separate experiments. Although drug 
treatment caused relatively consistent effects in terms of ratio to the control groups, 
the level of protein release showed variations in some experiments. Similarly, after 
the activation with LPS, not all macrophages upregulated the plasma membrane BK 
channels and the membrane IbTX sensitive BK current was observed in only around 
40% of the total cells recorded. The variability in response to LPS could be due to 
the phenotypic heterogeneity in macrophages. Macrophages are known to be highly 
plastic and heterogenetic in nature (Ravasi et al., 2002; Gordon et al., 2014). Their 
responses to immune stimuli could vary among some cell lines. Although the 
variability in basal levels, the results showed consistency in the effect of IbTX on 
cytokine release in terms of ratio to control groups, which would suggest that the 
interaction between BK channels and ADAM17 may occur consistently among 
macrophage populations. 
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Are there any in vivo studies which show a link between the BK channel and 
cytokine regulation? Three studies have investigated the involvement of BK 
channels in the models of sepsis (Cauwels and Brouckaert, 2008; O’Brien et al., 
2011; Xu et al., 2012a). In the most recent study an exaggerated mortality was seen 
in mice by selective knock-out of 1 subunit, targeting vascular smooth muscle BK 
channels after the induction of sepsis (Xu et al., 2012a). The study also showed that 
this was associated by an increased release of TNF- and IL-6 in these knock-out 
animals, suggesting an inhibitory role for BK channel in TNF- release. Although the 
data from this thesis does not agree completely, i.e. IL-6 release, this data on 
negative effect of BK channels in TNF- release would be in line with the results 
within this thesis. Secondary another study suggested that the inhibition of BK 
channel and small conductance calcium dependent potassium channels have a 
protective effect in endotoxin shock (Cauwels and Brouckaert, 2008). In this study, 
animals treated with BK channel inhibitors showed a decreased survival to LPS but 
not TNF- induced death. Again this could suggest that BK channels can regulate 
LPS activation mechanism. Finally, BK deficient mice have been shown to have 
reduced survival in a model of polymicrobial sepsis via mechanisms independent of 
hypotension (O’Brien et al., 2011). Again, it would be possible that this may related 
to the protective role of BK channels by reducing the release of TNF- shown in this 
thesis. 
 
How does the BK channel regulate ADAM17? 
It is known that ADAM17 undergoes a series of maturation steps before being 
expressed as an active enzyme on the plasma membrane. Reported mechanisms 
which are believed to contribute to the control of ADAM17 activity include; cleavage 
of the enzyme pro-domain by furin proteases, translocation of ADAM17 to plasma 
membrane by iRhom2 and the conversion of ADAM17 dimers to active monomers 
by dissociation of the endogenous inhibitor TIMP-3 (Schlöndorff et al., 2000; Adrain 
et al., 2012; McIlwain et al., 2012; Siggs et al., 2012; Xu et al., 2012b). The inhibition 
of BK channels appeared to show a mild effect on the protein expression of mature 
ADAM17, chapter 6 and Chapter 7 chapter 7. Therefore it appears that BK channels 
could regulate the enzyme activity at the level of expression or protein stability; 
however these results need further elucidation such as the expression at the plasma 
membrane level and the relationship between the molecular weight and the activity 
of ADAM17. In addition, alternative mechanisms for BK channel regulation of 
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ADAM17 cannot be discounted; for example, the opening of BK channel alters the 
membrane potential and ion compositions of the cells. These changes may directly 
or indirectly influence the activity of ADAM17. A recent paper suggested that the 
externalization of phosphatidylserine facilitates the interaction between the active 
site of the ADAM17 and cleavage site of its substrates via negatively charged 
residues on the phospholipid (Sommer et al., 2016). In this light, it is possible to 
suggest that the membrane depolarization associated with BK channels could 
modulate the ADAM17 confirmation to inhibit its activity on the plasma membrane. 
However to confirm this, further experiments are needed. Firstly it would be 
suggested to investigate the effect on the membrane potential by the BK channel 
opening, and the link between membrane potentials and the activity of ADAM17 and 
its substrate release. 
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Cytokines, growth factors Receptors Adhesion 
molecules 
Other 
molecules 
TNF- SEMA4D TNFR1 SORT1 GPIba ICAM-1 APP 
TGF LAG-3 TNFR2 CD91/APIER GPV VCAM-1 GP 
AREG DLL1 P75NTR PTPRF,PTP-
LAR 
GPVI NCAM CA9 
EREG KL-1 IL-6R EPCR SDC1 ALCAM PRNP, 
PrPc 
EPGN, Epigen KL-2 IL-1R2 ACE2 SDC4 L1-CAM KL 
NRG1, Heregulin MICA NTR1, 
TrkA 
LOX-1 KDR,VEGR2 EpCAM MUC-1 
HB-EGF MICB GHR NPR CD89 DSG2 LYPD3, 
C4.4A 
Pref1 Jagged CSF1R, 
M-CSFR 
HER4/ErbB4 Ptprz CD62L VASN 
Fractalkine/ 
CX3CL1 
LTA SORL1  Notch 1 IGF2-R CollagenXVII CD163 
TRANCE/RANKL TMEFF2 SORCS1 TNFRSF8, 
CD30 
M6P/IGF2R PVRL4 
Nectin-4 
PMEL17 
CSF-1 FLT-3L SORCS3 TNFRSF5, 
CD40 
 CD44  
 
Table 8-1 ADAM17 substrates 
Reported substrate molecules for ADAM17. Adapted from Scheller et al., 2011 
Trends Immunol. 32, 380–387. 
 
What regulates the expression and activity of BK channels in macrophages?  
Chapter 4 demonstrated that the activation of macrophages led to the upregulation 
BK channels on the plasma membrane. It is known that not only adaptive immune 
cells, but innate immune cells adjust their response to a subsequent stimuli (Netea 
et al., 2016). Well-known examples include endotoxin tolerance and priming. 
Endotoxin tolerance is a phenomenon whereby the immune cells become 
unresponsive to the subsequent immune activation. This phenomenon is widely 
observed in vitro, in vivo and in clinical settings (Biswas and Lopez-Collazo, 2009). 
Priming is a elevating of inflammatory responses in a subsequent response after the 
first immune activation with a low dose of LPS. Chapter 5 showed the down 
regulation of released and cellular TNF- protein, and an increase in IL-6 release in 
the groups received conditioning dose of LPS for 24 hours in prior to experiments. 
This result does not simply mimic the phenomenon of endotoxin tolerance or 
priming; however, it would be sufficient to say that the activation of these 
macrophages altered their phenotypes. Thus it can be suggested that the 
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upregulation of BK channels may be one of the adaptation mechanisms for 
macrophages to subsequent stimuli.  
 
Mechanisms by how macrophages upregulate the BK channels are not clear. This 
could be the translocation of the channel protein from the cytosol, or newly 
synthesized. It has been reported that chemical modifications of the channel protein 
can upregulate the cell surface expression of BK channels (Jeffries et al., 2010; Kyle 
and Braun, 2014). In the view of potential drug discovery, it would be useful to 
identify the mechanisms of BK channel expression change in macrophages. 
 
Classically the opening of BK channels requires a rise in intracellular Ca2+ and 
hyperpolarization, which are often observed in the neurons and smooth muscle cells 
(Hoshi et al., 2013). An important question is what increases the opening probability 
of BK channels in macrophages. In past decades, research has brought light into 
the new factors which markedly alter the activation states of the BK channel. Two 
possible factors must be considered when investigating the opening of BK channels, 
firstly the involvement/presence of endogenous signalling molecules and secondly 
the expression of unique BK subtype or co-assembly with accessory subunits. 
 
Firstly, several endogenous signalling molecules have been reported to activate BK 
channels (Hou et al., 2009). Importantly many of these endogenous openers are 
known to be produced in macrophages during inflammatory responses. These 
molecules include CO, prostaglandin E2 (PGE2) and poly-unsaturated fatty acid 
(PUFA). It should be noted that these molecules are associated with down-
regulation of inflammation in leukocytes. CO has been long recognised for its anti-
inflammatory effect and the PUFA is known to promote the resolution of 
inflammation (Perretti et al., 2015; Wallace et al., 2015). Many of these openers are 
produced in macrophages and act intracellularly on the C-terminus (Hou et al., 
2009). In future work, it would be useful to analyse the production of these 
endogenous openers in TLR4 activated macrophages. In addition, recent paper has 
reported that the extracellular application of -2-macroglobulin (2M) can activate 
BK channels. 2M can be produced by the activated immune cells and therefore 
indicates possible connection between the BK channel activation and inflammatory 
response (Wakle-Prabagaran et al., 2016).  
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However, the endogenous signalling molecules may not be the only factor when 
considering the opening of the channels. During the experiments, a few distinct 
resting membrane potential were observed in RAW264.7 cells, which were 60 mV, -
35 mV and/or to -10 mV. This pattern did not change after 10 ng/ml LPS treatment 
for 24 hours. With the relatively low membrane potential ranges, it would be 
reasonable to assume that there would be other mechanisms which support these 
channels to open. The subtype of the BK of macrophage BK channels and 
auxiliary subunit composition could alter the gating properties of this channel.      
 
The subtype of BK composition of the channel has not been determined in 
macrophages. A wide range of post transcriptional and/or post-translational 
modifications of the core channel protein modifies the gating properties of the 
channel (Kyle and Braun, 2014). These include alternative splicing of mRNA, 
chemical modifications such as phosphorylation and lipid insertion of the channel 
protein. Especially the alternative splicing of the channel mRNA results in a unique 
type of channel. For instance, BK channels found in glioma cells are known to have 
a distinct splice insert in BK at C-terminus. This results in faster activation and 
higher Ca2+ sensitivity than those BK channels found in neurons and/or smooth 
muscle cells (Liu et al., 2002).  BK channels found in mitochondria are known to 
have a splice insert in C-terminus, which direct the channel to cardiac mitochondria. 
This mitochondrial BK channels are also known to exhibit a high conductance, 
voltage dependency and Ca2+ sensitivity (Balderas et al., 2015). In RAW264.7 
macrophages, BK are found at a standard molecular weight of 120 kDa. In addition 
the auxiliary subunit composition can alter BK channel properties. 1subunit found 
in prostate cancer cells has been demonstrated to alter the gating of BK channels 
dramatically, enabling the channel to open at negative voltage with physiological 
Ca2+ concentrations (Yan and Aldrich, 2010). The co-expression of this subunit is 
suggested to enable the opening of this channel in non-excitable tissues. The other 
members of  subunits: 2-4 also alter the gating properties of the channel shifting 
the activation to a more negative voltage, but to a lesser degree than the  subunit 
(Zhang and Yan, 2014). From the whole cell recordings, the steepness of I-V plot of 
the IbTX sensitive current from RAW264.7 cells indicated that the channels would 
be less dependent on membrane voltages to open. Therefore it would be useful to 
test the expression of any member of  subunits in the RAW264.7 macrophages. 
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Furthermore the  subunits of BK channels contain LRRs, which are an important 
motif for the pathogen recognition by TLRs (Yan and Aldrich, 2012). It would be 
suggested to study the sequence similarity of LRRs between BK channel  subunits 
and TLRs, and intriguing could the BK channel be directly regulated by PAMPs or 
DAMPs.  
 
What could be the consequence of BK channel regulation of ADAM17 for TNF- 
and IL-6R function?  
ADAM17 is one of the best characterised members of membrane 
metalloproteinases and known to facilitate the release of at least 76 transmembrane 
proteins from cell surface (Gooz, 2010; Scheller et al., 2011; Giebeler and Zigrino, 
2016). These substrates include inflammatory cytokines, growth factors, cell 
adhesion molecules and receptors, which are particularly important in the regulation 
of immune responses. Therefore the proposed interaction between BK channels and 
ADAM17 may assign the channel an important role in inflammatory response from 
macrophages. 
 
It is known that not only circulating cytokines but membrane bound cytokines 
activate signalling cascades, leading to distinct physiological effects. Circulating 
TNF- has been reported to preferentially act on the TNFR1, while mTNF-binds to 
TNFR2 (Aggarwal et al., 2012). These two signalling cascades have been reported 
to induce different cellular responses. The activation of TNFR1 by circulating TNF- 
elicits a strong pro-inflammatory effect and the mTNF- signalling  through TNFR2 
have been known to generate anti-inflammatory/regenerative responses, while still 
maintain an anti-microbial effect (McCoy and Tansey, 2008; Sedger and McDermott, 
2014). In addition, it has been shown that mTNF- also acts as receptor on the cell 
surface and the ligation of TNFRs on neighbouring cells can activate signalling in 
the cells. This form is termed reverse signalling and has been suggested to activate 
apoptosis in monocytes and macrophages (Juhász et al., 2013). As a main 
membrane sheddase for TNF-, ADAM17 regulates the ratio between circulating 
and membrane bound form of TNF-and maintains the balance between the 
proinflammatory and tissue protective aspects of this cytokine. The inhibition of BK 
channels resulted in the enhanced activity of ADAM17. The increased activity of 
ADAM17 resulted in a decrease in mTNF- expression and the increased release of 
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TNF- in LPS activated RAW264.7 macrophages, chapter 6 and chapter 7. It is 
possible that active plasma membrane BK channel could shift TNF-away from a 
predominant pro-inflammatory effect towards a tissue protective by increasing 
proportion of mTNF- compared to its circulating form. The brain may represent a 
particular interesting area in which to look at this relationship (Probert, 2015). 
 
IL-6R is expressed as both transmembrane form and circulating form. ADAM17 
together with ADAM10 are known to facilitate the ecotodomain shedding of IL-6R. 
Both membrane bound IL-6R and circulating form IL-6R are able to initiate IL-6 
signalling in combination with gp130. However, the signalling via membrane-bound 
IL-6R and signalling via circulating IL-6R have different cellular responses 
(Schöbitz et al., 1995). IL-6 signalling via transmembrane IL-6R, termed classical 
signalling, leads to anti-inflammatory and regenerative process but signalling via 
circulating IL-6R is termed trans-signalling and known to promote inflammation. 
Especially, the circulating level of IL-6R has the impact on IL-6 trans-signalling 
process, which has been shown to have proinflammatory effect. Over activation of 
this IL-6 trans-signalling is associated with many inflammatory diseases, including 
rheumatoid arthritis and the control of circulating level of IL-6R is important in the 
treatment of these diseases (Hunter and Jones, 2015). Cleavage of ecotodomain of 
IL-6R by ADAM17 together with ADAM10, could modulate the balance between 
the two different signalling pathways, which may represent a new therapeutic target 
(Hunter and Jones, 2015).  
 
The ADAM17 is widely expressed and the substrates for ADAM17 are implicated in 
numerous fields of biology. Investigation of the proposed BK-ADAM17 interaction in 
other tissues which express ADAM17 and BK channels would be useful. In 
particular, endothelial cells are abundant in BK and ADAM17. ADAM17 mediated 
shedding of growth factors, cytokines and cell adhesion molecules are known to be 
important in controlling vascular biology (Dreymueller et al., 2012). In particular, 
ADAM17 mediated EGF-like growth factors are involved in endothelial migration 
(Maretzky et al., 2011) and have implications in vascular tissue maintenance. 
Moreover ADAM17 facilitates the shedding of VCAM-1 and regulates the leukocytes 
migration into the tissues, which are essential during acute inflammatory responses 
(Garton et al., 2006). It would be useful to study if the modulation of endothelial BK 
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channels have an impact on the phenomenon. Another cells would be important is 
glioma cells. These cells express unique variant BK channels as well as ADAM17. 
In U87 glioma cells, the enzyme has been suggested to promote migration, self-
renewal and development of malignant phenotype (Zheng et al., 2012; Chen et al., 
2013a, 2013b). It would be important to study the effect of BK channel modulation in 
on glioma cell phenotypes. 
 
The BK channel-ADAM17 axis in biology? 
This study was carried out in RAW264.7 macrophages. It would be important to 
evaluate the plasma membrane BK channel regulation of ADAM17 in animal models. 
However upon application to any other models, cautions have to be made to 
selectively modulate BK channels which are expressed on the plasma membrane. 
The channel has been reported at variable cellular localisation and location specific 
functions. In this thesis, nuclear BK channels are found in RAW264.7 macrophages 
and further variations in the channel location can be assumed in any types of 
macrophages. The conclusion from this thesis does not agree with the data from a 
paper using BK knock out mice which showed the down regulation of TNF- in BK 
channel deficient animals (Essin et al., 2009). In this thesis, the plasma membrane 
BK channels are selectively inhibited by IbTX and siRNA treatment. The difference 
in the results in Essin et al‘s paper and this thesis may be due to the difference 
between pan BK channel inhibition by knock down and the selective inhibition of the 
plasma membrane BK channels. When investigating this phenomenon in BK 
transgenic models, first it would be important to generate a model, which selectively 
silences the plasma membrane BK channel to achieve the selective inhibition. 
 
The thesis confirmed the expression of BK channels in nucleus of macrophages. 
The role for the nuclear BK channels in macrophage inflammatory response would 
be investigated in future.  A report has shown that BK channel exit in nuclear 
membrane of rodent neurons and regulates CREB mediated transcription (Li et al., 
2014). CREB is known to regulate innate inflammatory responses (Wen et al., 2010). 
It would be interesting to address whether the nuclear BK channels in macrophages 
may interact with the CREB mediated transcription. 
 
 
     Chapter 8  General discussion 
196 
 
Future works arising from this thesis  
As discussed above, this thesis opened up many possible directions of future 
research.  
Does this finding have physiological relevance? The application of this study into 
animal models would give insight into the significance of the phenomenon of plasma 
membrane BK channel regulation of ADAM17 observed in RAW264.7 macrophages. 
It is important that the plasma membrane BK channel is selectively inhibited upon 
application on animal models. 
 
How BK channels regulate ADAM17? In this thesis, the mechanisms of how plasma 
membrane BK channels regulate ADAM17 activity was not addressed. It is 
important to investigate this question in the future. Preliminary data suggested that 
the BK channel inhibition appeared to affect the expression level of 85 kDa ADAM17 
protein, which is considered to be biological active form. The relationship between 
the expression level of biological active ADAM17 on plasma membrane and BK 
channels could be elucidate further.  
 
Do immune stimuli regulate BK channel expression in macrophages? This thesis 
has shown that LPS caused upregulation of BK channels on the plasma membrane 
of the macrophages. Also previous research suggested the general trend of 
upregulation of K+ channels upon the activation or differentiation of immune cells 
(Feske et al., 2015). It would be interesting to investigate if LPS or other immune 
stimuli such as IFN or TNF- have this effect on human macrophages.  
 
What is the subtype and subunit compositions of BK channels in macrophages? The 
subtype of BK or  subunit expression was not determined from this thesis. It is 
important to study the expression of subunits and BK subtype to elucidate how 
these channel could function in inflammatory responses. Also this characterization 
of macrophage BK channels may suggest the possible way of selectively inhibiting 
the channels in macrophages. 
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Would ADAM17 and BK channels interact in other types of cells? ADAM17 and BK 
channels are widely expressed in the body. These two molecules are observed in 
other types of cells including endothelial cells and glioma cells, which express tissue 
specific type of BK channels (Baron et al., 1997; Liu et al., 2002). It is useful to 
repeat this study of the BK channel regulation of ADAM17 activity to further 
elucidate this phenomenon. 
 
Conclusion 
In conclusion, inflammatory response is a protective process, which facilitates the 
host defence and the maintenance of homeostasis; however, at the same time 
deregulated inflammation could lead to many diseases. Signalling cascades 
mediated by inflammatory cytokines are essential in the regulation of inflammatory 
responses. This thesis investigated the role of BK channels in TNF- production 
from macrophages. The BK channels are upregulated on the plasma membrane of 
macrophages during the TLR4 activation or siRNA transfection, suggesting the 
possible involvement of these channels in adaptation of innate inflammatory 
responses. Using the pharmacological modulators and gene silencing, this thesis 
demonstrated that the plasma membrane BK channel regulates the activity of 
ADAM17 and the release of ADAM17 substrates from RAW264.7 macrophages 
during TLR4 activation. ADAM17 is an important regulator of numerous cell 
signalling during inflammatory responses, tissue regeneration, growth, respiratory 
and cardiovascular systems, and tumour growth. This mechanism of ADAM17 
regulation by BK channels would possibly suggest a novel signalling axis, which 
directly link an ion channel and the activity of membrane metalloproteinase and 
would stimulate future research in these fields. Indeed further work is required, 
especially in vivo model, it is hoped that this finding may open up new therapeutic 
interventions.  
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Figure 8-1 BK channels opening down regulate ADAM17 activity 
The possible mechanisms for BK channels opening may be the (1) co-expression with 
accessory / subunits which modify BK channel gating properties. (2) LPS activation and/or 
siRNA treatment lead to the upregulation of BK on the plasma membrane of macrophages. 
The upregulated BK channels opening appeared to down regulates ADAM17 activity and 
decreased the release of TNF- and IL6R. (3) Binding of endogenous signalling molecule. 
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